clinical research organization basel

Department of Clinical Research, University of Basel, Switzerland

As leading institution for the promotion of academic clinical research, we stand for the partnership-based collaboration between clinical researchers and experts from all disciplines. We are committed to a scientific culture that creates the basis for evidence-based patient care of the future with the highest degree of innovation and quality.

As the Department of Clinical Research (DKF), we are the youngest unit of the Medical Faculty at the University of Basel and a member of the national cooperation platform Swiss Clinical Trial Organization (SCTO). We are based at the University Hospital Basel and support over 130 research groups from almost all medical disciplines with an interdisciplinary team of around 50 experts.

We offer a wide range of advice and services for the planning and implementation of clinical studies as well as various training options suitable for all employees in academic patient-oriented research. In addition, we continuously carry out innovation work at regional and national level to further develop and build new research infrastructures and host two research groups with a focus on improving research methodology

The research group leaders, Prof Matthias Briel and PD Dr Lars Hemkens, drive the methodological research agenda of the Basel Trial Forge Centre with a focus on resource planning, use of routine and cohort data, participant recruitment, and risk-based management of clinical trials.

They recently initiated the S wiss clinical T rials E mpirical A ssessment & M ethods (STEAM) Working Group to facilitate collaborative projects aiming to improve the Swiss clinical trial environment.

USEFUL STUFF

Trial forge guidance 1: what is a study within a trial (swat).

If you want to know what a Study Within A Trial is this document tells you and gives some practical tips on what to do.  You can also nuig-tmrn-trial-forge-flyer-cd020919-print .

TRIAL FORGE GUIDANCE 2: HOW TO DECIDE IF A FURTHER STUDY WITHIN A TRIAL (SWAT) IS NEEDED

The full conference programme https://bit.ly/4f6Jklm and workshop schedule https://bit.ly/3STTmN1 for #ICTMC2024 are now available. Book before 23 August to take advantage of the early bird rates! https://bit.ly/3WopP0d @prw_paula @eleanor_mitch @GilliesKatie

Stay in the loop

• ICH GCP (De)
• ICH GCP (En)
• ICH GCP (Es)
• ICH GCP (Fr)
• ICH GCP (It)
• ICH GCP (Pt)
• ICH GCP (Ru)
• AUSTRALIA (NHMRC)
• JAPAN (PMDA)
• US Clinical Trials Registry
• EU Clinical Trials Registry
• Pharmaceutical Companies
• Clinical Research Labs
• Service Companies
• Clinical Research Events
• Publications
• Researchers

List of Contract Research Organizations in Switzerland

Featured cros, across global in switzerland.

E-mail:   [email protected]

Web:   www.across.global

MTA Group Switzerland

Address: Via Antonio Riva, 6 - 6900 Lugano

Phone:   +41919605430

CEBIS International

COMMITMENT FOR A BETTER LIFE OF PATIENTSCEBIS International is a Global Swiss-Based Full Service Contract Research Organization (CRO) which provides clinical stage, regulatory and market entry support to biotech, pharmaceutical, medical devices and n...

Local, small- and mid-size Contract Research Organizations in Switzerland

AGINKO's mission is to provide the best quality pre-clinical laboratory services and clinical trial management to our clients in the pharmaceutical, biotechnological and medical device industries. This mission is achieved through our commitment to cu... View full profile

• Switzerland

Appletree CI Group the reference CSO With headquarters in Switzerland and local presence in 11 European countries, we are able to perform clinical research throughout Europe with our own staff, and offer regulatory services worldwide. Our experienced... View full profile

The Bioimaging and Optics platform (BIOP) is located in the faculty of Life Science (SV) at the Ecole Polytechnique Fédérale de Lausanne (EPFL) and part of a network of core facilities at the faculty. The general idea of the platform is to provide in... View full profile

COMMITMENT FOR A BETTER LIFE OF PATIENTSCEBIS International is a Global Swiss-Based Full Service Contract Research Organization (CRO) which provides clinical stage, regulatory and market entry support to biotech, pharmaceutical, medical devices and n... View full profile

CEPHA s.r.o. - Center for Pharmacology and Analysis - has been founded in 1992 by a group of scientists with extensive experience in clinical research, pharmacology, statistics, analytical chemistry and regulatory affairs as the first independent, pr... View full profile

• Czech Republic

Developharma provides pharmaceutical development services to Rivopharm as well as to third party pharmaceutical companies, either on an exclusive basis or as possibile joint development projects. View full profile

DRK Pharma Solutions provides Clinical Research Services from Phase II-IV through its highly experienced Clinical Operations’ team in Pakistan. Also, we are the First Licensed Clinical Research Organization in Pakistan according to the Bio Study Rule... View full profile

• United Kingdom

MD Biosciences is an industry-leading provider of preclinical, translational and clinical-phase contract research services for the development of pharmaceutical and diagnostic assets. Established in 1991, MD Biosciences offers expertise, services and... View full profile

• United States

Located in Switzerland, we are a passionate human-sized CRO composed of a team of experts. Our main objective is to provide the best services to satisfy our customers’ needs in two areas of activity: Consultancy relating to biological and pharmac... View full profile

SOCAR was founded in 1986, and has more than 25 years of experience in the design, conduct, analysis and reporting of phase I to IV clinical studies. Since our founding, SOCAR has become a leading independent clinical research organisation by deliver... View full profile

The name Solvias is derived from the Latin terms ‘solutio’ and ‘via’ – it is our promise to explore new ways to find solutions that fulfill your requirements. Building on a profound foundation of experience from a large multinational pharmaceutical c... View full profile

Global Contract Research Organizations in Switzerland

ACROSS Global is a unique, full-service, comprehensive alliance of qualified CROs and Specialist Service Providers dedicated to providing a professional, cost-effective, focused, and seamless service to the pharmaceutical, biopharma and medical devic... View full profile

• Bosnia & Herzegovina
• Congo, DR of
• Philippines
• Saudi Arabia
• South Africa
• South Korea
• United Arab Emirates

For more than 25 years, Aixial, the Contract Research Organisation (CRO) of the ALTEN Group, has been supporting pharmaceutical industry key accounts in Europe for various types of services: Insourcing & outsourcing. Aixial environments are vari... View full profile

With 15 years of experience, we have defined a process that consistently achieves success for our clients.RESEARCH that uncovers the real needs and delivers actionable insights.At the heart of any healthcare challenge lies a compelling narrative. To... View full profile

A global, full-service contract research organization. We take your trials personally. dMed Global, a full-service Clinical Contract Research Organization (CRO) based in Shanghai, China and Clinipace Incorporated, a full-service Clinical CRO with hea... View full profile

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. In Applied Translational Medicine, Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug a... View full profile

Established in 1999, Cyprotex Limited was acquired by Evotec AG (www.evotec.com) in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Watertown near Boston, USA. The company has dedicated and highly qualified... View full profile

HEMEX is a global provider of clinical research services to small and medium-sized life sciences companies in diverse therapeutic areas. By combining extensive clinical expertise, commitment to speed, and dedication to patient-centric approaches, HEM... View full profile

• Netherlands

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We are a global provider of consulting, and outsourced developme... View full profile

• New Zealand

IMS Health and Quintiles are now IQVIA, a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare - and human health - forward. Together with the companies we serve, we are enabling a more modern, m... View full profile

MakroCare is expert strategic development and commercialization global partner for pharmaceutical, biotechnology and medical device industries. Our experience, programs and processes bring a new dimension to development strategy, regulatory/risk plan... View full profile

Medidee’s CRO (Clinical Research Organisation) services are backed up by decades of experience in the fields of medical device engineering, quality and regulatory affairs. This unique combination of all relevant competences supports all aspects of yo... View full profile

NDA is a world leading drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board. Our goal is to streamline drug development in order to accelerate patient access to impo... View full profile

OPIS was founded in 1998 as a small Italian CRO. Over the past 20 years we have worked with passion and dedication to conquer the trust of clients and the scientific community, learning from each project and challenge convinced that investing in know... View full profile

For over 35 years, PAREXEL has proven to be a trusted partner for the complex development journey required of biopharmaceutical and medical device companies. We’re also an astute guide, able to simplify that journey for our clients, so safe new produ... View full profile

Our mission is to be the best CRO in the world as measured by our employees, clients, investigators, and vendors. Our teams work tirelessly to ensure that we deliver on time and on budget. You will always know what's going on with your study when you... View full profile

Rede Optimus is a medical device CRO with a global outreach to USA, EU and Brazil. Rede Optimus was founded by a group of  physicians dedicated to the medical device field which focusses on collaborative research and traditional CRO work. With our fo... View full profile

Life sciences services from SGS – optimize your development timelines to get medicines and medical devices to market quickly and safely. There is no other area of business that is more heavily regulated than the development, testing and distribution... View full profile

• Burkina Faso
• Cote d'Ivoire
• Dominican Republic
• El Salvador
• Equatorial Guinea
• Papua New Guinea
• Saint Lucia
• Trinidad & Tobago
• Turkmenistan

Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs a... View full profile

List of CROs by location

This site requires JavaScript to work properly.

How do i activate javascript in this web browser.

• Klinische Epidemiology

Department of Clinical Research

Clinical Epidemiology

• Global Health Research
• Research Methodology
• Insurance Medicine
• Clinical Research Global Health
• Global Mental Health
• Health Services Research Switzerland
• RELY studies
• Current research
• Publications
• Knowledge Transfer
• 2023 - Yearly Report
• 2023 Mini-Symposium

Division of Clinical Epidemiology

University Hospital Basel

University of Basel

Totengässlein 3

4051 Basel, Switzerland

+41 61 265 3819

Prof. Dr. Matthias Briel   Unit Head, CLinical Research Empirical Assessment and Recommenations (CLEAR)

Prof. Dr. Niklaus Labhardt   Head of Division, Clinical Epidemiology , Unit Head, International Clinical and Health Services Research (ICHSR)

Prof. Dr. Regina Kunz   Unit Head, Evidence-based Insurance Medicine (EbIM)

International Clinical and Health Services Research (ICHSR)

Clinical research empirical assessment and recommenations (clear), evidence-based insurance medicine (ebim), quick links, social media.

• © University of Basel

• About Roche Switzerland
• Our business
• Sustainability
• Our history
• Access to healthcare
• Health policy in Switzerland
• Focus areas
• Pharma solutions
• Clinical trials
• Personalised Healthcare
• Patient safety
• Our locations
• Basel & Kaiseraugst - Headquarter
• Basel - Roche Pharma (Schweiz) AG
• Rotkreuz - Roche Diagnostics
• Schlieren - Research and Development

Our research in Basel

At the Basel site, employees work in the fields of Oncology, Neuroscience, Infectious Diseases, Rare Diseases, and Ophthalmology, joined by colleagues from research & clinical operations, research informatics, and our strategy group. Also based in Basel are our development groups which represent the range of expertise needed to run clinical trials, including clinical research and exploratory development, clinical science, safety science, and regulatory affairs.

A new home is currently being built for pRED - the new Roche Innovation Center Basel - as part of the Roche Basel site. As of 2024, we will bring our research community, which at the moment is distributed all over the Basel site, under one state-of-the-art roof.

Where we work

The Roche Innovation Center Basel is a place where innovation happens to ensure a sustainable flow of medical solutions that address the unmet medical needs of patients. Our research labs and offices are currently distributed all over the Roche site in Basel.

New pRED Center

As of 2024, our colleagues will work under one roof: in the new pRED Center which we are currently building in Basel. The new pRED Center aims to provide flexible and state of the art workplaces where collaboration and communication are raised to the next level.

Institute of Human Biology

The Roche Innovation Center Basel is also home of The Institute of Human Biology (IHB), dedicated to research on human biology and human model systems such as organoids. Roche Pharmaceutical Research and Early Development (pRED) established the IHB to take maximum advantage of the scientific and research expertise in both academia and the pharmaceutical industry, it will bring them closer together using human model systems to better predict a drug’s validity, and so translate pioneering science into breakthroughs for patients.

Meet our scientists

Who is working in R&D at Roche Basel? And what do we do? Get a glimpse into our work.

If you love science and are passionate about developing medical solutions for patients to make a difference in their lives, join us!

The future starts here

Educating the next generation of scientific talents and nurturing kids' curiosity is important to us. We do this in many different ways. Find some information below.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

• Network / Institutions

INSTITUTIONS

The Neuroscience Network consists of a wide variety of research groups affiliated to different institutes and organizations of the Basel region:

© 2016 Template: WebThemez & Shapebootstrap | Bootstrap: Twitter | Webdesign:  Werner Indlekofer Webdesign

•    Studienangebot
•    Certificate of Advanced Studies
•   CAS Clinical Research I
• Sachgebiete
• Formale Kategorien
• Stichwortsuche

CAS Clinical Research I (Clinical Trial Planning and Conduct) Certificate of Advanced Studies

The goal of this program is to impart information and skills necessary to successfully start or enhance a new career as a clinical research professional. The program provides a profound background on the development of new therapies with a focus on drug development, covers key ethical aspects of conducting research involving human participants, teaches the regulatory and legal requirements of performing clinical studies and finally thoroughly explains the planning and performance competences of conducting clinical trials.

This continuing education program has been designed to meet the needs of young clinical research professionals from industry and academia (study nurses, study coordinators, study physicians, clinical trial/research associates, clinical monitors), as well as for new members of ethics committees. Furthermore, it provides an opportunity for graduates from life sciences and medical schools to gain a comprehensive understanding of the phases of clinical research and the practical aspects of clinical trial planning and conduct.

Students who are interested in a broader training on operational aspects of clinical trials including management and leadership skills may be interested in complementing their knowledge through an additional CAS Clinical Research II (Advanced Clinical Trial Management). After successful completion of both the CAS Clinical Research I and the CAS Clinical Research II, it is possible to receive the Diploma of Advanced Studies (DAS) Clinical Trial Practice and Management by composition of a diploma thesis and passing a final oral examination.

Aufbau / Form

This program consists of 3 modules in the amount of 11 ECTS. Each module comprises an online training for self-study and individual completion and a classroom training (2-3 days with practical exercises and group discussions).

Acquired competencies will be checked by multiple-choice tests and homework assignments. To gain insights into the daily work life in a clinical research profession, a one-week internship (work-shadowing) at a host site within the field of clinical research has to be completed. The host’s main field of activity should be different from the student’s main expertise. It is the responsibility of the student to find a suitable host for the internship.

Zielpublikum / Teilnahmevoraussetzungen

People working in any area of clinical research either in academia or in industry (study nurses, study coordinators, clinical research associates, study physicians, assistant physicians, etc.)

This program has been specifically developed for

• Candidates with a science or medical degree (minimum Bachelor's degree)
• Candidates without a university degree but with a professional qualification ("abgeschlossene Berufsausbildung" or similar) and at least two years of practical work experience in clinical research (based on "sur-dossier" decisions)

Very good command of oral and written English is a pre-requisite for admission to the program.

• Dr. Andrea Kiemen

The multidisciplinary teaching faculty consists of national and international experts in clinical research ethics, regulatory sciences and the different fields of operational clinical research.

Mareike Gräter Training and Education Departement of Clinical Research (DKF), University of Basel c/o University Hospital Basel Spitalstrasse 8/12 CH-4031 Basel

mareike.graeter@usb.ch Tel. +41 61 556 59 76 Training and Education Departement of Clinical Research

Available Mon-Thu 08.30h - 13.30h

Fees include course materials, provisions during coffee/tea breaks and overhead fees. The course fee will be collected in two equal tranches approximately 6 months apart.

The Department of Clinical Research (DKF) offers training grants for members of DKF clinical research groups . Applications for training grants can be submitted when registering for the program.

Cancellation and withdrawal Cancellations made prior to the closing date for enrolment will not be subject to any charge. If a cancellation is made after the closing date for enrolment, the full applicable fee will be charged. Course fees already paid will not be refunded. Should participants withdraw from the program or discontinue participation, no discount from the course fee will be granted and any share of the course fee will not be refunded.

Training & Education Courses of the Department for Clinical Research

Trägerschaft

Medical Faculty of the University of Basel

Classroom training dates 2025

• Modul 1, Basics of clinical research: February 10-11, 2025
• Modul 2, Clinical study planning: June 03-05, 2025
• Modul 3, Clinical study conduct: September 09-10, 2025

Online training material will be available approximately one month prior the respective classroom training.

Course certificates will be issued after successful completion of the module tests, submission of all homework assignments and submission of the work-shadowing report. Credit points: 11 ECTS

Course language Course materials, language of instruction and module tests are in English. Homework and reports may be submitted in English or German.

The next course cycle will be starting in February 2026.

Please register here

Registration deadline: November 15, 2024

• Studiengangreglement CAS Clinical Trial Practice and Management
• Reglement über das Weiterbildungsstudium
• Flyer CAS Clinical Research I (PDF, 1740 KB)
• Study Handbook DAS Clinical Trial Practice and Management (PDF, 472 KB)

• Industry overview
• Industrial biotech
• Swiss Biotech Report
• Success Stories
• Company directory
• Talent platform
• Networking platforms
• Our mission
• Insight Events

ICON Clinical Research (Switzerland) GmbH

• Swiss Biotech Association Member
• News, events, jobs
• Send an email
• Get directions

ICON plc is a global provider of outsourced drug development services and offers a flexible partnership model for biotechs, acting as a fully externalised project development team. We offer a full range of clinical, consulting and commercial services.

Products, services, technology

Consulting & Advisory services - Asset Development, Regulatory Affairs, Commercial Positioning, Tailored clinical development - over 8,000 employees worldwide dedicated exclusively to biotech clients, Therapeutic expertise - including CGT and novel first-in-class immunotherapies.

Cooperation possibilities

ICON can assist biotechs in establishing key clinical development processes and infrastructure internally, including: Due diligence and asset valuation processes, Asset development consulting, Quality management systems and standard operating procedures, Medical safety boards.

• http://www.iconplc.com/biotech
• [email protected]

Some insights

How does your company make the world a better place.

At ICON our reputation is built on enduring partnerships that are driven to advance medicine and make a difference in the world. Since our inception in 1990, we’ve partnered with biotech clients, collaborating, innovating, and finding new ways together to improve outcomes.

Why are you proud about your company?

ICON brings a suite of capabilities, expertise and technology to augment your operations, increase R&D efficiencies and improve site engagement to access patient populations and deliver timelines and milestones.

Picassoplatz 8, 4052 Basel, Switzerland

Additional address info

• c/o Experfina AG

Facts & figures

• Type of organization Public company
• Year of foundation 1990
• Number of employees in Switzerland 20-49

Key business

• Service provider

Core competencies

• Project & process management
• Medical devices/technologies

You may also be interested in

• Financial investor, R&D, Service provider
• 1066 Epalinges

At CxO, we drive biotech startups toward growth by optimizing resource management and operational efficiency. As partners, we empower firms to innovate and scale. Our veteran team offers strategic insights to accelerate timelines, optimize ROI, and enhance workflows, ensuring client success

• +3 Business development & strategy, Project & process management, Services

Avenza Consulting Sàrl

• R&D, Service provider

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.    

• +3 Business development & strategy, Project & process management, Therapeutics/vaccines (human)

Justin Stindt Consulting AG

Justin Stindt Consultants is a consulting firm specializing in Strategy & Market Access advisory services for the pharmaceutical, biotech and medical device industries.

• +5 Business development & strategy, Project & process management, Diagnostics, Therapeutics/vaccines (human), Medical devices/technologies
• Share via...

• Search Search Search …
• Search Search …

The Basel Breast Consortium is an interdisciplinary organization committed to the development of basic, clinical and translational research projects by supporting interdisciplinary communication and mutual education in Switzerland and neighbouring cities. The presence of outstanding basic science groups, a university hospital and a medical faculty with strong clinical oncology departments, and numerous pharma companies make Basel well-positioned to be the nexus of these collaborative activities.

To discuss, design and conduct scientific projects with the potential to advance knowledge in breast cancer basic biology and therapy to the highest level of targeted therapeutic efficacy while minimizing treatment-related toxicity.

Methodology:

The consortium’s mission is accomplished by regular meetings and networking opportunities among basic researchers, translational research scientists, clinicians – from academia and industry – dedicated to the study of mammary gland development, as well as breast cancer research and treatment in Switzerland and neighbouring cities. Participating clinicians and researchers may have a designated interest in basic or clinical research and originate from the fields of plastic, oncologic and oncoplastic surgery, radiation and medical oncology, gynecology, pathology, radiology and genetics. Participating basic researchers may originate, among others, from a variety of disciplines, including basic cell biology, genetics, immunology, computational biology, endocrinology and fundamental molecular biology.

We organize four joint lunchtime tricycle meetings per year. The format is three 15 minutes presentations from basic/translational researchers, clinicians, and industry, while providing 15 additional minutes for discussion and networking. We are confident that these interactions promote fruitful collaborations in the fields of breast development and breast cancer in Switzerland and neighbouring cities.

– 21-22 of October 2024 – 9th Annual BBC Meeting » Details and registration

Latest News:

September 23 2022: Dr. med. Walter Weber  and the TAXIS study  receive s  the  International Hologic Award » More information

June 3 2021:  Ana Luísa Correia (Bentires lab) & collaborators identify the interplay of hepatic stellate cells and NK cells as a master switch of cancer dormancy in her Nature publication » More information

November 6 2020 : Prof. Bentires-Alj receives the Max Cloëtta award from the Max Cloëtta foundation. » More information

January 27 2020 :  Prof. Dr. med. Walter Weber receives the Annemarie Karrasch Research Award from the Propatient Foundation. » More information

June 28 2019 : SAKK/Pfizer Award 2019 has been awarded to Prof. Dr. med. Walter Weber from University of Basel. » More information

June 27 2019 : The team of Dr. Santamaria from the University of Fribourg (CH) published on the influence of TGFBR1 inhibition on tumor and metastasis initiating capacity of breast cancer stem cells. » See article

Any help is welcome to support our activities. If you wish to donate please do so by bank transfer on the following account:

Basler Kantonalbank, 4002 Basel BLZ 770 / SWIFT BKBBCHBB Konto Nr. 16 477.336.09 IBAN: CH76 0077 0016 0477 3360 9 Lautend auf Universitätsspital Basel, Fonds, Hebelstrasse 36, 4031 Basel Important notice: FO141054 / YOUR NAME

Please contact [email protected] for any inquiry about sponsorship and donations.

Thank you for your support !

Strategies for commercialising oncology treatments for young adults

Icon innovation.

Our experience, knowledge and technological advancements converge to shape a better future for healthcare.

Applying AI to manage the risks and costs of postmarketing requirements

Translating intent to impact.

The triad of trust: Navigating real-world healthcare data integration

Uncover how reshaping data and integration strategies can empower your organisation.

Ensuring the validity of clinical outcomes assessment data

Important considerations and best practices for effective COA implementation.

Advancements in Artificial Intelligence for site selection

Using human-enabled AI to enhance decision-making and minimise risk.

A multifaceted risk factor: Addressing obesity's impact across the disease spectrum

Considerations for clinical trial design focused on obesity treatments.

Featured Solutions

Blended solutions

Bespoke, seamless solutions to meet unique sponsor challenges.

Digital Health Technologies

ICON acquires HumanFirst, a cloud-based technology company for life sciences supporting precision measurement in patient centred clinical research.

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Cardiac Safety Solutions

End-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO and MUGA studies.

Early Clinical and Bioanalytical Solutions

Innovative early clinical solutions that will advance your drug development strategy.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Market Access

Expertise in mission-critical pricing, market access, and reimbursement. 

Specialty Laboratory Solutions

Supporting precision medicine programs across all phases of drug diagnostic co-development.

Considerations for Oligonucleotide therapeutics in CMC

4 September 2024. Register today.

Regulatory submission writing for NDA success

10 September 2024. Register today.

Singlicate ADA analysis

11 September 2024. Register today.

ICON Insights

• 02 Sep 2024

Outcome Measures: Driving forward patient-centered clinical trials

• 28 Aug 2024

Enabling a new way to select fit-for-purpose COAs to simplify clinical protocols

• 19 Aug 2024

Enhancing diversity in clinical trials with AI and human expertise

• 14 Aug 2024

The rise of precision outcome measures

Understanding China's 2024 NRDL: Key changes and their impact

The race to develop combination vaccines – and the importance of indirect effects

Unlocking quality in machine translation: The impact of ISO 18587 certification on clinical research

• 02 Aug 2024

Outcome measures: Driving precision health strategies forward

Digital endpoints widely adopted in pharmaceutical and biotech-sponsored clinical trials

What’s happening in icon, how can we help.

• Cell and Gene Therapies
• Early Clinical
• Medical Device
• Rare & Orphan Diseases
• Real World Evidence
• Site & Patient Recruitment
• Strategic Solutions
• Regulatory Intelligence

370 Results

EPFL – Quartier de l'Innovation Bâtiment G 1015 Lausanne Switzerland Biocartis provides molecular diagnostic and multiplex detection platforms.

Basel, BS Switzerland Acino provides drug delivery solutions, out-licensing, brand marketing, and contract manufacturing.

Erlenstrasse 1 CH-4058 Basle Switzerland Acino provides drug delivery solutions, out-licensing, brand marketing, and contract manufacturing.

Mauerstrasse PO Box Basel, 4002 Switzerland

Bachem Holding AG Hauptstrasse 144 4416 Bubendorf Switzerland Bachem offers custom peptide synthesis and GMP peptide manufacturing services, including process development, scale-up production, analytical and process validation and stability studies.

Bachem AG Hauptstrasse 144 4416 Bubendorf Switzerland Bachem offers custom peptide synthesis and GMP peptide manufacturing services, including process development, scale-up production, analytical and process validation and stability studies.

Bachem SA Succursale de Vionnaz Route du Simplon 22 1895 Vionnaz Switzerland Bachem offers custom peptide synthesis and GMP peptide manufacturing services, including process development, scale-up production, analytical and process validation and stability studies.

Bachem Distribution Services GmbH Hegenheimer Strasse 5 79576 Weil am Rhein Germany Bachem offers custom peptide synthesis and GMP peptide manufacturing services, including process development, scale-up production, analytical and process validation and stability studies.

Schützenstrasse 12 Liestal, CH-4410 Switzerland Adipogen Life Sciences is a leading manufacturer focusing on Inflammation and Immune Responses. In addition to catalog antibodies, proteins, ELISA Kits, and small molecules, custom services for antibody and protein production are available.

Lörrach, BW Germany AHEAD, is a specialized consulting agency that supports clients in the planning, generation and dissemination of health economic evidence as well as in obtaining market access and reimbursement.

Elisabethenstrasse 43 Basel, Basel, 4051 Switzerland Aelysia helps scientists develop their projects with two principal domains of expertise: gathering the information they need to begin telling their scientific story by manually identifying, classifying, and tracing their data. Then, helping them shape their narrative by revising their scientific manuscripts for errors in logic, language, and style. Services are tailored to each project and developed cooperatively wherever required.

Leisibachstr. 30 Buchrain, Lucerne, 6033 Switzerland ariadne.ai ag is a contract research organization (CRO) for automated high-throughput biomedical image analysis and cutting-edge image processing technology — scalable in throughput and consistent in quality. We accelerate your research and development efforts by solving your image processing and analysis bottlenecks. Let your team focus on staining and imaging while we take care of the rest. No matter whether you have a workflow which you want automated or whether you want a completely new workflow. We do it and allow you to scale your experiments. Our interdisciplinary team of scientists and machine-learning experts combines human and artificial intelligence to turn terabytes of imaging data into quantitative results. We develop novel, imaging-based, AI-powered biomarkers that leverage existing imaging assays with the power of deep-learning and extract revolutionary new information from biomedical images. Our portfolio contains workflows, for High-throughput screening Colocalization Image alignment and registration Light microscopy Fluorescence microscopy Electron microscopy Spatial biology

1 Meeraner Platz 79539 Lörrach, BW, 79539 Germany Analytica LASER is a scientific consultancy that specialises in Real World Data, Analytics and HEOR and Market Access services. A significant portion of this work involves developing rigorous, evidence-based materials to help guide research and healthcare decisions. Our international team is a diverse group of experts with a breadth of experience, including high level (MSc and PhD) researchers, former payers, pharmaceutical industry leaders, noted academics, and highly experienced industry consultants. Our diverse scientific team includes statisticians, epidemiologists, mathematicians, economists, physicians, pharmacists and other pertinent expertise that assures the development of scientifically rigorous, insightful and actionable deliverables for our customers. PGRx Real World Datasets are targeted case registries that operate in multiple disease areas. PGRx provides quality data for most real world studies required by our HEOR and market access clients such as burden of illness, treatment patterns, drug utilisation, health resource use and quality of life studies. Programs for new pathologies can be rapidly deployed as a result of the validated protocol/tools and the extensive network of specialists created over the years that PGRx has been operating. PGRx uniquely links detailed medical data and HRU information from the physician with extensive patient-reported data on drug usage, adherence, quality of life and productivity impact. This gives a rich source of ‘deep’ data on patients, their management, possible drivers of effectiveness and the associated patient outcomes. Our other Real World Data solutions services include electronic database analytics, chart reviews, patient/physician surveys and advanced outcomes research and pharmacoepidemiology studies. Analytica LASER has been at the forefront of advising clients on market access issues with strategic consultancy, development of global value dossiers, evidence synthesis amongst other services.

Route de l’ancienne Papeterie Marly, FR, 1723 Switzerland Aginko Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development. Given our expertise, know-how, and network in the field of osteoarticular pathologies, Aginko today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.

Route de l'ancienne Papeterie PO Box 30, 1723 Marly, Switzerland Aginko Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development. Given our expertise, know-how, and network in the field of osteoarticular pathologies, Aginko today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.

14 Sternenfeldstrasse Birsfelden, BL, 4127 Switzerland Synlab Pharma offers method validation/development, physicochemical characterization, stability studies, impurity profiling, bioanalytics, PK/PD studies, clinical trial support, reference standards, and release analysis services.

Basel, BS Switzerland AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health technology companies across the world. What makes us different is our agile and highly collaborative approach, which allows us to put together the right expertise from across our business to deliver high-quality, technically accurate and compelling content for different audiences, through the selective use of key communication channels. AMICULUM has grown steadily since 2001 with significant repeat business from our clients and recommendations from the leading experts we have worked with. We now have a team of over >350 healthcare communications professionals based in Europe, Asia-Pacific, MENA, and the USA.

Wagistrasse 23 Schlieren, Zurich, 8952 Switzerland Anjarium Biosciences is a cell and gene therapy tools and technology company based in Switzerland. We design, manufacture and deliver synthetic DNA products with unprecedented purity, speed and customization to help our customers optimize research, development and production of genetic medicines. Anjarium’s novel, cell-free, enzymatic approach for producing linear, double-stranded DNA offers significant advantages to customers seeking faster alternatives, more complex constructs, and reduced contamination risk versus traditional plasmid-based processes. Look to Anjarium DNA to catalyze your advanced therapy research and clinical development programs across AAV, mRNA, Lentivirus and other applications.

Hammerstrasse 49 Liestal, 4410 Switzerland AnaPath Services is an independent, Swiss based contract laboratories focused on histopathology services. AnaPath Services was founded in 2012 and is GLP certified 2013. AnaPath Research S.A.U is an AnaPath Services subsidiary located in Barcelona for the conduct of in vivo saftey assesment studies. AnaPath is a team of scientists of different nationalities who are internationally recognized. AnaPath Services were founded to provide reliable, competent and timely services in toxicological and experimental pathology and anatomy. Furthermore, our work combines not only the core business of toxicological pathology but also neuropathology, inhalation pathology, bone marrow evaluations, immunological processes, pathology in unusual laboratory species (fish, amphibian, birds, and invertebrates), hard material techniques, immunohistochemistry, fetal pathology and image analysis. Pathologists, anatomists and other staff members offer their more than 500 years of combined experience from basic consulting via advising study designs and offers for education, to traditional histopathology as well as complex evaluations. In addition, AnaPath GmbH and AnaPath Services are working together with a worldwide network of partners.

Hammerstrasse 49 Liestal, BL, 4410 Switzerland AnaPath Services is an independent, Swiss based contract laboratories focused on histopathology services. AnaPath Services was founded in 2012 and is GLP certified 2013. AnaPath Research S.A.U is an AnaPath Services subsidiary located in Barcelona for the conduct of in vivo saftey assesment studies. AnaPath is a team of scientists of different nationalities who are internationally recognized. AnaPath Services were founded to provide reliable, competent and timely services in toxicological and experimental pathology and anatomy. Furthermore, our work combines not only the core business of toxicological pathology but also neuropathology, inhalation pathology, bone marrow evaluations, immunological processes, pathology in unusual laboratory species (fish, amphibian, birds, and invertebrates), hard material techniques, immunohistochemistry, fetal pathology and image analysis. Pathologists, anatomists and other staff members offer their more than 500 years of combined experience from basic consulting via advising study designs and offers for education, to traditional histopathology as well as complex evaluations. In addition, AnaPath GmbH and AnaPath Services are working together with a worldwide network of partners.

Chemin des Moines 3b Cossonay, Not Applicable, 1304 Switzerland High throughput transcriptomics. Made simple, with BRB-seq.

Route de la corniche 5 Epalinges, VD, 1066 Switzerland High throughput transcriptomics. Made simple, with BRB-seq.

Route de la Corniche 8, level -2 Epalinges , VD, 1066 Switzerland High throughput transcriptomics. Made simple, with BRB-seq.

c/o Küng Rechtsanwälte Poststrasse 13 Zug, 6300 Switzerland A Bio-techne brand based in Silicon Valley, ACD’s products and Pharma Assay Services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1500+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to 2-3 weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine. Through ACD's Pharma Assay Services, tissue sectioning, ISH staining, high resolution full slide scanning, scoring, and image analysis are performed by a dedicated team of highly trained specialists, scientists, and board-certified pathologists. With direct access to the developers of the technology, PAS provides unparalleled expertise in ACD’s ISH platforms and delivers fast, high quality data designed to meet your study objectives and timelines.

Kägenstrasse 17 Reinach, CH-4135 Switzerland BURECO offers cell based assays, immunoassays, endotoxin testing, and immunogenicity testing services.

BioFocus Gewerbestrasse 16 CH-4123, Allschwil Switzerland BioFocus offers a comprehensive suite of discovery products and services. These are available separately or as an integrated drug discovery solution, backed by a centralized project management system.

Bern, BE Switzerland Biosmart GmbH is an accredited testing laboratory for molecular biological analyses of food, feeding, cosmetics and environment.

Weihergasse 11 CH-3005 Bern Switzerland Biosmart GmbH is an accredited testing laboratory for molecular biological analyses of food, feeding, cosmetics and environment.

Augst, BL Switzerland BMA Biomedicals focuses on generation, manufacturing and marketing of antibodies.

Rheinstrasse 28–32 Augst, CH-4302 Switzerland BMA Biomedicals focuses on generation, manufacturing and marketing of antibodies.

Rütistrasse 22, 8952 Schlieren, Switzerland Our independent laboratory serves the chemical and microbiological analysis of environmental samples. High level of expertise, a strong customer focus and an uncompromising focus on quality are especially important to us.

CH-1006 Lusanne, 0 Switzerland BioCentric is a woman-owned medical communications and learning solutions company. We create impactful, value-based, and customer-centric engagements that support the drug development and commercialization process from bench, to clinic, to HCP, to patient/caregiver.

Courroux, JU Switzerland Bausch Advanced Technology Group offers complete pharmaceutical packaging lines for syringes, cartridges, vials, bottles, ampoules and I.V. bags.

Rue De La Source 1, CH-2822 Courroux, Switzerland Bausch Advanced Technology Group offers complete pharmaceutical packaging lines for syringes, cartridges, vials, bottles, ampoules and I.V. bags.

Rietlistr. 4 9422 Staad Switzerland BIOSYNTH AG supplies APIs, intermediates, reagents, building blocks, imaging dyes, and other products in addition to supporting custom manufacturing services.

4 Rietlistrasse Staad, SG, 9422 Switzerland BIOSYNTH AG supplies APIs, intermediates, reagents, building blocks, imaging dyes, and other products in addition to supporting custom manufacturing services.

Switzerland The foundation biobank-suisse (BBS) is a collaborative network of biobanks in Switzerland. The network is open to all biobanks operating within Switzerland. The key contributions are currently made by the Institutes of Pathology from Basel, Bern, and Lausanne.

Thurgauerstrasse 40 8050 Zurich Switzerland Bioniche Pharma specializes in manufacturing injectable pharmaceutical products.

Benkenstrasse 254 Witterswil, 4108 Switzerland Biolytix AG has been a leading, independent specialist laboratory for molecular biological and microbiological analysis with ISO 17025 accreditation since it was founded in 1998. Biolytix wants to be a leading partner for micro- and molecular-biological analyzes, which, with its headquarters in Switzerland, works with customers in all major international markets. In its core competencies (real-time PCR, ELISA), Biolytix wants to take a leading position worldwide.

Neumattweg 16 Dittingen, 4243 Switzerland Biolytix AG has been a leading, independent specialist laboratory for molecular biological and microbiological analysis with ISO 17025 accreditation since it was founded in 1998. Biolytix wants to be a leading partner for micro- and molecular-biological analyzes, which, with its headquarters in Switzerland, works with customers in all major international markets. In its core competencies (real-time PCR, ELISA), Biolytix wants to take a leading position worldwide.

Baselstr. 55 Schönenbuch, CH-4124 Switzerland BÜHLMANN Laboratories supplies molecular diagnostic and clinical chemistry assay kits.

Elsässerstrasse 231 4013 Basel Switzerland Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio.

Basel, BS Switzerland Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio.

Bleicherweg 10 BC Platforms Zurich, 8002 Switzerland BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice. BC Platforms operates the Global Data Partner Network BCRQUEST.com, which provides access and analytics on genomic and clinical cohort data for drug developers currently providing access to over 16m subjects across five continents. Our technology drives the infinite loop between personalized care and research discoveries, leveraging latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing platforms enable high throughput genomic data production, flexible data integration, secure data management, efficient analysis and interpretation of molecular and clinical information. Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in Boston, USA, London, UK and Singapore. For more information, please visit www.bcplatforms.com.

Wagistrasse 21 Schlieren, Zurich, 8952 Switzerland Biognosys offers services and tools that cover two distinctive research areas for protein analysis needs: discovery and targeted proteomics. Biognosys’ discovery proteomics platform allows for quantification of thousands of proteins per sample and is well suited for identifying statistically relevant protein abundance changes at the proteome level without the need for any previous knowledge of specific protein biomarkers. In contrast, Biognosys’ targeted proteomics platform provides an accurate quantification screening method (absolute or relative) for up to 150 pre-defined protein biomarkers that can be analyzed in a high throughput fashion, for up to several thousand samples. The most popular service offering that Biognosys provides to its clients is its proprietary Next-Generation proteomics profiling analysis using Hyper Reaction Monitoring (HRM) technology, which provides unmatched proteome coverage with reproducible and precise quantification that can reach up to 9’000 proteins per sample. The HRM discovery service offering is ideal for identifying differentially expressed proteins from a wide variety of biological sample types and species (i.e. cell lines, tissues, serum/plasma, CSF, plant and microbe). The highly multiplexed, quantitative proteomic results that are obtained from these types of studies are ideally suited for downstream bioinformatics analysis, such as hierarchical clustering to confidently identify protein biomarker signatures that can be used to correlate against a particular phenotype, a specific disease condition or as an indicator for appropriate drug response. Biognosys has led the development of Next- Generation proteomics and is committed to enable others to adopt this transformative technology for deep, proteome quantitation through the use of its software and product offerings as well.

B'SYS GmbH Benkenstrasse 254 Witterswil, 4108 Switzerland B'SYS Biological Monitoring Systems offers biophysics, ion channel services, cell line design, pharmacology, mechanism determination, screening services, and expression stability studies. Patch clamp studies are performed on our 10 manual patch clamp rigs and our 3 automated patch clamp platforms. FLuorescence assays (FLIPR, FlexStation), Luminescence assays and Impedance/field potential platformss are available

Benkenstrasse 254 CH-4108 Witterswil Switzerland B'SYS Biological Monitoring Systems offers biophysics, ion channel services, cell line design, pharmacology, mechanism determination, screening services, and expression stability studies. Patch clamp studies are performed on our 10 manual patch clamp rigs and our 3 automated patch clamp platforms. FLuorescence assays (FLIPR, FlexStation), Luminescence assays and Impedance/field potential platformss are available

Rietlistrasse 4 Staad , SG 9422 Switzerland Biosynth is an innovative global life sciences reagents, custom synthesis, and manufacturing services company that secures the fragment pharma and diagnostic supply chain. With an unrivaled research product portfolio and end-to-end manufacturing services, Biosynth is science-led and customer-focused on solving problems and delivering key reagents at scale and with quality. Our expertise and capability runs across fine chemicals/small molecules, peptides and key biologics all from one trusted partner. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and many hundreds of complex manufacturing service projects. Our small molecule chemistry specialties include enzyme substrates, carbohydrate and nucleoside chemistry, as well as intermediates, APIs and controlled substances. Customers can partner across the full product life cycle with no need to change suppliers, with manufacturing services from the first idea to the finished product, from route scouting and optimization to GMP or ton-scale production at sites across Europe and Asia. Biosynth’s peptide division, based in the US and Europe, has over 40 years of expertise in assisting pharma and diagnostics customers and specializes in custom peptide synthesis from nmol up to multiKg scale. From peptide discovery and lead optimization, including our own CLIPS™ technology to lock peptides into active conformations, to GMP NCEs and neoantigens to cover all your needs. Biosynth has a synergistic offering of critical biological raw materials, including mono- and polyclonal antibody production and our unique epitope mapping service as a platform to support your antibody development, including patent applications. Biosynth’s enzyme products and solutions are at the forefront of biocatalysis and also include custom enzyme development and production. Through the Biosynth group, we also offer the development of antibodies, antigens, and supply of plasma for in vitro diagnostics. *Biosynth and the Biosynth Group includes the previous and associated brands: Carbosynth, vivitide, New England Peptide, Peptides International, Pepscan, Eucodis Bioscience, Aalto Bio Reagents, Fitzgerald Industries International, Cambridge Research Biochemicals (CRB) & Celares For more information please visit our website: https://www.biosynth.com/

Churerstrasse 65B 8808 Pfäffikon SZ Switzerland CryoSave Private Cord Bank, with more than 250,000 samples preserved, is the leading family stem cell bank in Europe. We are accredited as a Licensed Organ & Tissue Establishment for the collection, analysis, processing and preservation of stem cells from umbilical cord blood and cord tissue.

Neuchâtel, NE Switzerland CSEM provides customized microsystems, microelectronic design, high tech coatings, fluidics handling, and surface engineering.

Rue Jaquet-Droz 1 Neuchâtel, 2007 Switzerland CSEM provides customized microsystems, microelectronic design, high tech coatings, fluidics handling, and surface engineering.

Im Budler 8 Lupsingen, CH-4419 Switzerland CaroteNature offers carotenoids of high standard, as analytical standards or in larger quantities for analytical purposes. We also offer services such as analysis of carotenoids in plant and other extracts, custom synthesis or isolation, and consultancy in the field of carotenoids.

11A Grabenstrasse Schlieren, ZH, 8952 Switzerland Crystallise! AG is a company that provides crystallographic services for the identification of small molecule compounds. The full service comprises of crystallization, X-ray measurement and data analysis, interpretation of the data, as well as shipping of sample and results. Our service is also offered for any kind of sensitive (air, moisture, temperature) substances. We are unique in that we are one of the few worldwide who are able to crystallize and characterize liquid samples using X-ray crystallography. If you are interested in the absolute configuration of your sample, we can provide you the absolute structure by using X-ray crystallography. The main goal of the company is to provide all kinds of crystallographic services to the chemical, pharmaceutical and agro industry. If the characterization of your new or "unknown" substance is incomplete, please contact us. We will crystallize your sample and deliver you the missing information as a result of a complete crystal structure analysis.

Grabenstr. 11a 8952 Schlieren Switzerland Crystallise! AG is a company that provides crystallographic services for the identification of small molecule compounds. The full service comprises of crystallization, X-ray measurement and data analysis, interpretation of the data, as well as shipping of sample and results. Our service is also offered for any kind of sensitive (air, moisture, temperature) substances. We are unique in that we are one of the few worldwide who are able to crystallize and characterize liquid samples using X-ray crystallography. If you are interested in the absolute configuration of your sample, we can provide you the absolute structure by using X-ray crystallography. The main goal of the company is to provide all kinds of crystallographic services to the chemical, pharmaceutical and agro industry. If the characterization of your new or "unknown" substance is incomplete, please contact us. We will crystallize your sample and deliver you the missing information as a result of a complete crystal structure analysis.

Muttenz, BL Switzerland Clariant offers custom synthesis of specialty chemicals.

Muttenz, Switzerland Clariant offers custom synthesis of specialty chemicals.

Crossover CRI AG, Industriestrasse 7, CH-6300 Zug Crossover provides clinical research units, regulatory affairs, GCP training, and quality assurance.

25 Glattbrugg, Zürich, 8152 Switzerland CellEDIT – CRISPR Cell Line Engineering Service by Cytosurge AG, implements advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and the manufacturing of high-precision gene-engineered cell lines. By leveraging the unique capability of the CellEDIT Service, researchers and scientists gain unparalleled control over cellular experiments, enabling groundbreaking discoveries in various fields from disease modeling to Immuno-oncology research. Whether you require precise gene engineering, knock-in, knock-out and multiplexing, the CellEDIT offers the service and expertise to advance your scientific endeavors and accelerate your research progress. Take advantage of our unique single-cell gene editing service today and obtain reliable and high-quality edits on your cell line of choice. Your next customized cell line will help you move forward with your research, target validation or during your drug development process. The CellEDIT' custom CRISPR Cell Line Engineering workflow is celebrated for its gentle approach and accurate editing, thanks to a careful intra-nuclear injection of CRISPR editing reagents. The intra-nuclear injection minimizes the impact of transfection on the cells, but it also allows for complex genetic modifications with unparalleled control on hard-to-transfect mammalian cell lines. **Key Features and Capabilities** 1. Vector-free Single-Cell Transfection: CellEDIT empowers researchers to perform precise and targeted direct intra-nuclear injections. This capability is invaluable for introducing specific gene edits – knock-ins, knock-out, large insertions, multiplex editions (editing) - into cells with utmost accuracy. 2. High Precision and Control: The CellEDIT service offers exceptional accuracy and control in single-cell transfection. With its unique microfluidic force probing cantilever technology, we can precisely control the injected volume of CRISPR Cas9 RNP into the nucleus, reducing off-targeting effect. 3. Versatility and Compatibility: CellEDIT is compatible with mammalian cells. Researchers can tailor the service to their specific research needs, enabling a wide range of applications across multiple scientific disciplines, including cell biology, immunology, neuroscience, regenerative medicine, and drug discovery. 4. Expert Support: The CellEDIT service offered through Scientist.com is backed by a team of experienced scientists and technical experts. They provide guidance and support throughout the project, ensuring researchers and scientists to achieve optimal results and maximize the potential of the CellEDIT Service ***About Cytosurge*** Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting-edge solutions based on its patented FluidFM® technology. At the heart of this technology are the hollow FluidFM Probes – the Micropipette, Nanopipette, and the Nanosyringe – specifically designed to offer a wide range of unique applications for single-cell manipulation in biology research. Cytosurge's current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, contributing to human well-being through advancements in single-cell technologies. As the partner of choice for precision gene engineering cell line manufacturing, Cytosurge enables next-generation biologic production and cell and gene therapy treatments, empowering people to live longer and healthier lives. With a unique single-cell workflow and dynamic gene expression analytics, Cytosurge manufactures advanced gene-engineered cell lines, empowering next-generation treatments to benefit human well-being.

Sagereistrasse 25 Zürich, Zürich, 8152 Switzerland CellEDIT – CRISPR Cell Line Engineering Service by Cytosurge AG, implements advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and the manufacturing of high-precision gene-engineered cell lines. By leveraging the unique capability of the CellEDIT Service, researchers and scientists gain unparalleled control over cellular experiments, enabling groundbreaking discoveries in various fields from disease modeling to Immuno-oncology research. Whether you require precise gene engineering, knock-in, knock-out and multiplexing, the CellEDIT offers the service and expertise to advance your scientific endeavors and accelerate your research progress. Take advantage of our unique single-cell gene editing service today and obtain reliable and high-quality edits on your cell line of choice. Your next customized cell line will help you move forward with your research, target validation or during your drug development process. The CellEDIT' custom CRISPR Cell Line Engineering workflow is celebrated for its gentle approach and accurate editing, thanks to a careful intra-nuclear injection of CRISPR editing reagents. The intra-nuclear injection minimizes the impact of transfection on the cells, but it also allows for complex genetic modifications with unparalleled control on hard-to-transfect mammalian cell lines. **Key Features and Capabilities** 1. Vector-free Single-Cell Transfection: CellEDIT empowers researchers to perform precise and targeted direct intra-nuclear injections. This capability is invaluable for introducing specific gene edits – knock-ins, knock-out, large insertions, multiplex editions (editing) - into cells with utmost accuracy. 2. High Precision and Control: The CellEDIT service offers exceptional accuracy and control in single-cell transfection. With its unique microfluidic force probing cantilever technology, we can precisely control the injected volume of CRISPR Cas9 RNP into the nucleus, reducing off-targeting effect. 3. Versatility and Compatibility: CellEDIT is compatible with mammalian cells. Researchers can tailor the service to their specific research needs, enabling a wide range of applications across multiple scientific disciplines, including cell biology, immunology, neuroscience, regenerative medicine, and drug discovery. 4. Expert Support: The CellEDIT service offered through Scientist.com is backed by a team of experienced scientists and technical experts. They provide guidance and support throughout the project, ensuring researchers and scientists to achieve optimal results and maximize the potential of the CellEDIT Service ***About Cytosurge*** Cytosurge AG, founded in 2009, is a biotechnology company that manufactures and distributes cutting-edge solutions based on its patented FluidFM® technology. At the heart of this technology are the hollow FluidFM Probes – the Micropipette, Nanopipette, and the Nanosyringe – specifically designed to offer a wide range of unique applications for single-cell manipulation in biology research. Cytosurge's current systems compatible with FluidFM probes include the FluidFM ADD-ON for AFM systems and the standalone semi-automated FluidFM OMNIUM system. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, contributing to human well-being through advancements in single-cell technologies. As the partner of choice for precision gene engineering cell line manufacturing, Cytosurge enables next-generation biologic production and cell and gene therapy treatments, empowering people to live longer and healthier lives. With a unique single-cell workflow and dynamic gene expression analytics, Cytosurge manufactures advanced gene-engineered cell lines, empowering next-generation treatments to benefit human well-being.

10 Avenue de la Gare Lausanne, Vaud, CH-1003 Switzerland ChemAlive SA serves an online computational chemistry platform that delivers highly accurate analytics for all of chemistry through its managed cloud computing, its in-house automation algorithms and its large-scale database. Through one-button, barrierless, access to state-of-the-art methods in chemical theory, the platform allows for fast and efficient results with up-to-date methodologies useful to experts and non-experts alike in academia, pharmaceuticals, fine chemicals and contract research (manufacturing) organizations (CR(M)Os). The ultimate goal of ChemAlive SA is to allow the full and automatic calculation of reliable quantum data for molecular properties and synthetic reactions available to all chemists from basic 2D chemical syntax towards the total in silico prediction of chemical processes.

Zugerstrasse 76 Wadenswil, Zurich, 8820 Switzerland By bringing together modern label-free technology, application development know-how and sophisticated software, Creoptix offers a unique optical biosensor tool for binding kinetics. Engineered around our proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment.

Bubendorf, BL Switzerland CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. Discover our innovative chemistry solutions at: www.carbogen-amcis.com.

Bubendorf, Switzerland CARBOGEN AMCIS is a leading service provider, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. Discover our innovative chemistry solutions at: www.carbogen-amcis.com.

Eulerstraße 55 Basel, 4051 Switzerland, Europe Celonic provides production of biologics, scale up, cultivation, assays, toxicity testing, and cell line development.

Basel, Switzerland Celonic provides production of biologics, scale up, cultivation, assays, toxicity testing, and cell line development.

Technoparkstrasse 1 Zürich, 8005 Switzerland ChromaCon AG is a private Swiss Life Science tool company, developing and commercializing proprietary chromatographic process technology. Our vision is to transform bioprocessing to continuous and our mission is to provide best-in-class tools consisting of equipment, reagents and discovery technologies to help our customers to create, develop and manufacture next-generation chemical and biological medicines. We facilitate the conversion from batch to more efficient continuous processes by offering equipment, processes and software designed to ease the conversion from batch to continuous chromatography. We are unique in providing laboratory-scale FPLC and HPLC equipment for the purification of proteins and small molecules. The systems have multiple process capabilities allowing our customers to choose the best purification process for any given purification challenge: conventional batch and two-step connected batch for efficient high throughput batch purification periodic countercurrent processes (PCC) for continuous capture and continuous polish purification novel processes for discovery applications facilitating the isolation of minor components from complex mixtures Continuous manufacturing offers 30-50% reduction in CAPEX and OPEX compared to conventional batch manufacturing and is emerging to replace batch manufacturing. ChromaCon is unique in having a full range of process and process control patents and offering together with its scale-up partner a one-stop solution from laboratory to GMP process scale.

Technoparkstrasse 1 8005 Zürich, Switzerland ChromaCon AG is a private Swiss Life Science tool company, developing and commercializing proprietary chromatographic process technology. Our vision is to transform bioprocessing to continuous and our mission is to provide best-in-class tools consisting of equipment, reagents and discovery technologies to help our customers to create, develop and manufacture next-generation chemical and biological medicines. We facilitate the conversion from batch to more efficient continuous processes by offering equipment, processes and software designed to ease the conversion from batch to continuous chromatography. We are unique in providing laboratory-scale FPLC and HPLC equipment for the purification of proteins and small molecules. The systems have multiple process capabilities allowing our customers to choose the best purification process for any given purification challenge: conventional batch and two-step connected batch for efficient high throughput batch purification periodic countercurrent processes (PCC) for continuous capture and continuous polish purification novel processes for discovery applications facilitating the isolation of minor components from complex mixtures Continuous manufacturing offers 30-50% reduction in CAPEX and OPEX compared to conventional batch manufacturing and is emerging to replace batch manufacturing. ChromaCon is unique in having a full range of process and process control patents and offering together with its scale-up partner a one-stop solution from laboratory to GMP process scale.

Rottenstrasse 7 Visp, Valais, 3930 Switzerland Contract Research Service Provider (CRO): Pharma/Nutrition/Cosmetic sectors Indications: Dermatology, Inflammation, Immuno-oncology, Regenerative biology, Metabolism, Toxicity Screening platforms for organelle specific targets : lysosomes, mitochondria, Endoplasmic reticulum Method development for Batch/Lot release - bioassays Clinical Research : cell based or serum/plasma - biomarker analysis in vitro OECD tests

BioArk (Biotech Park) 4th floor Rottenstrasse 5 Visp, VS, 3930 Switzerland Contract Research Service Provider (CRO): Pharma/Nutrition/Cosmetic sectors Indications: Dermatology, Inflammation, Immuno-oncology, Regenerative biology, Metabolism, Toxicity Screening platforms for organelle specific targets : lysosomes, mitochondria, Endoplasmic reticulum Method development for Batch/Lot release - bioassays Clinical Research : cell based or serum/plasma - biomarker analysis in vitro OECD tests

Rte des Combes 101 Grimisuat, Valais, 1971 Switzerland Contract Research Service Provider (CRO): Pharma/Nutrition/Cosmetic sectors Indications: Dermatology, Inflammation, Immuno-oncology, Regenerative biology, Metabolism, Toxicity Screening platforms for organelle specific targets : lysosomes, mitochondria, Endoplasmic reticulum Method development for Batch/Lot release - bioassays Clinical Research : cell based or serum/plasma - biomarker analysis in vitro OECD tests

Chemspeed Technologies, AG Wölferstrasse 8 4414 Füllinsdorf, Switzerland Switzerland Chemspeed Technologies is the leading provider of high-throughput and high-output research & development workflow-solutions from single bench-top/standalone automated workstations (powder dispensing – sample preparation – synthesis – process development – formulation – application – testing) up to complete and integrated product development workflows for the entire product development processes in the chemical, material science, renewables & energy, pharmaceutical, agrochemical, specialty chemical, home care, cosmetics and nutrition industries, as well as academia.

Augst, Switzerland Chemspeed Technologies is the leading provider of high-throughput and high-output research & development workflow-solutions from single bench-top/standalone automated workstations (powder dispensing – sample preparation – synthesis – process development – formulation – application – testing) up to complete and integrated product development workflows for the entire product development processes in the chemical, material science, renewables & energy, pharmaceutical, agrochemical, specialty chemical, home care, cosmetics and nutrition industries, as well as academia.

avenue Gratta-Paille 2 1018 Lausanne, Switzerland Caris Life Sciences offers molecular profiling (WES/WTS), clinical trial enrollment, and IVD/CDx development services.

St. Jakobsstrasse 199 Basel, 4052 Switzerland Caris Life Sciences offers molecular profiling (WES/WTS), clinical trial enrollment, and IVD/CDx development services.

Schützengasse 23 Zurich, 8001 Switzerland CovalX offers a complete solution for the full characterization of biotherapeutics. Our company is a leader in protein interaction analysis by mass spectrometry taking benefits of its unit technology platform (Epitope mapping HDX-MS and XL-MS; aggregation analysis, protein complex stoechiometry, cmpds/target interactions, SPR affinity analysis) . CovalX is offering all the analytical services for the characterization of your biotherapeutics: Denovo sequencing, LC-MS, MALDI-MS, Glycans characterization and the complementary analysis for the preparation of IND subimission following ICH-Q6B guidlines.

Unterdorfstrasse 21, Wangen - Suisse, CH- 8602 Switzerland CliniSciences is a French company headquartered in Paris. CliniSciences is a distributor products & services from suppliers based all around the world. CliniSciences owns 10 other companies (Anawa, Biotrend, Generon, Hexabiogen, Kyvobio, Quimigen) based throughout Europe including the United Kingdom, Germany, Spain, Italy, The Netherlands & Switzerland. Through these companies we offer life science reagents, services and instruments. We sell products & services for research and diagnostic use. Products include reagents, cells, human samples and more. Services include antibody development, peptide synthesis, bulk manufacture, humanization and more.

Stauffacherstr 130A Bern, Schweiz, 3014 Switzerland CELLnTEC is a leading provider of fully defined, animal component-free media for precision cell culture in research, translational medicine, and clinical applications, and for deployment in regenerative medicine, cosmetics/cosmeceuticals, clean beef and other emerging in vitro cell culture applications. CELLnTEC specializes in primary human cell culture models, offering reagents and tools for cell culture and tissue engineering and with a focus on stem cells, iPSC, and 2D / 3D culture. CELLnTEC offers applications for a range of cell or tissue types: Epithelia, Endothelia, Mesenchyme, Melanocyte, MSC, iPSC. Epithelial tissues include skin, cornea, airway, prostate, bladder, and mammary. Analytical services include cell and molecular biology, flow cytometry, RNA isolation, microarrays, and histology.

Stauffacherstrasse 78 Bern, 3014 Switzerland CELLnTEC is a leading provider of fully defined, animal component-free media for precision cell culture in research, translational medicine, and clinical applications, and for deployment in regenerative medicine, cosmetics/cosmeceuticals, clean beef and other emerging in vitro cell culture applications. CELLnTEC specializes in primary human cell culture models, offering reagents and tools for cell culture and tissue engineering and with a focus on stem cells, iPSC, and 2D / 3D culture. CELLnTEC offers applications for a range of cell or tissue types: Epithelia, Endothelia, Mesenchyme, Melanocyte, MSC, iPSC. Epithelial tissues include skin, cornea, airway, prostate, bladder, and mammary. Analytical services include cell and molecular biology, flow cytometry, RNA isolation, microarrays, and histology.

Stauffacherstrasse 78 BERN, 3014 Switzerland CELLnTEC is a leading provider of fully defined, animal component-free media for precision cell culture in research, translational medicine, and clinical applications, and for deployment in regenerative medicine, cosmetics/cosmeceuticals, clean beef and other emerging in vitro cell culture applications. CELLnTEC specializes in primary human cell culture models, offering reagents and tools for cell culture and tissue engineering and with a focus on stem cells, iPSC, and 2D / 3D culture. CELLnTEC offers applications for a range of cell or tissue types: Epithelia, Endothelia, Mesenchyme, Melanocyte, MSC, iPSC. Epithelial tissues include skin, cornea, airway, prostate, bladder, and mammary. Analytical services include cell and molecular biology, flow cytometry, RNA isolation, microarrays, and histology.

Eichenweg 1 Liestal, BL, 4410 Switzerland CordenPharma is an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies link their requirements for product success with their patients’ healthier lives. Formed as a pharmaceutical branch of International Chemical Investors Group in 2006, CordenPharma provides specialised technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services. Full-Service CMO for a Global Market As a full-Service CMO we are committed to bringing inspired global service and flexible solutions spanning the entire pharmaceutical product continuum. Your pharmaceutical development projects will benefit from a legacy of expertise through our: Big Pharma / Biotech calibre facilities with stringent quality systems and standards Proven track record of success in small and large-scale API and Drug Product cGMP Contract manufacturing and Development Network of global cGMP manufacturing facilities with combined capabilities and successful track record of inspections by all relevant Health Authorities Dedicated project managers supported by a project team to ensure consistent coordination, communication and alignment of progress throughout all project phases With multiple cGMP compliant facilities across Europe and the United States, CordenPharma is the flexible, efficient, and cost-effective solution for all of your contract manufacturing needs.

34 Einsiedlerstrasse Wädenswil, ZH, 8820 Switzerland The Culture Collection of Switzerland (CCOS) supports the life sciences community with biological material, cryostorage and services.

Wiesenstrasse 8 8034 Zurich Switzerland DKSH offers consumer goods, healthcare products, luxury items, performance materials and technology.

Zürich, ZH Switzerland DKSH offers consumer goods, healthcare products, luxury items, performance materials and technology.

Birkenweg 13 Eiken, 5074 Switzerland DECLTech consulting was founded in 2013 with the aim to provide pharmaceutical, healthcare and biotech stakeholders with the right scientific expertise and technical guidance to successfully implement DECL technologies in drug/ligand discovery programs in order to maximise DECL potentials with tailored solutions. Contact us for: DECL Technology consulting DECL tech-transfer and implementation guidance DECL Technology tailored solutions Project Management support Collaboration, services and partnership mediator DECL fund rising & grant application review Project risk and opportunities assesment

Gempenstrasse 12 4008 Basel, Switzerland Divis Laboratories provides production of APIs, intermediates, building blocks, carotenoids, and chiral ligands.

Dottikon, Switzerland Dottikon Exclusive Synthesis provides custom synthesis, chemistry products, hazardous reaction services, and waste treatment.

Chemin Messidor 5, 1006 Lausanne, Lausanne, Vaud, Switzerland Debiopharm Group specializes on the development of innovative therapies and prescription drugs that target unmet medical needs.

Wagistrasse 25 Schlieren, 8952 Switzerland DINAMIQS is a science-driven Contract Development and Manufacturing Organization (CDMO) offering end-to-end viral vector manufacturing solutions to accelerate gene therapy projects from DNA design to commercial scale. Our platform offers a comprehensive and customized range of AAV manufacturing services, process development, quality control and analytics solutions for companies and institutions developing genetic medicines. • End-to-end solutions from R&D to commercial manufacturing: o Fully scalable and integrated platform including analytical solutions o GMP-compatible processes from early phase, reducing efforts, time and costs in transition from R&D to GMP o Upstream and downstream process development o Seamless scale-up and vector-specific optimization studies o Preclinical AAV vector manufacturing from 0.5L to 50L scale o cGMP scale production up to 500L • Highly skilled team with 80+ years combined experience: o Demonstrated track record of achievement in viral vector manufacturing o Experienced with multiple AAV serotypes and scales o Focus on innovation o Deep understanding of regulatory requirements specific to gene therapies • Customer-centric partner tailored to meet your needs o Flexible internal methods enable integrated, efficient, and time-saving pathways o Close collaboration with effective communication o Continuous development support and assistance • Member of the Siegfried network, a globally leading CDMO: o Full access to Siegfried's sterile drug products manufacturing network in US and Europe o Full support to transform from a start-up to a state-of-the-art CDMO

Barfüsserplatz 3 Basel, Basel, 4051 Switzerland Digital Chameleon is an owner-managed strategy advisory for digital transformation in the healthcare and life science sector. We support our customers with an experienced and competent Quality & Compliance Team, consisting of various experts from Pharma, BioTech and Medtech (BioTechnologists, Pharmacists, Pharmacists, Medical Technologists, Information Technologists, UX / Usability & Requirement Engineers). We specialize in digitalization in healthcare and orchestrate customers in the introduction and improvement of quality management in an agile environment in an environment restricted by regulations. Areas of tension are: Lean quality management systems, agile computer software validation and qualification, software as a medical device, digital health apps and digital health platforms, as well as quality & audit readiness of ultra-modern bio-tech laboratories and production facilities. In our methodology, we apply deep knowledge and understanding of regulations, standards and best practices from Pharma, BioTech and MedTech (EU GMP, FDA, MDR), future-oriented methods from UX / Usability & Requirement Engineering and agile software development frameworks (Scrum, Kanban ) at. We can therefore offer our customers a quality management system specially tailored to their needs, which navigates them easily and efficiently through the regulatory maze.

84 hallwylstrasse zurich, zurich, 8004 Switzerland DataMart AI is a sole proprietorship Data Analytics and Machine Learning company based in Zurich. The company has two main activities: (1) Indepedent scientific research in the field of drug discovery and development. (2) Consulting and freelance services in data management, statistical data analysis and machine learning. I work with different clients from the pharmaceutical and healthcare research fields in (cheminformatics, PBPK and translational safety) For more information, please visit www.datamartai.com or contact me on [email protected]

EPFL Innovation Park Building D Lausanne, VD, 1015 Switzerland DOPPL - Disrupting healthcare with our high resolution, automated organoid factory Exploiting the power of bioengineered technologies, DOPPL is the leading platform for high-throughput organoid culture and screenings for many tissue types and multiple phenotypic readouts. The DOPPL platform features a large cohort of organoid models and their associated data in a biobank, automated workflows for unlimited organoid expansion and use in large scale screens, and imaging capabilities. DOPPL engages in partnered projects for novel in vitro model generation and screening in drug development. Applications include patient-specific targeted therapy screening in cancer organoids, novel T-cell killing assay methodologies for immuno-oncology studies, toxicity assessment and transport studies on gastrointestinal organoids, and on organoid-based blood-brain barrier model.

EPFL Innovation Park Batiment D Lausanne, CH-1015 Switzerland DOPPL - Disrupting healthcare with our high resolution, automated organoid factory Exploiting the power of bioengineered technologies, DOPPL is the leading platform for high-throughput organoid culture and screenings for many tissue types and multiple phenotypic readouts. The DOPPL platform features a large cohort of organoid models and their associated data in a biobank, automated workflows for unlimited organoid expansion and use in large scale screens, and imaging capabilities. DOPPL engages in partnered projects for novel in vitro model generation and screening in drug development. Applications include patient-specific targeted therapy screening in cancer organoids, novel T-cell killing assay methodologies for immuno-oncology studies, toxicity assessment and transport studies on gastrointestinal organoids, and on organoid-based blood-brain barrier model.

Bärengasse 23 Zofingen, 4800 Switzerland Consulting services in the field of Regulatory Affairs, organisational development, training and coaching of staff

11A Grabenstrasse Schlieren, ZH, 8952 Switzerland Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialising in elucidating protein-protein interaction in the living cells focussing at the cell membrane. We identify the targets of your extracellular ligands using the ligand-receptor capture LRC-TriCEPS™ technology. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment. The LRC-TriCEPS™ platform can also be used to identify new drug targets by identifying new cell-cell interactions also on primary cells (analogue to PD-1/PDL-1 interactions of T-cells with tumor cells). With Flow-TriCEPS™ (Prestest TriCEPS™) we provide a tool to use in flow cytometry to identify the best binding conditions for your ligand of interest without the need of a detection antibody. Further, it can be used to identify the the best conditions for the expression of the unknown targets. Flow-TriCEPS can be used in functional assays to test if a TriCEPS coupled ligand is functionally active. Flow TriCEPS couples the ligand by using primary amines (N-Term and Lysines) and since it contains a biotin, can be detected by a streptavidin fluorophore conjugate using flow cytometry.

Duggingerstrasse 23 CH-4153 Reinach Switzerland Evolva provides products and processes to companies in the food and beverage, consumer health and pharmaceutical sectors.

Obere Ruetistrasse 6 Stein, CH-4332 Switzerland Business Development, Sales and Marketing, Consulting Services for the Pharmaceutical-, Agrochemical-, Chemical- and Medical Device Industries

CE 3 316 (Centre Est), Station 1 Lausanne, CH-1015 Switzerland Ecoles Polytech. fédérales de Lausanne provides chemistry, research, and technology transfer.

1 Althau Würenlingen, AG, 5303 Switzerland To provide nano-patterning services and equipment for applications in photonics, electronics, optoelectronics, displays, biotechnology and other areas.

Route de l'ile-au-bois 1A CH-1870 Monthey, Valais Switzerland ExcellGene offers mammalian cells, protein production, purification, recovery, recombinant protein synthesis, vector construction, and process development services.

26 Mattenstrasse Basel, BS, 4058 Switzerland he Quantitative Genomics Facility (QGF) is a central research and service facility located in the Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zurich in Basel, supported and run jointly with the University of Basel. QGF was established at D-BSSE in 2008 to allow researchers of the life science community in Basel and at ETH Zurich direct access to next generation sequencing (NGS) and complementary genomics technologies, and thereby facilitating the systematic quantitative investigation of genome-wide experiments.

Gewerbestrasse 25 CH-4123 Allschwil, Switzerland The company Endotell AG was founded in 1991. As a trading and service company in the field of in vitro diagnostics. The Endotell AG focuses on the distribution of high-quality test systems and offers above-average customer.

Gewerbestrasse 8 Cham, CH-6330 Switzerland Elchrom Scientific develops and supplies technologies and reagents for nucleic acid separation including electrophoresis gels, buffers, and markers.

Rämistrasse 101 Zurich , 8092 Switzerland Our university for science and technology dates back to the year 1855, when the founders of modern-day Switzerland created it as a centre of innovation and knowledge. At ETH Zurich, students discover an ideal environment for independent thinking, researchers a climate which inspires top performance. Situated in the heart of Europe, yet forging connections all over the world, ETH Zurich is pioneering effective solutions to the global challenges of today and tomorrow. Various licensing opportunities of ETH Zurich are available

Wolleraustrasse 41B 8807 Freienbach Switzerland EffRx Pharmaceuticals offers products based on alternative drug delivery technologies for both the prescription and OTC markets.

EPFL SV ISREC Station 19 Lausanne, CH-1015 Switzerland ISREC is integrated into the School of Life Sciences at EPFL, where it shares a new building (Bâtiment SV) with the Global Health Institute. Its faculty continues to investigate a spectrum of fundamental biological systems that are variously co-opted or disrupted during the development of cancer. Prominent amongst the research topics are signalling pathways that normally regulate aspects of embryogenesis and organogenesis, and mechanisms orchestrating the cell division cycle and the maintenance of genomic integrity during cell proliferation. Increasingly, genetically engineered mouse models of human cancer are being employed to elucidate the roles of such signalling circuits and regulatory mechanisms in tumors, as well as the complex interplay of cancer cells with ostensibly normal cells in their collective "tumor microenvironment"; such heterotypic cell-cell interactions are proving instrumental for malignant progression of tumors to lethal disease. The new director - Douglas Hanahan, from the University of California at San Francisco - is developing a novel strategic plan for ISREC, involving increasing focus via new faculty recruitments on directly studying mechanisms of cancer in model systems and in human tumors, notably involving outreach to the medical oncology community in the region. Toward that end ISREC will establish a bridge-building 'translational' oncology branch at the University of Lausanne's medical campus (CHUV) intended to foster by its proximity and emphasis catalytic interactions and cooperative research with clinical cancer researchers. Both branches of ISREC will seek to expedite progress toward deeper understanding of the biology and genetics of cancer, in turn leveraging new knowledge forthcoming to develop and test innovative drug targeting strategies aimed to disrupt critical mechanisms of the disease and thereby improve the benefits of cancer therapy. The independent ISREC Foundation (http://www.isrec.ch) is focussed on supporting innovative cancer research in Lausanne and western Switzerland, in particular at the frontier of translational oncology that has promise to positively impact the future treatment of human cancer.

c/o Joachim Diez Stadtturmstrasse 5 Baden, AG, 5400 Switzerland We provide services and expertise in the field of X-ray protein crystallography to pharmaceutical and biotechnological companies. Our services include: * Data collection and screening of protein and small molecule crystals at the Swiss Light Source * Processing and analysis of the data * Protein structure solution and ligand refinement We strive to integrate the work we provide seamlessly and efficiently into the processes and workflow of our customers.

Eawag BU F 15-19 Überlandstrasse 133 CH-8600 Dübendorf The Ecotox Centre Eawag-EPFL is the centre for applied ecotoxicology in Switzerland. Its objective is to detect and assess the effects of chemicals on our environment and to mitigate the associated risks. Focusing on knowledge management as well as knowledge and technology transfer, it builds an important bridge between research and application. The Ecotox Centre functions as a knowledge hub and provides the dialog platform for experts from practice and science. With its own projects and in scientific cooperations, it fills gaps in applied ecotoxicology. Due to the active dialog with its stakeholders, the Ecotox Centre is able to detect current problems at a very early stage and contribute to their solution. An important mission is to pass on expert knowledge and thus impart professional skills. Therefore, the employees are engaged in training and continuing education and make their accumulated knowledge and findings available as documentation.

Av. Etienne Guillemin 16 P.O. Box 64 CH-1009 Pully Switzerland ECOM Agroindustrial Corp. Ltd is a leading global commodity merchant and sustainable supply chain management company. As an origin-integrated business operating in over 40 major producing countries worldwide, ECOM focuses primarily on coffee, cotton, and cocoa, as well as participating in selected other agricultural product markets.

Parkstrasse 10 Schönenwerd, 5012 Switzerland The Eurofins Scientific AG laboratory is continuing a tradition of 4 Swiss laboratories, from which the Eurofins was branded in 2000. In addition to food and feed analysis, we also carry out high-quality pharmaceutical analyzes on more than 1000 m2 of laboratory space. Our team of the inspection department carrie out special requests for our clients. Our customers range from the small to international companies. We have built up a long-standing customer base and are committed to the interests of our clientele through our network. Our laboratory Eurofins AG Switzerland is part of the globally active Eurofins Group, which was founded in 1987 in Nantes as a laboratory for the authenticity testing of wines. Eurofins has more than 800 laboratories in over 47 countries worldwide. Through the Eurofins Group you get access to the most modern analytical methods and to experts in a variety of analytical fields. Each year, we analyze about 45,000 samples. We are involved in the market through long-term customer relationships and various national committees. As a recognized provider of laboratory services, legal opinions and complete solutions for food safety, we have many years of experience.

Baselstrasse 109 Arlesheim, Baselland, 4144 Switzerland Proofreading and/or editing English documents and manuscripts, translations German or French to English

Technology Park Basel Hochbergerstrasse 60C Basel, Basel-Stadt , 4057 Switzerland Edelweiss Connect provides the expertise to carry out in a tiered manner in silico modeling & in vitro testing, including our SaferWorldbyDesign partners supporting an integrated approach to safety testing and assessment for customers. Edelweiss Connect is currently offering a free data management service supported by EdelweissData to COVID-19 researchers. More information at www.saferworldbydesign.com

Industriestrasse 17 Lausen, 4415 Switzerland Enzo Life Sciences, Inc. is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of proteins, antibodies, peptides, small molecules, labeling probes dyes and kits provides life science researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

Raeffelstrasse 24 TIC Building - Floor 1 Zürich, ZH, 8045 Switzerland Ectica Technologies is an innovative Swiss life science company dedicated to advance pre-clinical drug discovery by offering new tools, materials and technologies to the biotech and pharma industry. Ectica Technologies is a manufacturer of high-tech hydrogel-based tools and hydrogel specialty chemicals. In few years only, our company managed to become the trusted manufacturer for fully synthetic hydrogel products of leading life science and biopharma companies in North America, Europe and Asia. Products are manufactured under Ectica's brand or under Private Labels. The flagship product is called the 3DProSeed hydrogel well plate. It is a 96-well black glass bottom imaging plate featuring pre-casted, optically transparent fully synthetic hydrogels in each well. The hydrogels are manufactured with state-of-the art Poly(ethylene glycol) (PEG) -bioconjugates. The hydrogels are delivered hydrated ready for cell seeding. The goal of this product is to combine the advantages of hydrogel-based cultures with the same workflow of standard polystyrene cultureware. The key innovation is the patented hydrogel surface which consists of an in-depth crosslinking density gradient promoting the active infiltration of cells into the hydrogel and establishment of a 3D environment. The seeding process can be repeated multiple times with different cell populations during the assay (sequential seeding). The sequential seeding enables the establishment of a stromal environment (e.g. fibroblastic matrix, endothelial cells, adipocytes, hepatic stellate cells etc...) followed by the addition of tumor cells to the preformed stromal model, to address complex questions in cancer biology. A product presentation can be downloaded in the Marketing section. Ectica Technologies has a skilled team of scientists to engage in collaborative projects with biotech and pharma clients interested in a rapid and smooth integration of our technologies into the existing project and workflows. Our skills are primarily focused on oncology research and discovery, specifically on the investigation of tumor-stroma interactions, ex-vivo and in screening-compatible settings.

c/o Switzerland Innovation Park Basel Area AG Hegenheimermattweg 167A Allschwil, 4123 Switzerland ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss technology and service company that was founded in 2019. ELDICO develops, manufactures and commercializes solutions based on the electron diffractometer (micro ED). ELDICO’s clients are industrial and academic researchers in large and fast-growing areas such as the health care, energy storage and advanced materials applications. ELDICO’s headquarters is based in Villigen, Switzerland, at the Park Innovaare next to Paul Scherrer Institute. At ELDICO’s experience centre and application lab in Basel, we offer product demonstrations, customer training and routine analysis on commercial samples. ELDICO’s Electron Diffractometer, the ELDICO ED-1, is a novel analytical instrument for electron crystallography, enabling researcher to investigate nano-crystalline samples with particle size below 1000 nm. The ELDICO ED-1 is an Electron Diffractometer developed by scientist for scientists and is therefore intuitive to operate. The unique patented goniometer enables researchers to get molecular structure information on their nanoparticles in less than a minute also under cryogenic conditions. ELDICO offers the following analyses on your nanosized materials: • Crystal structure determination • Absolute configuration confirmation • Crystal mapping of phase mixtures • Identification of crystalline impurities • Polymorphism characterisation • Detection of micro-crystallinity in amorphous materials Customer-specific needs can also be discussed and tailored to provide solutions together with our experts. Contact details: ELDICO Scientific AG PARK INNOVAARE: delivery LAB 5234 Villigen Switzerland www.eldico-scientific.com [email protected]

c/o swissmade CreativeLAB Badenerstrasse 790 Zurich-Altstetten, 8048 Switzerland ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss technology and service company that was founded in 2019. ELDICO develops, manufactures and commercializes solutions based on the electron diffractometer (micro ED). ELDICO’s clients are industrial and academic researchers in large and fast-growing areas such as the health care, energy storage and advanced materials applications. ELDICO’s headquarters is based in Villigen, Switzerland, at the Park Innovaare next to Paul Scherrer Institute. At ELDICO’s experience centre and application lab in Basel, we offer product demonstrations, customer training and routine analysis on commercial samples. ELDICO’s Electron Diffractometer, the ELDICO ED-1, is a novel analytical instrument for electron crystallography, enabling researcher to investigate nano-crystalline samples with particle size below 1000 nm. The ELDICO ED-1 is an Electron Diffractometer developed by scientist for scientists and is therefore intuitive to operate. The unique patented goniometer enables researchers to get molecular structure information on their nanoparticles in less than a minute also under cryogenic conditions. ELDICO offers the following analyses on your nanosized materials: • Crystal structure determination • Absolute configuration confirmation • Crystal mapping of phase mixtures • Identification of crystalline impurities • Polymorphism characterisation • Detection of micro-crystallinity in amorphous materials Customer-specific needs can also be discussed and tailored to provide solutions together with our experts. Contact details: ELDICO Scientific AG PARK INNOVAARE: delivery LAB 5234 Villigen Switzerland www.eldico-scientific.com [email protected]

Brunaustrasse 185 Fahrweid, Zurich, 8951 Switzerland ​evitria is an established, global antibody expression service provider located in Zurich, Switzerland. We are specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). ​ With a track record of more than 120,000 transfections performed and more than 20,000 antibodies/antibody-based molecules expressed and purified for our clients from the Americas, Europe, Asia and Australia – ranging from academic laboratories and small biotech start-ups to global biopharmaceutical companies – you can benefit from our expertise when looking to entrust someone with your complete antibody production or to manage capacity bottlenecks with single projects.

Ankerstrasse 53 PO Box 8026 Zurich Switzerland Hermes Sweeteners markets and distributes table top sweeteners.

Route de l'Ancienne Papeterie P.O. Box 110 Marly, Fribourg CH-1723 Switzerland Frimorfo offers in vivo studies in mice and rats including preclinical efficacy, drug target validation, and exploratory toxicology studies.

Winterthurerstrasse 190 CH-8057 Zurich Switzerland The Functional Genomics Center Zurich (FGCZ) is a joint state-of-the-art research and training facility of the ETH Zurich and the University of Zurich. With the latest technologies and key expertise for Omics research, the FGCZ carries out research projects and technology development in collaboration with the Zurich Life Science research community. Genomics: Illumina Sequencing Full Services: Project planning to data analysis. We start by discussing your project. You provide the biological know-how and we bring the NGS expertise. Based on our discussion, we will perform the library preparation, sequencing, and basic data analysis. Single Cell Sequencing: We offer technologies that can examine the sequence information from individual cells Spatial Transcriptomics: Whole transcriptome and targeted spatial profiling solutions starting with sectioned tissues. Long Read Sequencing: We offer full package services including project discussion, DNA/RNA quality Control, Library Preparation, Sequencing, and data QC. Downstream Data Analysis is provided upon request. Whole Genome Imaging - Optical Mapping: We offer access to the Bionano Saphyr workflow in user lab mode Genome Informatics: Whether you have an established or a customized implementation of advanced models and algorithms, we run them all Genome Engineering: Proteomics: Proteome Identification and Quantification: We support proteomics projects from initiation to final data analysis. This includes project discussions, sample preparation, mass spectrometry, and bioinformatics analyses Interaction Proteomics: Our interaction proteomics packages include project discussion, mass spectrometry, and bioinformatics analyses. Protein interaction partners can be identified and quantified by: Affinity purification mass spectrometry (AP-MS) and Proximity labeling (BioID, TurboID, APEX) Characterization of purified biomolecules: We combine mass determination and proteomics approaches for the characterization of purified biomolecules. Examples include: determine the molecular weight of intact proteins (incl. antibodies), confirm the identify of a protein, analyse protein-​metal complexes, characterize protein disulfide bridges and N-​termini, identify protein post-​translational modifications and characterize oligonucleotides

66 Maulbeerstrasse Basel, BS, 4058 Switzerland Exploiting new tools for biomedical discovery Scientists at the FMI pursue basic biomedical research, making use of genetic approaches in model organisms detailed proteomic and genomic analyses quantitative and live fluorescence imaging structure determination in their studies of the mechanisms of cancer, epigenetics and neurobiology. The FMI has established cutting-edge technology platforms that develop and exploit new tools for research, placing FMI scientists at the forefront of biomedical discovery. Coupling academic research and biomedical application Affiliated with the Novartis Institutes for BioMedical Research and as an affiliated institute of the University of Basel, the FMI is situated at the interface of academic research and biomedical application. Findings are published and presented to the scientific community, contributing to the collective understanding of human disease. Through collaborative efforts with Novartis, FMI scientists also contribute to the development of both diagnostics and medicines. FMI students and postdoctoral fellows are not only exposed to the latest in molecular and genetic approaches, but are constantly encouraged to examine the biomedical application of their discoveries. Encouraging intellectually daring approaches FMI provides an open, collegial environment for research and encourages the exploration of novel areas with innovative approaches. Our scientists aim to continually push back the horizons of knowledge with original ideas and techniques. Interdisciplinary collaborations and cross-feeding from one field to another occur daily at the FMI. This tradition allows FMI scientists to play a leading role amongst the many institutes engaged in biomedical research.

Steinbuehlweg 69 CH - 4123 Allschwil Switzerland Fisher Bioservices offers biorepository and biobanking services, clinical trial sample management, specimen processing, DNA/RNA extraction, and PCR/QPCR services including WGA PCR, cell therapy storage and logistics, and biologic API transport, storage and handling.

Hochbergerstrasse 60C Basel, BS, 4057 Switzerland FGen is a Swiss contract research organization specialized in synthetic biology and high throughput analysis of cells. FGen has commercialized the nanoliter-reactor screening platform which enables the phenotypic high throughput analysis of large number of cells. The technology is based on encapsulation of cells in hydrogel beads, which allows to analyze 3D cell cultures, such as spheroids, and the characterization with respect to secreted products. For example, the nanoliter-reactor platform represents a powerful tool for screening of antibody producing cells in discovery as well as in cell line development, or for the identification and analysis of cancer spheroids in mixed cell populations. We would be happy to learn how we can support you in the analysis of large numbers of cells with an unique and powerful technology platform.

17 rue du fort Huningue, Grand Est, 68330 France Firalis Molecular Precision provides to its customers a broad range of technologies to help them scale by increasing their analytical capacities in the most flexible and customizable way. We are an official service provider for Olink technologies, HTG EdgeSeq technologies, 10X genomics single cell analysis and Vizgen MERSCOPE technology. Firalis Molecular Precision is the preferred partner for patient’s sample management thanks to a strong expertise in protocol design, biobanking, and multidimensional samples analysis. Whether it is in the patient's perspective for diagnostic, prognostic, prediction and monitoring of the disease progression; or from the drug’s perspective to evaluate toxicity and efficiency. Beyond its multi-omic approach, analytical capacities and scientific expertise, Firalis group is an end-to-end partner which offers clinical qualification, biobanking infrastructure, assay development, bioanalytical testing, data analysis and production facilities to empower your team and fasten your projects. Genomics: Firalis Molecular Precision is a French high throughput sequencing center equipped with the latest disruptive technologies. We provide all the platforms and experts required to perform genomic and transcriptomic analysis from DNA/RNA extraction to qPCR or DNA/RNA sequencing according to your requirements in terms of price, sensibility, analytes and acquisition time. In addition, the cutting-edge single cell analysis system brings powerful oncological section analysis, allowing study and characterization of the Tumor Microenvironment on a cell-by-cell basis. Our company offers a complete range of genomic analysis including detection of SNPs, CNVs, variants, ctDNA, gene identification, species identification, and genome structural organization. About transcriptomic, we provide whole transcriptomes to targeted sequencing analysis, allowing identification of novel transcripts, alternative splicing and differential gene transcription quantification. The characterization of rare cell types and biomarkers is also assessed on a cell-by-cell basis. Proteomics: When it comes to proteomic, our scientific team offers a large panel of services, ranging from large screening and new drug target discovery (Olink Explore 3072 proteins in 1 uL) to target validation and monitoring with extremely sensitive technologies such as the Quanterix SR-X and SP-X. More than a hundred of analytes are already validated on our platforms. Firalis group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified NF S 96-900 for its biobank and accredited ISO 17025 (GCLP compliant) for testing laboratory.

17 rue du fort 68330 Huningue, 68330 France Firalis Molecular Precision provides to its customers a broad range of technologies to help them scale by increasing their analytical capacities in the most flexible and customizable way. We are an official service provider for Olink technologies, HTG EdgeSeq technologies, 10X genomics single cell analysis and Vizgen MERSCOPE technology. Firalis Molecular Precision is the preferred partner for patient’s sample management thanks to a strong expertise in protocol design, biobanking, and multidimensional samples analysis. Whether it is in the patient's perspective for diagnostic, prognostic, prediction and monitoring of the disease progression; or from the drug’s perspective to evaluate toxicity and efficiency. Beyond its multi-omic approach, analytical capacities and scientific expertise, Firalis group is an end-to-end partner which offers clinical qualification, biobanking infrastructure, assay development, bioanalytical testing, data analysis and production facilities to empower your team and fasten your projects. Genomics: Firalis Molecular Precision is a French high throughput sequencing center equipped with the latest disruptive technologies. We provide all the platforms and experts required to perform genomic and transcriptomic analysis from DNA/RNA extraction to qPCR or DNA/RNA sequencing according to your requirements in terms of price, sensibility, analytes and acquisition time. In addition, the cutting-edge single cell analysis system brings powerful oncological section analysis, allowing study and characterization of the Tumor Microenvironment on a cell-by-cell basis. Our company offers a complete range of genomic analysis including detection of SNPs, CNVs, variants, ctDNA, gene identification, species identification, and genome structural organization. About transcriptomic, we provide whole transcriptomes to targeted sequencing analysis, allowing identification of novel transcripts, alternative splicing and differential gene transcription quantification. The characterization of rare cell types and biomarkers is also assessed on a cell-by-cell basis. Proteomics: When it comes to proteomic, our scientific team offers a large panel of services, ranging from large screening and new drug target discovery (Olink Explore 3072 proteins in 1 uL) to target validation and monitoring with extremely sensitive technologies such as the Quanterix SR-X and SP-X. More than a hundred of analytes are already validated on our platforms. Firalis group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified NF S 96-900 for its biobank and accredited ISO 17025 (GCLP compliant) for testing laboratory.

35 rue du fort 68330 Huningue, 68330 France Firalis Molecular Precision provides to its customers a broad range of technologies to help them scale by increasing their analytical capacities in the most flexible and customizable way. We are an official service provider for Olink technologies, HTG EdgeSeq technologies, 10X genomics single cell analysis and Vizgen MERSCOPE technology. Firalis Molecular Precision is the preferred partner for patient’s sample management thanks to a strong expertise in protocol design, biobanking, and multidimensional samples analysis. Whether it is in the patient's perspective for diagnostic, prognostic, prediction and monitoring of the disease progression; or from the drug’s perspective to evaluate toxicity and efficiency. Beyond its multi-omic approach, analytical capacities and scientific expertise, Firalis group is an end-to-end partner which offers clinical qualification, biobanking infrastructure, assay development, bioanalytical testing, data analysis and production facilities to empower your team and fasten your projects. Genomics: Firalis Molecular Precision is a French high throughput sequencing center equipped with the latest disruptive technologies. We provide all the platforms and experts required to perform genomic and transcriptomic analysis from DNA/RNA extraction to qPCR or DNA/RNA sequencing according to your requirements in terms of price, sensibility, analytes and acquisition time. In addition, the cutting-edge single cell analysis system brings powerful oncological section analysis, allowing study and characterization of the Tumor Microenvironment on a cell-by-cell basis. Our company offers a complete range of genomic analysis including detection of SNPs, CNVs, variants, ctDNA, gene identification, species identification, and genome structural organization. About transcriptomic, we provide whole transcriptomes to targeted sequencing analysis, allowing identification of novel transcripts, alternative splicing and differential gene transcription quantification. The characterization of rare cell types and biomarkers is also assessed on a cell-by-cell basis. Proteomics: When it comes to proteomic, our scientific team offers a large panel of services, ranging from large screening and new drug target discovery (Olink Explore 3072 proteins in 1 uL) to target validation and monitoring with extremely sensitive technologies such as the Quanterix SR-X and SP-X. More than a hundred of analytes are already validated on our platforms. Firalis group is certified ISO 13485 (GMP compliant) and ISO 9001 for the development and production of CE-marked assays, certified NF S 96-900 for its biobank and accredited ISO 17025 (GCLP compliant) for testing laboratory.

Postfach 1146 D-79629 Grenzach-Wyhlen Germany GP Grenzach Produktions offers production, packaging and distribution of pharmaceuticals, cosmetic articles, food supplements and medical devices.

Institute of Pathology - University of Bern Lab L 640 - Murtenstrasse 31 CH-3010 Bern - Switzerland The Institute of Pathology, the Inselspital and the Medical Faculty of the University of Bern operate for an indefinite period, the tissue bank of Bern. In the tissue bank samples and information of patients at Bern Hospital and other hospitals be included in the catchment area of the Institute of Pathology Bern and for the use in diagnosis and treatment as well as in the context kept current and in still undetermined research projects of biomedical nature. The collected material will be provided qualified research groups at the request, by means of a written petition research available.

Dienerstrasse 7 Zürich, Zürich, 8004 Switzerland Genexa is a service provider for bioinformatic analyses based in Switzerland. We cover genomics (genome assembly, metagenomics, variant calling, comparative genomics, consulting, and other) as well as transcriptomics (bulk- and single-cell RNA-seq, consulting, and other).

via Industria 24 Biasca 06710 Switzerland Helsinn Chemicals provides analytical services, CMC, manufacturing, clinical trials, organic synthesis, and process development.

5A Via Murate Bellinzona, TI, 6500 Switzerland The Company is focused on discovering and developing fully human monoclonal antibodies to treat serious infections.

Via Mirasole 1 Bellinzona, 6500 Switzerland The Company is focused on discovering and developing fully human monoclonal antibodies to treat serious infections.

Gundeldingerstrasse 174 Basel, 4053 Switzerland Hetcat offers custom synthesis and supplies various fine chemicals.

Industriestrasse 35 CH-9101 Herisau Switzerland Hänseler offers raw materials and the production of commercial and branded pharmaceuticals.

Benkenstrasse 260 4108 Witterswil Switzerland Our scientists have expertise in bacteriology, entomology, plant pathology and physiology, soil science, weed science, and formulation and surfactant chemistry for all pesticides. We have conducted extensive research and development on both agronomic and horticultural crops as well as Turf and Ornamental production systems.

Robert-Walser-Platz 7 Biel, 2503 Switzerland ISS AG, Integrated Scientific Services provides services to medtech companies for the development of medical devices, their introduction into the market and their maintenance. Typical services include embedded software development, regulatory affairs and clinical evaluation report writing, clinical research, quality management, qualification and validation. The combination of these services with scientific work methods and project management puts ISS AG into a unique position as a service provider for the medtech industry.

Marie-Curie-Straße 8 D-79539 Lörrach Germany IL-CSM provides clinical supplies manufacturing, packaging, labelling, kit assembly, storage of medication units and worldwide distribution.

Im Hemmet 1 D-79664 Wehr Germany IGS Aerosols offers contract filling of pharmaceutical, cosmetic and chemical-technical products.

Center Bern Murtenstrasse 42 3008 Bern The Interregional Blood Donation SRK AG Supplying the regions Bern and Vaud with blood products is our mission. Our core competencies are the procurement, processing, testing and delivery of blood products, and the need in the transfusion medicine field diagnosis and counseling. We employ around 350 staff. mission We provide patients and customers with blood products and transfusion medicine services. Blood supply and services Our tasks we fulfill in compliance with clear ethical principles and guarantee high quality and safety of our products and services. As far as possible, we provide other public and private organizations at home and abroad with our products and services. Research & Development, Teaching We make a significant contribution in the transfusion medicine research and development and are actively working with our partners of the blood donation system SRK Switzerland, the various university hospitals, as other public and private institutions and partners. We ensure that our employees have the necessary training and develop their skills and knowledge continuously. Succession planning we proactively. In the service of patients and blood donors , we are aware of our responsibility to the patient and blood donors. Through a professional and contemporary blood management we ensure a long-term security of the blood supply.

Dr. Bernard Gabard Dornacherstrasse 324 CH-4053 Basel Bernard Gabard, nationalité française, né en 1947, est certifié Expert Pharmacologue par la Société Allemande de Pharmacologie et Toxicologie expérimentale et clinique [Fachpharmakologe der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT)] et est titulaire du diplôme „Scientific Basis of Dermatology“ délivré par l’université du Pays de Galles (University of Wales College of Medicine) à Cardiff (UK). Il a travaillé comme pharmacologue aux Laboratoires „Arzneimittel Dr. Willmar Schwabe“ (Karlsruhe, D) et était en même temps responsable des études de toxicologie. Aux Laboratoires Spirig Pharma SA (Egerkingen, CH), il dirigeait le Département de Biopharmacie et était coordinateur Recherche et Développement. Sa responsabilité s’étendait au développement des produits dermo-cosmétiques, plus particulièrement concernant leur efficacité et leur tolérance. En 2001, Bernard Gabard a fondé iderma SA (Münchenstein/Basel, Schweiz), un CRO indépendant pour la dermatologie et la cosmétique, qu’il a dirigé jusqu’en 2004. Depuis cette date, Bernard Gabard travaille comme consultant scientifique indépendant pour l’industrie pharmaceutique et la cosmétique. Bernard Gabard est secrétaire honoraire et membre du bureau de la SWISS SCC (Société Suisse des Chimistes Cosméticiens), et membre des sociétés savantes suivantes : International Society for Biophysics and Imaging of the Skin (ISBS; membre du bureau) Société Francophone d’Ingénierie et d’Imagerie Cutanée (SF2IC; membre du bureau) Deutsche Gesellschaft für wissenschaftliche und angewandte Kosmetik (DGK) European Society for Dermatological Research (ESDR) European Society of Contact Dermatitis (ESCD) American Contact Dermatitis Society (ACDS) Deutsche Gesellschaft für experimentelle Pharmakologie und Toxikologie (DGPT) European Society of Toxicology (EST)

Gubelstrasse 11 CH-6300 Zug Switzerland Informa provides epidemiological studies, pharmacovigilance, medical writing, and clinical studies.

Neuchâtel, NE Switzerland Intercosmetica Neuchâtel S.A., Switzerland, was founded in 1956 by the German group Wella under the name of "Usine de Produits Chimique Neuchâtel S.A". The company changed its name to "Intercosmetica Neuchâtel S.A. in 1992 and in 1996 it was acquired by Zepter International which concentrates entirely on the development and manufacturing of cosmetics products. During this year important investments in the production facilities were made.

Vesalgasse 1 Basel, CH-4051 Switzerland InPheno specializes in virology and offers assay development and profiling services for HIV, hepatitis viruses, and respiratory viruses.

Basel, BS Switzerland InPheno specializes in virology and offers assay development and profiling services for HIV, hepatitis viruses, and respiratory viruses.

Industriestrasse 25 8604 Volketswil Switzerland Invetech provides product development, instrument development, custom automation, and contract manufacturing.

Rte. de l’Ile-au-Bois 1A Monthey/VS, 1870 Switzerland International Health Management Associates (IHMA) and its affiliates specialize in infectious disease and offer a creative and comprehensive menu of products and services to companies developing and marketing antimicrobial agents or antimicrobial susceptibility tests.

Avenue Des Uttins 3 1180 Rolle Switzerland Backed by decades of experience in developing and licensing industrial-scale technology, INEOS Bio creates more sustainable communities and transportation by converting waste and non-food crop biomass into advanced biofuel. The INEOS Bio bioenergy technology solution uses a flexible approach that is safe, fast and reliable, allowing it to be commercialized wherever there is waste. By taking this localized approach, INEOS Bio reduces landfill and air pollution, creates jobs, generates tax revenue and safely produces renewable fuel and clean energy.

c/o Apleona HSG AG Klybeckstrasse 141, K-105 Basel, BS, CH-4057 Switzerland At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic researchers and clinicians work hand in hand to advance the understanding of vision, its diseases and to develop new therapies for vision loss. IOB started operations in 2018. Within the Institute, the Single-Cell Genomics Platform is very active in developing new and establishing existent single-cell sequencing methods that can be then offered to internal users as well as external customers

Bahnhofstrasse 35 Sisseln, Aargau, 4334 Switzerland Analytical company focussing on surface properties and solids characterization to identify characterize and understand different behaviours of solid forms of APIs and excipients. One key method is based on dynamic gas adsorption, also called Inverse Gas Chromatography.

Benkenstrasse 260 4108 Witterswil Switzerland IES LTD IS AN INDEPENDENT AND PRIVATELY OWNED GLP-CERTIFIED CONTRACT RESEARCH ORGANIZATION (CRO) WHICH PERFORMS ENVIRONMENTAL FATE, ANIMAL AND CROP METABOLISM, AQUATIC AND TERRESTRIAL ECOTOXICOLOGICAL, OPEX AND ANALYTICAL CHEMISTRY TESTING TO SUPPORT THE DEVELOPMENT, REGISTRATION AND STEWARDSHIP OF AGROCHEMICAL, BIOCIDAL AND CHEMICAL PRODUCTS.

Europe Branch Office Switzerland Schaffhauserstrasse 28, CH-4332 Stein Ina Research offers non-clinical and clinical studies including expertise in toxicology, safety pharmacology, drug dependence, drug efficacy, and health food development services.

Chemin Es Males Vignes 2a Grandson, Vaud, 1422 Switzerland IntelDrug Consulting is a Swiss-based consulting firm that provides expert advisory services in molecular drug design, discovery and development. IntelDrug is specialized in AI-enhanced features of molecular drug design, molecular docking, target hunting, and therapeutic target utilisation using advanced computational chemistry software.

Headquarter in Zürich INVITRO-CONNECT GmbH Schwäntenmos 6 CH-8126 Zumikon Switzerland INVITRO-CONNECT offers REACH analysis, in vitro assays, and physical chemical analysis services. INVITRO-CONNECT GmbH is the 1. independent Provider of Laboratory Services cooperating with a network of over 80 test laboratories and service providers for the Pharmaceutical, Chemical, Cosmetic and Medical Device Industry and connecting laboratory services with professional customer support such as tests and analyses for most cost-effective price-performance ratio.

Zumikon, ZH, 8126 Switzerland INVITRO-CONNECT offers REACH analysis, in vitro assays, and physical chemical analysis services. INVITRO-CONNECT GmbH is the 1. independent Provider of Laboratory Services cooperating with a network of over 80 test laboratories and service providers for the Pharmaceutical, Chemical, Cosmetic and Medical Device Industry and connecting laboratory services with professional customer support such as tests and analyses for most cost-effective price-performance ratio.

Steinenvorstadt 33 Basel, 4051 Switzerland Consultants in nonclinical biopharmaceutical preclinical development including experts in regulatory, bioanalytics, pharmacokinetics-pharmacodynamics, immunogenicity strategy / data interpretation and risk assessment, nonclinical safety assessment and toxicological pathology disciplines . Experience includes small and large molecules but with emphasis on biopharmaceuticals including protein therapeutics, antibody-drug conjugates and advanced therapy products such as cell & gene therapies.

Lauchefeld 31 Matzingen, 9548 Switzerland IBR Inc., Institute for Biopharmaceutical Research is a Swiss GxP-compliant contract research organization founded in 1998. We are a first-in-class site in the field of bioanalytical services for therapeutic antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines covering the bioanalytical needs from pre-clinical to clinical development. We are experienced in driving studies on cytokines, chemokines and other biomarkers, drug/target binding and immunogenicity. Furthermore, we perform cell-based assays with a broad variety of readouts. Our team has vast experience with primary cells, transformed cell lines, transfected cells, reporter-gene cell systems and 3D cell-based assays. IBR Inc. moves on with rapid and constantly growing advances in technology and offers advanced platforms including Alpha Technology, Time Resolved Fluorescence (TRF), MSD® ECL, Gyrolab™, state-of-the-art Flow Cytometry / Cytometric Bead Array and real time PCR, beside a broad variety of classical techniques. With IBR Inc. your studies are supported from assay development to assay validation and sample measurement. We have capability to perform studies in compliance with regulatory guidelines for GxP and GCP quality standards, following the principles of ICH Q2 (R1), USP 1032, 1033 and 1034. Our study reports are compliant with eCTD requirements.

Benkenstrasse 260 Witterswil, Solothurn, 4108 Switzerland IES Ltd is an independent and privately owned GLP-certified contract research organisation (CRO) based near Basel in Switzerland. We support our international clients by offering scientific studies to not only ensure the safety of the tested products, but also to confirm that the products adhere to the applicable international environmental guidelines.

TechCenter Kägen Kägenstrasse 18 Reinach, Switzerland, 4153 Switzerland We help our clients achieve Total Quality Assurance through customized, flexible, contract services. Our scientists, auditors and regulatory experts work with you at every stage of development, providing GMP and CMC Laboratory Services, Biopharmaceutical Development Support, Medical Device Development Support, GMP Auditing, GLP/GCP Bioanalysis, Regulatory and Toxicology Consulting, and Pharmaceutical Manufacturing Support. We have delivered flexible Total Quality Assurance contract services to the global pharmaceutical industry for over 30 years and currently provide high-quality technical services to some of the world's largest and most innovative pharmaceutical companies. GMP and CMC Laboratory Services: Regulatory-driven, phase-appropriate laboratory services in support of CMC programs. Our regulatory labs include centres of excellence for method development and validation, analysis and characterisation for biologics, mRNA, oligos, cell and gene therapies or vaccine products, inhaled product development, nasal drug development, ICH stability testing and storage, extractables and leachables, formulation development, clinical trial materials manufacturing, cGMP quality control testing, and cGMP batch release testing. Bioanalysis Services: In addition to conducting regulated bioanalytical studies for small and biologics, we provide biomarkers services. Learn more: www.intertek.com/pharmaceutical https://www.intertek.com/pharmaceutical/analysis/inhalation-product-development/ https://www.intertek.com/pharmaceutical/analysis/stability/ https://www.intertek.com/pharmaceutical/analysis/extractables-leachables/ https://www.intertek.com/pharmaceutical/biopharmaceuticals/

Rue de Neuchâtel 15A St-Blaise, Neuchâtel, 2072 Switzerland INVENesis is a swiss biotechnology company based in Neuchâtel. We provide R&D services for drug discovery to industrial partners in the Animal Health, Plant Protection (Crop) and Pharmaceutical fields as well as Academia. We are an agile structure offering electrophysiology (on Xenopus oocytes and invertebrates) and organism-based (model organisms and parasitology) platforms to look for drugs, pheromones, bio-control and biologics with applications in parasitology, agriculture and human medicine. We provide the Science and the Technologies allowing you to screen chemical compounds and generate your own Intellectual Property. We offer a flexible business model where you pay for what you need.

Wagistrasse 27a Schlieren, CH-8952 Switzerland InSphero is a leading provider of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company partners with pharmaceutical and biotechnology researchers to accurately recreate human physiology in vitro, helping them make informed decisions. InSphero's 3D InSight™ human tissue platforms are widely used by major pharmaceutical companies to improve efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases, and oncology, with a focus on immuno-oncology and PDX models. The scalable Akura™ technology underlying the company's 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system, which facilitates efficient innovation throughout the drug development process.

Weidenmattweg 4, Ch-4448, Laufelfingen Switzerland Jupiter Bioscience provides amino acids, peptide synthesis, process development, and scale up.

St. Alban-Vorstadt 90 CH-4002 Basel Switzerland Jungbunzlauer is one of the world's leading producers of biodegradable ingredients of natural origin. We enable our customers to manufacture healthier, safer, tastier and more sustainable products. Due to continuous investments, state-of-the-art manufacturing processes and comprehensive quality management, we are able to assure outstanding product quality. Our mission "From nature to ingredients®" commits us to the protection of people and their environment.

St. Alban-Vorstadt 90 Basel, CH-4002 Switzerland Jungbunzlauer is one of the world's leading producers of biodegradable ingredients of natural origin. We enable our customers to manufacture healthier, safer, tastier and more sustainable products. Due to continuous investments, state-of-the-art manufacturing processes and comprehensive quality management, we are able to assure outstanding product quality. Our mission "From nature to ingredients®" commits us to the protection of people and their environment.

Luzernerstrasse 147a 
CH-6014 Lucerne Switzerland Kinematica supplies instruments and machines in the field of dispersing technology for the laboratory, pilot plant and production applications.

95 Rorschacher Strasse Sankt Gallen, SG, 9000 Switzerland At the Institute for Immunobiology, third-funded basic research on clinically relevant topics is carried out. (Ii) development and function of primary and secondary lymphatic organs (thymus, lymph nodes and spleen), and (iii) biology of coronavirus infection. The main focus of the research is on (i) immunopathological processes in various organ systems (brain and heart).

Rorschacher Strasse 95 St.Gallen, CH-9007 Switzerland At the Institute for Immunobiology, third-funded basic research on clinically relevant topics is carried out. (Ii) development and function of primary and secondary lymphatic organs (thymus, lymph nodes and spleen), and (iii) biology of coronavirus infection. The main focus of the research is on (i) immunopathological processes in various organ systems (brain and heart).

Baarerstrasse 43 Zug, Zug, 6300 Switzerland Scientific Services for Patient-Centered Drug and Medical Device Development

Abendweg 18 Lucerna Chem is a research products supplier and offers antibody services, protein services, custom chemistry services, and drug discovery.

Ruehrbergstrasse 21 Birsfelden, CH-4127 Switzerland Legacy Pharmaceuticals International offers contract manufacturing services in addition to specializing in generics.

105 Schärenmoosstrasse Zürich, ZH, 8052 Switzerland

Lausanne, VD Switzerland Lyncée Tec is making the invisible visible enabling you to characterize your samples like you couldn’t before!

Hegenheimer Strasse 2 D-79576 Weil am Rhein Germany Lipomed provides reference standards and pharmaceuticals for the treatment of rare diseases.

Fabrikmattenweg 4 CH-4144 Arlesheim Switzerland Lipomed provides reference standards and pharmaceuticals for the treatment of rare diseases.

LKC Switzerland Ltd Hauptstrasse 10 P.O. Box 167 4414 Füllinsdorf Switzerland LKC was founded in 2001 by Dr. David F. Kane to provide independent registration and development management services in Europe to the international speciality chemicals industry.Today, LKC is truly international with affiliates in the USA and Japan and staff from many European countries, all attracted by an environment of intellectual freedom and scientific challenge. Their scientific background is similarly diverse: biology, toxicology, environmental sciences, chemistry and business administration — and more on the way. LKC has its head office near Basel in Switzerland, a safe country with excellent infrastructure. The Basel area is the home of many large and small companies. Famous universities (Basel, Bern, Freiburg, Fribourg, Strasbourg, Zürich) are close by and provide a pool of know how for many businesses and services. In the triangle between Switzerland, France and Germany people are multi-lingual and open-minded, with world-wide connections.

Route de Lully 5C Tolochenaz, Vaud, 1131 Switzerland Lunaphore is a Swiss firm born with the vision of bringing spatial biology mainstream. Lunaphore develops innovative tissue staining platforms based on a cutting-edge technology, providing high quality results much faster than current techniques and aiming to automate some of the most sophisticated assays thanks to high-precision fluidics. We further enable digital pathology through the integration of imaging systems such as a microscope with sequential data extraction. Lunaphore has been repeatedly recognized for its innovation.

EPFL Innovation Park, building A Lausanne, VAUD, 1015 Switzerland Lunaphore is a Swiss firm born with the vision of bringing spatial biology mainstream. Lunaphore develops innovative tissue staining platforms based on a cutting-edge technology, providing high quality results much faster than current techniques and aiming to automate some of the most sophisticated assays thanks to high-precision fluidics. We further enable digital pathology through the integration of imaging systems such as a microscope with sequential data extraction. Lunaphore has been repeatedly recognized for its innovation.

Wagistrasse 13 Schlieren, 8952 Switzerland Microcaps enables precision microencapsulation at industrial scale – we develop novel formulations, R&D and production equipment to address current needs in pharmaceuticals, nutraceuticals and cosmetics.

Park InnovAARE Parkstrasse 1 Villigen, Aargau, 5234 Switzerland leadXpro is a lead discovery company focussing on membrane protein drug targets. We are committed to the application of biophysical and structure based methods for the discovery and optimization of next generation lead compounds. We capitalize on our knowledge and experience in membrane protein science from expression, solubilisation, nanoparticle formulation, purification to apply state of the art biophysical methods and structural biology. Core expertise includes X-ray crystallography and single particle electron microscopy (cryo EM).

Park Innovaare PSI Ost Warenannahme Villigen, aargau, 5232 Switzerland leadXpro is a lead discovery company focussing on membrane protein drug targets. We are committed to the application of biophysical and structure based methods for the discovery and optimization of next generation lead compounds. We capitalize on our knowledge and experience in membrane protein science from expression, solubilisation, nanoparticle formulation, purification to apply state of the art biophysical methods and structural biology. Core expertise includes X-ray crystallography and single particle electron microscopy (cryo EM).

PARK innovAARE Villigen, CH - 5234 Switzerland leadXpro is a lead discovery company focussing on membrane protein drug targets. We are committed to the application of biophysical and structure based methods for the discovery and optimization of next generation lead compounds. We capitalize on our knowledge and experience in membrane protein science from expression, solubilisation, nanoparticle formulation, purification to apply state of the art biophysical methods and structural biology. Core expertise includes X-ray crystallography and single particle electron microscopy (cryo EM).

Hofackerstrasse 40A Muttenz, BL, 4132 Switzerland LabForce AG is a Swiss company, founded in January 1999. We have the largest portfolio of antibodies, proteins and assay kits in Switzerland accomplished by innovative and best in class laboratory equipment in the field of cellular and molecular biology. For the diagnostics and pathology field we offer a wide range of excellent products. It is our goal to offer innovative products at fair prices to advance life science research and clinical diagnostics in Switzerland. Both customers from research and diagnostics, as well as patients shall be able to benefit. We look for the best possible solutions to meet the needs of our customers, to advise and support them professionally. The cornerstone for this is professional and competent support from the LabForce team. We aspire to achieve quality, high utility and maximum security. The focus is on our customer as a person and business partner with his or her goals and needs.

Baumackerstrasse 24 Zurich, 8050 Switzerland We represent more than 120 recognized suppliers and over 5 million life science products. We serve our customers in Switzerland and pride ourselves in working with most Swiss pharma & biotech companies and start-ups. With our experienced and motivated team, we aim to provide an efficient, reliable and professional service to our clients. LubioScience is proud to be a carbon neutral company and we compensate our full carbon footprint by investing in reforestation projects in Central Africa. LubioScience is a preferred supplier of the Swiss Biotech Association and a member of the Pivotal Scientific Limited Alliance. We offer a large collection of antibodies, ELISA kits, recombinant proteins, small molecule inhibitors, assay kits, oligos, peptides, molecular biology enzymes, gel doc systems and human blood products such as fresh & frozen leukopaks, whole blood, PBMCs, and much more.

Visp, VS, 3930, Switzerland Lonza provides advanced cell biology and cell engineering solutions that support customers from discovery to the clinic. We provide primary human cells, specialized media, advanced cell culture and transfection tools, supported by best-in-class quality, regulatory and scientific support. We support customers from basic research through preclinical and process development stages of small molecules, biologics, and cell and gene therapy programs in drug discovery and immuno-oncology. This includes immunogenicity prediction and assessment, manufacturability risk assessment and protein re-engineering.

Muenchensteinerstrasse 38 Basel CH-4002 Switzerland Lonza provides advanced cell biology and cell engineering solutions that support customers from discovery to the clinic. We provide primary human cells, specialized media, advanced cell culture and transfection tools, supported by best-in-class quality, regulatory and scientific support. We support customers from basic research through preclinical and process development stages of small molecules, biologics, and cell and gene therapy programs in drug discovery and immuno-oncology. This includes immunogenicity prediction and assessment, manufacturability risk assessment and protein re-engineering.

Hochbergerstrasse 60G Basel, 4057 Switzerland Lonza provides advanced cell biology and cell engineering solutions that support customers from discovery to the clinic. We provide primary human cells, specialized media, advanced cell culture and transfection tools, supported by best-in-class quality, regulatory and scientific support. We support customers from basic research through preclinical and process development stages of small molecules, biologics, and cell and gene therapy programs in drug discovery and immuno-oncology. This includes immunogenicity prediction and assessment, manufacturability risk assessment and protein re-engineering.

Hünenberg, ZG Switzerland Meditrial Europe offers clinical research services such as clinical trials, study management, data management, and biostatistics.

3rd Floor, Aeschenvorstadt 36, 4051 Basel, Switzerland

Wagistrasse 14 8952 Zürich-Schlieren Switzerland Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. We are developing a powerful new class of potent, specific and versatile small protein therapies called DARPins. We’re called Molecular Partners for a reason. Partnership is the core value that defines our company, our research and our product candidates. Our management team includes many of the scientists who discovered DARPins at the University of Zurich, and we continue to bring together talented individuals from many disciplines who share our commitment to developing breakthrough medicines for serious diseases. Our multi-benefit DARPins also function as a team, combining multiple small proteins with high-specificity, potency and versatility in one therapy. This approach allows us to design medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer and sight-threatening diseases and other disorders. We work with industry leaders in the fields of ophthalmology, oncology and immunology to leverage the full potential and reach of our multi-benefit DARPin platform, creating value for both sides of each partnership.

4 Route de la Corniche, Epalinges, VD 1066, CH MYMETICS: THE POWER OF A UNIQUE TECHNOLOGY TO DEVELOP NEXT-GENERATION PROPHYLACTIC VACCINES FOR INFECTIOUS DISEASES Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of 5 vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncytial Virus (RSV) vaccine. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Astellas Pharma, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB.

Solothurnerstrasse 259 CH-4600 Olten microsTECH offers a wide variety of microbiology, molecular biology and chemical analyses applicable to diverse industrial products in the area of agronomy, food, water, cosmetics, pharmaceuticals, environment, hygiene and many others. microsTECH activities includes research and development on proprietary projects and in response to customer needs, bringing innovative Life Science products to the benefit of the market.

Auberg 2, CH-4051 Basel Switzerland Medpace is a Full Service CRO and offers clinical development services including medical writings, biometrics, regulatory affairs and quality assurance. Also offered are Central Lab Services, Bio-Analytical, Biomarker Testing, BioSample Storage and Management, Long-term BioRepository, Core Lab Services, Imaging, and a Phase I Safety Clinic.

Gewerbestrasse 9 Zürich, 8132 Egg b. Switzerland MD Bioproducts, a division of MD Biosciences, supplies antibodies, cell culture reagents, ELISAs, proteins, and western blot kits.

Geffelbachstr. 6 Weil am Rhein, 79576 Germany Are you looking for a hands-on consultancy with a strategic vision for the D-A-CH region? MArS has years of experience in planning, filing and negotiating in the three D-A-CH countries and will lead you successfully with your product to your commercial objective! MArS Market Access & Pricing Strategy is a specialized consulting agency in the health care market access area with a special focus and experience in the following key areas: • Market access & pricing as well as global clinical development strategies from a health care payer's perspective in the various lifecycle stages of a product (Phase I-Phase IV) • German market access strategies and implementation for pharmaceuticals (AMNOG: German Law for Reforming the Market for Pharmaceuticals), medical devices including digital solutions (DiGA) • Swiss and Austrian market access strategies and implementation for parmaceuticals

Baslerstrasse 15 Rheinfelden , 4310 Switzerland MILAN ANALYTICA AG markets innovative biologicals and reagents for the development and manufacturing of pharmaceuticals, diagnostics, and for in vitro diagnosis. We are a key supplier of innovative biologicals and reagents to the diagnostic industry, the pharmaceutical industry, and to research laboratories.

Schützenstrasse 15 Balgach, 9436 Switzerland Microsynth (founded in 1989) is a European leading company in the area of DNA/RNA synthesis & analysis. The main activities are divided into following three business areas: 1. DNA/RNA SYNTHESIS DNA/RNA oligos & probes for R&D Antisense oligos (e.g. 2'-MOE or LNA-gapmers) for drug discovery DNA oligos for diagnostic applications Pilot scale synthesis (gram quantities) 2. DNA/RNA Analysis and Sequencing Sanger sequencing (incl. GMP sequencing) NGS sequencing (16S/ITS, RNA-Seq, etc.) PCR & qPCR & digital PCR Genotyping (GBS, cell lines, fragment analysis) DNA/RNA isolation 3. Contract Research/Outsourcing Assay development (e.g. IVD, liquid biopsy, etc.) Assay validation (e.g. validation of assays according to ICH guidelines) Biological tests (e.g. batch and release tests for drugs) Gene editing/gene therapy (e.g. CRISPR editing analysis, rAAV characterization) At its headquarter in Balgach close to St. Gallen Microsynth employs a staff of about 60 people. Microsynth has subsidiaries in Austria (Microsynth Austria GmbH) and Germany (Seqlab GmbH).

Thurgauerstrasse 130 Nycomed focuses on research and development of new therapeutics and offers contract manufacturing services.

Zürich, ZH Switzerland Nycomed focuses on research and development of new therapeutics and offers contract manufacturing services.

im Kirschgarten 30 New Brunswick Scientific offers optimization, cell expertise, computer-controlled strategies, and media formulation.

Eichenstrasse 22 Moehlin, CH-4313 Switzerland New Concept Lab (NCL) offers customized services to set up miniaturized assays on their proprietary IMAPlateTM 5RC96 and manufacture/develop products.

EPFL Innovation Park Chemin de la Dent d’Oche 1A 1024 Ecublens Switzerland We are scientists, working for scientists. Our belief is that each and every Biologist, Researcher and Physician should be able to explore and interact instantly with living cells without damaging them. We want to support the study of how living cells and bacteria work, evolve and react, thus building a solid base for new drugs and therapies, in order to enable breakthrough researches. This is the reason why we have developed the 3D Cell Explorer. Nanolive SA was incorporated in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, by Dr. Yann Cotte (CEO) and Dr. Fatih Toy (scientific advisor), following the completion of their respective PhD theses at the EPFL Microsystems laboratory of Prof. Christian Depeursinge (Head of Scientific Advisory Board). Late 2013, Dr. Andreas Kern and Dr. Sebastien Equis joined as Co-Founders to lead the software development and hardware construction respectively. Now the team is composed by eleven people from very different backgrounds and geographical origins: engineers, biologists, physicists and business. Dr. Lisa Pollaro was hired Spring 2014 as Communication Manager, Dr. Sorin Pop as Software Engineer for Image Processing and Nicolas Pignier as Mechanical Engineer. In 2015 the team expanded with Dr. Bastien Dalla Piazza who joined as head of scientific software, Álvaro Hernández Prieto, as head of embedded software and electronics, Sabine Bautz as operation specialist and Martina Biserni as R&D biologist.

Route Cantonale Lausanne, VD, 1015 Switzerland We are scientists, working for scientists. Our belief is that each and every Biologist, Researcher and Physician should be able to explore and interact instantly with living cells without damaging them. We want to support the study of how living cells and bacteria work, evolve and react, thus building a solid base for new drugs and therapies, in order to enable breakthrough researches. This is the reason why we have developed the 3D Cell Explorer. Nanolive SA was incorporated in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, by Dr. Yann Cotte (CEO) and Dr. Fatih Toy (scientific advisor), following the completion of their respective PhD theses at the EPFL Microsystems laboratory of Prof. Christian Depeursinge (Head of Scientific Advisory Board). Late 2013, Dr. Andreas Kern and Dr. Sebastien Equis joined as Co-Founders to lead the software development and hardware construction respectively. Now the team is composed by eleven people from very different backgrounds and geographical origins: engineers, biologists, physicists and business. Dr. Lisa Pollaro was hired Spring 2014 as Communication Manager, Dr. Sorin Pop as Software Engineer for Image Processing and Nicolas Pignier as Mechanical Engineer. In 2015 the team expanded with Dr. Bastien Dalla Piazza who joined as head of scientific software, Álvaro Hernández Prieto, as head of embedded software and electronics, Sabine Bautz as operation specialist and Martina Biserni as R&D biologist.

Hohlstrasse 515 Zurich, ZH, 8048 Switzerland NEBION is a Swiss biocuration and data integration company. Our expertise is in working with public and private transcriptomic data, from single-cell RNA-Seq to bulk tissue level (RNA-Seq and microarray). We provide collections of deeply curated, analysis-ready public data from different research areas, user-friendly software solutions (GENEVESTIGATOR®), and various expert services for exploratory, preclinical, and clinical research applications. Services include curation of gene expression datasets of choice, scouting services to identify relevant public studies, statistical consulting, and analysis services. Since July 2021, we are part of immunai. For more information please contact us at [email protected] or see our flyers.

EPFL Innovation Park building B Lausanne, Lausanne, 1015 Switzerland NIMGenetics provides advanced Genomics, Transcriptomics, Bioinformatics and cell line characterization services leveraging NGS, Single-cell and arrayCGH technologies and expertise to support Biopharma Industry, CROs and Academic Researchers. With the recent purchase of Gene Predictis SA in Switzerland, we also include molecular microbiology analyses, polygenic risk scores development, genotyping platform & possibility to design custom genotyping arrays and validated based on our DNAtek, in vitro diagnostics development and pharmacogenetics At NIMGenetics, we pride ourselves on the Speed, Competitive Pricing and Tailored R&D Services we can offer our partners. Furthermore, NIMGenetics becomes the first human genetic diagnosis company in the world to be certified as a B Corp, thus accrediting its generation of positive social and environmental impact through its activity. We integrate the most modern technologies with an internally developed pipeline for genomic analysis, applying our own bioinformatics tools, Artificial Intelligence (AI), Machine Learning (ML) and a large proprietary genetic database. In addition, NIMGenetics’ Clinical Relationships, in Leading Hospitals and Clinics, as well as our Repository of Clinical Genomics Data, makes us an especially interesting partner to support R&D projects from the Earliest Discovery and Preclinical Stages to Clinical Trials and Companion Diagnostics (CDx). NIMGenetics offers Research and Development Support Services such as: Whole-Genome and Exome Sequencing, Gene Expression (RNASeq, Single Cell and Methylation Profiling), DNA-Encoded Chemical Libraries, Genomics for Cell and Gene Therapy, Optical Genome Mapping, CRISPR Off-target Effects, Viral Vector Integration Analysis, Bioinformatics Analysis, a growing Genomics Database of under-represented populations from the Iberian Peninsula and Latin America, and tailor-made R&D Consultancy projects. We support researchers in Oncology, Rare Diseases, Regenerative Medicine, Neurodevelopmental and Neurodegenerative Diseases, Gynecology and Reproductive Medicine, GastrointestinaI, Microbiome and a wealth of other Research Areas.

Via alle Fornaci CH-6930 Bedano Switzerland Osmopharm is specialized in modified oral drug delivery systems.

Bahnhofstraße 3-5 Orgentis Chemical provides synthesis, validation, extraction, isolation and purification services for natural products.

Hertistrasse 1 Wallisellen, 8304 Switzerland Ortho-Analytic was founded in 1998 as a spin-off of the company "Burgerstein Vitamine" in Rapperswil (SG). The focus of the analysis at that time was the hair-mineral analysis, which was carefully set up by Birgit and Hugo Schurgast - both pharmacists. Over the years, the spectrum of orthomolecular medicine has expanded with additional disciplines in environmental medicine (drinking water and soil analysis). In the following years, the offer was again increased with stool diagnostics (cultivation method) and the comprehensive clarification of food intolerances. The acquisition by the Medisupport Group in 2015 set new trends in integrative medicine. Following this integration into the large Swiss laboratory network, the company invested in state-of-the-art analytics (Next Generation Sequencing, ICP-MS) and focussed on four main areas - functional stool diagnostics with microbiome analytics, trace elements and heavy metal analysis (hair mineral analysis), acquired mitochondriopathies and food intolerances , New highly efficient processes have been developed in cooperation with partner laboratories from the network network as well as local universities. These are offered as an integrative supplement to conventional medical parameters

Seidenstrasse 2 Lachen, 8853 Switzerland Octapharma develops and produces medicines based on human proteins from human cell lines and human plasma, sourced from our own plasma donation centers and other external sources.

Station 17 Lausanne, Vaud, 1004 Switzerland Orly Photonics is a laboratory instrumentation startup that uses proprietary light scattering technology to develop solutions for the life science industry. Our first product revolutionizes solubility measurement providing fast, reliable, accurate and sustainable (min-imum use of compounds) solubility measurements – as easy as nephelometry and as reliable as LC-MS.

Avenue de Sevelin 28 Lausanne, Vaud, 1004 Switzerland Orly Photonics is a laboratory instrumentation startup that uses proprietary light scattering technology to develop solutions for the life science industry. Our first product revolutionizes solubility measurement providing fast, reliable, accurate and sustainable (min-imum use of compounds) solubility measurements – as easy as nephelometry and as reliable as LC-MS.

Baselstrasse 109 Arlesheim, BL, 4144 Switzerland

Baarerstrasse 113a, 6300 Zug, Switzerland PSI CRO offers clinical research services including regulatory affairs, data management, pharmacovigilance, and quality assurance.

Zug, ZG Switzerland PSI CRO offers clinical research services including regulatory affairs, data management, pharmacovigilance, and quality assurance.

Baarerstrasse 94 CH-6300 Zug Switzerland PharmaSwiss offers regulatory services, manufacturing and pharmaceutical products.

Duerrenhuebelstrasse 9 We are PDS Pathology Data Systems Ltd., the company and people behind PathData®, ToxData® and ReproData®.

Chriesbaumstrasse 2 PFC Pharma Focus offers clinical research services such as phase I-IV clinical studies, study management, clinical monitoring, data management/analysis, regulatory affairs and quality assurance.

Passage 6, 4104 Oberwil (BL), Switzerland. We are a Swiss-headquartered research and consulting firm, specializing in scientific and analytical market access programs in the healthcare domain. phamax has developed a unique set of offerings, synergistically using our scientific and analytical skills and experience. Our clients are healthcare authorities, physician and patient associations and pharmaceutical companies. Founded in 2011, we provide services to our global clients through the global headquarters in Basel (Switzerland), our offices in Bangalore (India) and Singapore. Our team consists of physicians, sales and marketing experts, and data analytics professionals from diverse backgrounds, including NGOs, physician associations, hospital management, pharmaceutical companies and more. Our geographic focus is Emerging Markets, especially Africa, Middle East, Eastern Europe, CIS and Asia Pacific where we have executed more than 100 scientific and analytical projects in the last three years. phamax hosts the Focus Scientific Research Center ("FSRC"). Through this dedicated research platform we develop and implement scientific programs to improve general disease awareness and patients’ access to diagnosis, treatment and follow up. Through FSRC's activities we have established a broad international network of disease experts, universities, patient groups and healthcare authorities. By leveraging this network, we provide solutions to our clients that are pragmatic, actionable and local in nature. With more than 100 projects and programs developed and implemented over the last couple of years, we have the right solution for you and your organization.

Zugerstrasse 72 Progenitor International Research offers phase II-IV clinical research development, trial monitoring, project management, quality assurance, regulatory affairs, and data management services.

Steingasse 4 Progenitor International Research offers phase II-IV clinical research development, trial monitoring, project management, quality assurance, regulatory affairs, and data management services.

Route de la Corniche 4 Epalinges, CH-1066 Switzerland Preclin Biosystems AG offers a comprehensive in vivo preclinical testing platform for the identification and validation of lead candidate therapeutics. We specialize in preclinical models of chronic inflammatory and infectious diseases. We offer a fully customizable service ensuring your development goals are achieved. We provide the expertise to unravel a drugs mechanism of action, optimal route and regime of administration, and efficacy in defined disease indications.

44 Falknerstrasse Basel, BS, 4001 Switzerland ProductLife offers consulting and support services for life sciences including expertise in regulatory affairs and pharmacovigilance.

Baarerstrasse 135 CH-6300 Zug Switzerland Pharma Clinical provides clinical development services for pharmaceutical , bio-technology and medical devices companies.

Zug, ZG Switzerland Pharma Clinical provides clinical development services for pharmaceutical , bio-technology and medical devices companies.

Route du Simplon 22 Sochinaz offers cytotoxic API production, chiral synthesis, high pressure reactions, high potency compounds, and manufacturing services.

Riedmattstrasse 9 PolyGene offers transgenic rat model development and gene targeting in mice.

Hegenheimermattweg 125 Polyphor offers target validation, assay development, protein expression, hit identification, hit to lead, lead optimization, and clinical development expertise.

Via della Posta 10 Pharmasafe, through it's partnering laboratories, provides a wide range of services including toxicology, pharmacology, ADME, and custom synthesis services.

4 Weidenmattweg Läufelfingen, BL, 4448 Switzerland PeptART Bioscience GmbH is a Swiss chemical manufacturing company located near Basel. Since 2008 our group has been manufacturing high quality products, on schedule, meeting industry standards in quality, occupational and environmental safety. The product range includes pseudoproline building blocks, amino acid derivatives, peptides and related products from the field of peptide chemistry. We sell our products around the world. We are experts in the field of peptide synthesis and their derivatives. We focus on delivering highest quality at a competitive price. Our fully equipped production facility provides the infrastructure to handle the entire manufacturing process of amino acids and peptides including the potential for future growth and development. As a small company, we make sure that our production process is efficient with short turnaround times. Since 2015 we operate under the name PeptART Bioscience GmbH. We comply with ISO 9001:2015 and have our facility regularly inspected and approved by the Swiss Association for Quality and Management Systems (SQS) and various API manufacturers, qualifying us as a supplier of GMP starting materials.

Duerrenhuebelstrasse 9 CH-4133 Pratteln, Basel, Switzerland PDS Life Sciences provides the all-encompassing services to get your preclinical data SEND-ready. PDS aggregates and translates data to produce SEND export files, including the Study Data Reviewer's Guide as recommended by the FDA.

Am Paradiesrain 14 Postfach 427 Allschwil , CH-4123 Switzerland Provitro offers immunohistochemistry, tissue microarray, cell culture, mutation analysis, hybridization, sequencing, cytokines, stem cell and culture media services. Provitro is recognizing the importance of biospecimens as essential tools for drug and diagnostic development by becoming a worldwide provider of high quality, well-characterized human tissue samples to scientists in pharmaceutical and biotechnology industries. Provitro’s well-established human tissue heritage contains samples not only from a wide range of different tumor entities but also from a broad spectrum of inflammatory or degenerative diseases. Matched pairs of normal/tumor tissue or primary/relapsed tumor tissue and other combinations help to enhance the selection of most promising drug candidates and development of new in vitro diagnostic products. acovos AG manages all orders outside EEA

Bonstettenstrasse 7 Uster, 8610 Switzerland Qinos GmbH is providing consulting services to the Pharma, Biotec and Cell&Gene Industry, mainly focussing on Project Management and Quality Management.

EPFL, Innovation Park Building G Lausanne, Vaud, 1015 Switzerland QGel develops and commercializes biotechnology products of therapeutic relevance to improve methods for research and diagnostics in the field of life science, including 3D cell culture extracellular matrices.

Benkenstrasse 254 Witterswil, CH–4108 Switzerland ROOTec bioactives specializes in the production of phytochemical compounds.

Witterswil, SO, 4108 Switzerland ROOTec bioactives specializes in the production of phytochemical compounds.

Pharmaceutical Laboratories 6928 Manno (Lugano) Switzerland Rivopharm offers development and manufacture of pharmaceutical products in the generic field.

Z.I. du Vivier 22 CH-1690 Villaz-St-Pierre Switzerland A new dimension to biomedical engineering regenHU is an innovative biomedical company located in Switzerland, belonging to the CPA Group SA. regenHU acts as a biosystem architect exploiting new biomanufacturing solutions in order to respond to the emerging challenges facing the biomedical industry. regenHU benefits from exclusive patented technologies resulting from many years of research within international universities and partners.

Villaz-Saint-Pierre, FR, 1690 Switzerland A new dimension to biomedical engineering regenHU is an innovative biomedical company located in Switzerland, belonging to the CPA Group SA. regenHU acts as a biosystem architect exploiting new biomanufacturing solutions in order to respond to the emerging challenges facing the biomedical industry. regenHU benefits from exclusive patented technologies resulting from many years of research within international universities and partners.

Industriestrasse 47, Postfach 7461 Zug, Zug, 6302 Switzerland Remap Consulting is a specialist pharmaceutical and biotech pricing and market access consultancy We work with people responsible for the pricing and reimbursement of products who are asking: -What is the optimal price for our product? -Have we got the right evidence to support pricing and market access at launch? -Do we have the right training capabilities in house to secure pricing and reimbursement? -What is the pricing and market access potential for our business development opportunities?

Seefeldstrasse 69 Zurich, 8008 Switzerland Regulatory Scientific & Health Solutions (R-S-S) supports the biopharmaceutical industry using former regulatory experts with the added advantage of executing and delivering a number of key services including: (i) statistical analyses and trial design for multiple disease areas (our experts have assessed in nearly every conceivable disease area), and phases of drug development. (ii) Health economic modelling and HTA reimbursement across markets supporting Market Access needs, including PIMS , EAMS schemes and PRIME (EMA); Systematic Literature Review and Network Meta-Analyses for Reimbursement. (iii) Regulatory consulting for FDA/EMA including response to questions and dossier preparation. (iv) Data management services - specializing in early (Phase I-II), clinical pharmacology data management and analyses using EDC systems.

Oberer Steisteg 18,Po Box 148, 6430 Schwyz, Switzerland Randox Laboratories, through its business units, offer diagnostic services, life science reagents, biomarker testing services, antibody/drug assay development, and toxicology services.

60A Speicherstrasse Teufen, AR, 9053 Switzerland RC TRITEC specializes in radioisotopes. With nearly 60 years of experience in the safe handling of large quantities of tritium gas and over 1 million Ci tritium processed, we have acquired a vast know-how in radiochemistry. We deliver 3H-labeling solutions for the pharmaceutical, CRO, agrochemical, food and cosmetic care industry, using state-of-the-art technologies. Our services reach from synthesis, purification and analysis of tritium labelled compounds over to storage, stability testing and consultation of labeling strategies.

Muenchensteinerstrasse 38 CH-4002, Basel, Switzerland Switzerland Scientist.com is the world’s largest marketplace for medical research. We help pharmaceutical scientists discover life-saving medicines in less time and at lower cost. Our mission is to make it possible to cure all human disease by 2050. By connecting scientists and enabling them to exchange ideas and transact seamlessly online, Scientist.com is speeding up and reducing the cost of medical research. We were founded in 2007, launched our first research outsourcing marketplace in 2008 and built our first enterprise marketplace for Pfizer in 2009. Today, we operate enterprise marketplaces for 24 of the world’s top 30 pharmaceutical companies, 100+ biotechnology companies and the US National Institutes of Health (NIH).

P.O.Box 327 Marly Marly, Fribourg CH-1723 Switzerland Swant supplies antibodies to Calbindin D-28k, Calretinin, Parvalbumin, Calmodulin and to Na2+-Ca2+-exchangers, Ca2+ channels subunits, Ca2+ pumps, Neurotransmitters, as well as their respective antigens.

2 Fabrikweg Brüttisellen, ZH, 8306 Switzerland SCANCO Medical supplies microCT systems and offers scanning, analysis and consulting services for a wide range of applications.

190 Winterthurerstrasse Zürich, ZH, 8057 Switzerland

Neuchâtel, NE Switzerland Skin Test Institute specialises in in vivo efficacy and safety testing of cosmetic products, cosmetic ingredients, and nutritional complements for skin. Both bioengineering and sensory evaluation studies are performed with different volunteer groups (e.g. ethnical, age or skin type).

Gouttes d'Or 30 2008 Neuchâtel Switzerland Skin Test Institute specialises in in vivo efficacy and safety testing of cosmetic products, cosmetic ingredients, and nutritional complements for skin. Both bioengineering and sensory evaluation studies are performed with different volunteer groups (e.g. ethnical, age or skin type).

Güterstrasse 82, Bau 3 Pratteln 4133 Switzerland SynphaBase provides chemical routes, APIs, bioconjugates, libraries, biologics, and scaffolds.

Switzerland The Paul Scherrer Institute is a multi-disciplinary research centre for natural sciences and technology.

5232 Villigen PSI, Switzerland The Paul Scherrer Institute is a multi-disciplinary research centre for natural sciences and technology.

Obere Wiltisgasse 48, Küsnacht, , 8700 Switzerland SanaSweet was founded in 2004. Together with our competent partners we are specialising in international distribution and marketing of ingredients for the food, animal feed, pharmaceutical OTC and cosmetics industries. We have established an excellent position in the market and are one of the leading distributors for Sweeteners and Vitamins. Our international network system enables us to provide fast and creative sourcing and logistic solutions for our customers. Through our local office in China we can monitor and guarantee a continuous quality system of our manufacturing partners. Our strength is to supply high quality material, fast and efficient service and implement the requirements and suggestions of our customers. A strong relationship with our partners is the key to our success.

Obere Wiltisgasse 48, 8700 Küsnacht, Switzerland SanaSweet was founded in 2004. Together with our competent partners we are specialising in international distribution and marketing of ingredients for the food, animal feed, pharmaceutical OTC and cosmetics industries. We have established an excellent position in the market and are one of the leading distributors for Sweeteners and Vitamins. Our international network system enables us to provide fast and creative sourcing and logistic solutions for our customers. Through our local office in China we can monitor and guarantee a continuous quality system of our manufacturing partners. Our strength is to supply high quality material, fast and efficient service and implement the requirements and suggestions of our customers. A strong relationship with our partners is the key to our success.

Zofingen, Aktiengesellschaft Switzerland Siegfried Group offers API services, chemical reactions, regulatory services, and inhalation products.

Untere Bruehlstrasse 4 Siegfried Group offers API services, chemical reactions, regulatory services, and inhalation products.

Switzerland Scientific Timesharing Systems provides consulting for informatics, education solutions, gene therapy, and stem call biology.

Dielsdorf, ZH Switzerland Senn Chemicals offers reagents, building blocks, libraries, analytical standards, process scale-up, and cGMP production.

Guido Senn-Strasse 1 Senn Chemicals offers reagents, building blocks, libraries, analytical standards, process scale-up, and cGMP production.

Walzmühlestrasse 48 CH-8500 Frauenfeld Switzerland Songwon is the second largest manufacturer of polymer stabilizers in the world. Our vision is to be Salient in Additives and become the supplier of choice for polymer additives through our continued commitment to providing better quality, better service and better value to our customers. We are firmly focused on delivering growth by anticipating the needs and desires of our customers and by aspiring to be a leading example in additives technology development.

Husenstrasse 35 Kirchberg/SG 9533 Switzerland Swiss Caps offers analytical services, dosage form development, drug delivery systems, manufacturing, packaging, and scale-up.

11A Grabenstrasse Schlieren, ZH, 8952 Switzerland Synergene Biotech is a Swiss molecular biology service company that originated in 2001 as a spin-off of the University of Zurich. Synergene is an active member of the Bio-Technopark Schlieren that was founded in 2003. Philosphy We focus our activities on strong personal relationships with our customers with the goal of optimising each molecular biology project as a whole. Thus, we take the customer's lab workflow into account when designing a project as this is the only way to optimise any project in terms of time and finances. We also help customers to reduce their own sample preparation costs and show them how to implement their own sequencing data management systems.

Grabenstrasse 11a CH-8952 Schlieren Switzerland Synergene Biotech is a Swiss molecular biology service company that originated in 2001 as a spin-off of the University of Zurich. Synergene is an active member of the Bio-Technopark Schlieren that was founded in 2003. Philosphy We focus our activities on strong personal relationships with our customers with the goal of optimising each molecular biology project as a whole. Thus, we take the customer's lab workflow into account when designing a project as this is the only way to optimise any project in terms of time and finances. We also help customers to reduce their own sample preparation costs and show them how to implement their own sequencing data management systems.

Allschwil, BL, 4123 Switzerland Swiss Pharma Contract offers clinical research services including bioequivalence and bioavailability studies, proof of concept studies, and biostatistics with expertise in neurology, cardiology, rheumatology, oncology, and immunology.

Lettenweg 118, CH-4123 Allschwil, Switzerland Swiss Pharma Contract offers clinical research services including bioequivalence and bioavailability studies, proof of concept studies, and biostatistics with expertise in neurology, cardiology, rheumatology, oncology, and immunology.

Sternenfeldstrasse 14 Birsfelden, BL, 4127 Switzerland

Sternenfeldstrasse 14 Birsfelden, 4127 Switzerland

Sternenfeldstarsse 14 Birsfelden, 4127 Switzerland

Kreuzstrasse 2 Allschwil, 4123 Switzerland Since its founding in 1943, the Swiss Tropical Institute (STI), now Swiss Tropical and Public Health Institute (Swiss TPH) has become a world-renowned Institution for teaching, research and services in the field of International Health Development. The multi- and cross-disciplinary activities and experience of scientific laboratory studies, conceptual clinical work and practical transfer of technical expertise to health system planning and programmes in local, national and partner countries are the building blocks of our success. Today over 700 colleagues from 40 nations work worldwide for the Swiss TPH in research, teaching and service provision with the single goal to facilitate and contribute to health development worldwide with a strong focus on low and middle income countries. We are determined to improve public health, strengthen health systems and reduce poverty through partnerships, mutual learning, contribution and achievement. As an associate institute of the University of Basel, the Swiss TPH takes part in teaching within the medical, philosophy, natural sciences, and historical philosophy faculties, as well as is engaged in post-graduate education and advanced training on national and international levels. The Swiss TPH is a public organisation of the Basel-City region receiving 19% of its core budget from Basel-City and Basel-Land (12%) and the Swiss federal government (7%). The remaining contributions (81%) are received through competitive fundraising and the earnings of our service departments.

7 Rütistrasse Haag, SG, 9469 Switzerland Sulzer is a global leader in fluid engineering. We specialize in pumping, agitation, mixing, separation and purification technologies for fluids of all types. Our customers benefit from our commitment to innovation, performance and quality and from our responsive network of 180 world-class manufacturing facilities and service centers across the globe. Sulzer has been headquartered in Winterthur, Switzerland, since 1834.

12 Grundstrasse Rotkreuz ZG, ZG, 6343 Switzerland Sulzer is a global leader in fluid engineering. We specialize in pumping, agitation, mixing, separation and purification technologies for fluids of all types. Our customers benefit from our commitment to innovation, performance and quality and from our responsive network of 180 world-class manufacturing facilities and service centers across the globe. Sulzer has been headquartered in Winterthur, Switzerland, since 1834.

Neuwiesenstrasse 15 8401 Winterthur Switzerland Sulzer holds leading positions in its key markets: oil and gas, power, and water. We are dedicated to creating long-term value, providing sustainable solutions, and strengthening the competitive position of our customers.

StartLab, Biopole, Building SE-B Route de la Corniche 5 Epalinges, Vaud, 1066 Switzerland At SEED Biosciences we make DISPENCELL, an automated laboratory instrument designed for fast, easy and gentle single cell isolation. Designed by scientists for scientists, DISPENCELL has been thought to quickly integrate your lab routine in a plug-and-play approach. Flexible and effortless, DISPENCELL operates equally under sterile conditions in a culture hood, or on a simple benchtop.

51 Hochstrasse Basel, BS, 4053 Switzerland

Kemptpark 18 Kemptthal, Zurich, 8310 Switzerland Synple Chem utilises a unique digital platform that consists of screenable, novel, diverse, and tractable chemical space, which is entirely accessible 'on-demand' using Synple's automated cartridge-based synthesis technology. The combination of Synple-trained models and filters for creation of the chemical space, along with Synple's pre-optimised automated reaction protocols ensures that molecules in the chemical space can be rapidly prepared in a highly predictable, automated manner. Machines and cartridges are available for in-house synthesis or molecules of interest can be ordered for synthesis by the Synple team, ensuring that all researcher have the opportunity to accelerate their discoveries.

1 Nordring Aesch, BL, 4147 Switzerland SOTAX leads the way in the development and manufacture of high-quality pharmaceutical testing equipment and associated services. Our equipment is used worldwide in the development and production processes of our customers and the pharmaceutical and science industries. SOTAX develops, produces and markets system solutions for pharmaceutical testing and does so in close cooperation with pharmaceutical and scientific partners. Our extensive market and process know-how enables us to meet our customers’ requirements and comply with the key directives relevant to them. We are also open to cooperation with new industries. SOTAX is a leading independent company for pharmaceutical testing equipment. The company owes its independence to its sustained economic success. The SOTAX Group is a global success story and has subsidiaries around the world that are familiar with local needs and practices. We maintain our competitive edge by excelling in flexibility, performance, quality and safety.

24 avenue de Bâle Saint Louis, 68300 France SOTAX leads the way in the development and manufacture of high-quality pharmaceutical testing equipment and associated services. Our equipment is used worldwide in the development and production processes of our customers and the pharmaceutical and science industries. SOTAX develops, produces and markets system solutions for pharmaceutical testing and does so in close cooperation with pharmaceutical and scientific partners. Our extensive market and process know-how enables us to meet our customers’ requirements and comply with the key directives relevant to them. We are also open to cooperation with new industries. SOTAX is a leading independent company for pharmaceutical testing equipment. The company owes its independence to its sustained economic success. The SOTAX Group is a global success story and has subsidiaries around the world that are familiar with local needs and practices. We maintain our competitive edge by excelling in flexibility, performance, quality and safety.

Wallbrunnstr. 24 Lörrach, 79539 Germany SOTAX leads the way in the development and manufacture of high-quality pharmaceutical testing equipment and associated services. Our equipment is used worldwide in the development and production processes of our customers and the pharmaceutical and science industries. SOTAX develops, produces and markets system solutions for pharmaceutical testing and does so in close cooperation with pharmaceutical and scientific partners. Our extensive market and process know-how enables us to meet our customers’ requirements and comply with the key directives relevant to them. We are also open to cooperation with new industries. SOTAX is a leading independent company for pharmaceutical testing equipment. The company owes its independence to its sustained economic success. The SOTAX Group is a global success story and has subsidiaries around the world that are familiar with local needs and practices. We maintain our competitive edge by excelling in flexibility, performance, quality and safety.

112 Seestrasse Seestrasse 112 Kilchberg, ZH, 8802 Switzerland

Technology Park Basel Hochbergerstrasse 60C Basel, Basel-Stadt, CH-4057 Switzerland We are committed to protecting the wellness and safety of consumers and the environment. Our part in this goal is to support the design of intelligent, effective, and safer products by providing integrated solutions to test and assess individual ingredients and formulations. https://saferworldbydesign.com/

Römerpark 2 Kaiseraugst, AG, 4303 Switzerland Solvias offers a broad range of scientific analytical services including but not limited to method development and validation for physical chemistry and bioanalytical methods, routine testing under GMP and ISO, stability studies and storage, microbiology, bioassays, protein characterization for the CMC part of your dossier, screening, DNA sequencing, qPCR, extractables and leachables studies, trace analysis, solid state analysis, API and custom chemical synthesis services sich as synthesis, catalysis and ligand production. We serve the pharmaceutical and biopharmaceutical market as well as the cell and gene therapies space. We Also work with medical devices. We operate out of one hub in the Basel area in Switzerland.

Mattenstrasse 24 WRO1047-3 Basel city, Basel, 4058 Switzerland SpiroChem is a Swiss CRO, headquartered in Basel, Switzerland. SpiroChem is covering the entire discovery chemistry value chain, from proprietary screening libraries (high-sp3 fragments, covalent fragments, macrocycles) to design (FBDD, SBDD, CADD) and synthesis of bioactive molecules (Medicinal Chemistry, Medicinal Chemistry-Enabling platforms), all the way to early CMC (Route-Scouting). With cutting-edge know-how in drug design and proprietary process chemistry technologies, SpiroChem offers innovative chemical solutions to pharmaceutical, agrochemical, and life science companies of all sizes. Operating from Basel, Switzerland, our clients are located worldwide. Discover more: https://spirochem.com/about-us

WRO1047-3, Rosental area Mattenstrasse 24 Basel, BS, 4058 Switzerland SpiroChem is a Swiss CRO, headquartered in Basel, Switzerland. SpiroChem is covering the entire discovery chemistry value chain, from proprietary screening libraries (high-sp3 fragments, covalent fragments, macrocycles) to design (FBDD, SBDD, CADD) and synthesis of bioactive molecules (Medicinal Chemistry, Medicinal Chemistry-Enabling platforms), all the way to early CMC (Route-Scouting). With cutting-edge know-how in drug design and proprietary process chemistry technologies, SpiroChem offers innovative chemical solutions to pharmaceutical, agrochemical, and life science companies of all sizes. Operating from Basel, Switzerland, our clients are located worldwide. Discover more: https://spirochem.com/about-us

14 Lagerstrasse Dübendorf, ZH, 8600 Switzerland SuSoS AG specializes in the fields of surface modification and characterization.

Gewerbestrasse 24, 3th Floor Allschwil, Basel-Land, 4123 Switzerland We provide services in hit finding targeting RNA. We use Nuclear Magnetic Resonance (NMR), machine learning (ML), cheminformatics and fragment based screening (FBS) to find small molecules targeting RNA. We provide NMR services to understand ligand/RNA interaction and ligand/proteins interaction list of services includes: RNA sourcing RNA target selection RNA construct design and validation by NMR Fragment screening 19F library Fragment screening 1H library Follow-up selection from archive (based on hits) Test compounds for binding Resonance assignment 2D TOCSY / NH Binding site mapping Kd determination, titration 2D TOCSY feasibility study INPHARMA pharmacophore mapping (inlcude list of inter ligand NOEs assignment ligand spectra and IL-NOEs) INPHARMA docking mode (include docking poses of ligands ranking of the docking poses simulation of INPHARMA spectra using relaxation matrix calculations) screening paramagnetic library 2nd-site screening (19F lib) structural information, design linker DG,DH, DS, Kd Method development DG,DH, DS per ligand

Gewerbestrasse 24, 3th Floor Allschwil, BL, 4123 Switzerland We provide services in hit finding targeting RNA. We use Nuclear Magnetic Resonance (NMR), machine learning (ML), cheminformatics and fragment based screening (FBS) to find small molecules targeting RNA. We provide NMR services to understand ligand/RNA interaction and ligand/proteins interaction list of services includes: RNA sourcing RNA target selection RNA construct design and validation by NMR Fragment screening 19F library Fragment screening 1H library Follow-up selection from archive (based on hits) Test compounds for binding Resonance assignment 2D TOCSY / NH Binding site mapping Kd determination, titration 2D TOCSY feasibility study INPHARMA pharmacophore mapping (inlcude list of inter ligand NOEs assignment ligand spectra and IL-NOEs) INPHARMA docking mode (include docking poses of ligands ranking of the docking poses simulation of INPHARMA spectra using relaxation matrix calculations) screening paramagnetic library 2nd-site screening (19F lib) structural information, design linker DG,DH, DS, Kd Method development DG,DH, DS per ligand

Industriestrasse 12 Sursee, Lucern, CH-6210 Switzerland Scailyte AG is a spin-off from ETH Zurich combining single-cell technologies, high-quality clinical datasets and machine learning methods to identify ultra-sensitive biomarkers in oncology and immunology. We have developed ScaiVision - a best-in-class single-cell data analysis platform for biomarker discovery and AI-driven clinical applications. ScaiVision can analyse various single-cell data types (DNA-/RNA-/TCR-/BCR-seq, CITE-seq, proteomics, mass & flow cytometry ) in combination with physiological and clinical parameters. We have multiple patent-pedning biomarkers and a growing pipeline of discovery and co-development projects with leading medical Universities and biotech companies. For more information, go to https://scailyte.com and connect via @LinkedIn

12 Industriestrasse Sursee, LU, 6210 Switzerland Scailyte AG is a spin-off from ETH Zurich combining single-cell technologies, high-quality clinical datasets and machine learning methods to identify ultra-sensitive biomarkers in oncology and immunology. We have developed ScaiVision - a best-in-class single-cell data analysis platform for biomarker discovery and AI-driven clinical applications. ScaiVision can analyse various single-cell data types (DNA-/RNA-/TCR-/BCR-seq, CITE-seq, proteomics, mass & flow cytometry ) in combination with physiological and clinical parameters. We have multiple patent-pedning biomarkers and a growing pipeline of discovery and co-development projects with leading medical Universities and biotech companies. For more information, go to https://scailyte.com and connect via @LinkedIn

WSJ-500.1.101, Lichtstrasse 35 Basel, 4056 Switzerland Scailyte AG is a spin-off from ETH Zurich combining single-cell technologies, high-quality clinical datasets and machine learning methods to identify ultra-sensitive biomarkers in oncology and immunology. We have developed ScaiVision - a best-in-class single-cell data analysis platform for biomarker discovery and AI-driven clinical applications. ScaiVision can analyse various single-cell data types (DNA-/RNA-/TCR-/BCR-seq, CITE-seq, proteomics, mass & flow cytometry ) in combination with physiological and clinical parameters. We have multiple patent-pedning biomarkers and a growing pipeline of discovery and co-development projects with leading medical Universities and biotech companies. For more information, go to https://scailyte.com and connect via @LinkedIn

Lichtstrasse 35 4056, Basel, 4056 Switzerland Scailyte AG is a spin-off from ETH Zurich combining single-cell technologies, high-quality clinical datasets and machine learning methods to identify ultra-sensitive biomarkers in oncology and immunology. We have developed ScaiVision - a best-in-class single-cell data analysis platform for biomarker discovery and AI-driven clinical applications. ScaiVision can analyse various single-cell data types (DNA-/RNA-/TCR-/BCR-seq, CITE-seq, proteomics, mass & flow cytometry ) in combination with physiological and clinical parameters. We have multiple patent-pedning biomarkers and a growing pipeline of discovery and co-development projects with leading medical Universities and biotech companies. For more information, go to https://scailyte.com and connect via @LinkedIn

Hofackerstrasse 40A Muttenz, Basel-Land, 4132 Switzerland

Kägenstrasse 18 Reinach, 4153 Switzerland bioanalytical services for small and large molecules

Sternenfeldstrass 14 Birsfelden, 4127 Switzerland SGS helps pharmaceutical, biopharmaceutical, and medical device companies by providing services along the entire drug development pathway. As a global contract research organization, our global Health Science team provides integrated solutions from preclinical activities to Phase I-IV clinical trials, bioanalytical, pharmaceutical development, biologics characterization, biosafety, and quality control testing of small and large molecules, raw materials, containers and finished products. In an ever-changing world, with technological change reaching breakneck speed, SGS helps navigate the sometimes complex process to successfully deliver high quality, safe and medical devices to market. SGS boasts a wealth of global health science expertise. We will support you every step of the way as you deliver first-class, fully compliant biopharmaceutical, pharmaceutical and medical device products. Our expert staff is trained to the highest standards and has an in-depth knowledge of their fields and your business needs.

c/o Kellerhals Carrard Basel KlG Henric Petri-Str. 35 Basel, 4051 Switzerland STEMCELL Technologies provides products and services to support life sciences research, including human primary cells, specialized culture media, cell separation technologies, instruments, accessories, and scientific services. Find out more about our featured tools and resources Buy One Bottle of eTeSR™ and Receive a Free Bottle of CloneR™2* Improve the genetic stability of your human pluripotent stem cell (hPSC) cultures when performing routine single-cell passaging by using eTeSR™, an enhanced feeder-free culture medium. Specifically developed for single-cell applications, which typically involve shorter passaging schedules at high density, eTeSR™ can be used for routine maintenance, gene editing, or cloning workflows. Until May 31, 2024, you can now save on your single-cell hPSC research needs! To take advantage of this offer, request a quote on scientist.com and reference “eTeSR. In the meantime, you can explore the data that showcase how eTeSR™ improves the genetic stability of hPSC cultures maintained long-term using single-cell passaging. *Offer is valid for EU and NA regions only. Please contact your Sales representative or Product & Scientific Support at [email protected] for further information. About STEMCELL Technologies Inc. Get the Cells You Need from STEMCELL Technologies Driven by science and a passion for quality, STEMCELL Technologies supports life sciences research with more than 2500 specialized cell culture media, cell separation technologies, instruments, accessory products, and scientific services. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our products and services. At STEMCELL, we are dedicated to improving lives through advanced knowledge and scientific discovery, our commitment to fostering diversity and inclusion in STEM, and our investments in sustainability, community, and social responsibility. We are a company of Scientists Helping Scientists, and we care deeply about making the world a better place. About Our Offerings on Scientist.com Partner with the Right Primary Cell Supplier The success of your primary cell-based research depends on partnering with the right cell supplier. Having a dependable source of quality human primary cells that consistently meet your requirements can reduce experimental uncertainty and increase confidence in your results. STEMCELL’s human primary cell products are ethically sourced using Informed Consent Forms (ICFs) and protocols approved by either an Institutional Review Board (IRB), the Food and Drug Administration (FDA), the U.S. Department of Health and Human Services, and/or an equivalent regulatory authority. You can choose human primary cells based on donor specifications that include sex, age range, BMI range, ethnicity, blood type, smoker status, and more. Ensure you get the cells you need by placing multiple lots on hold for testing, and save time by using our characterization services, including high-resolution HLA typing (Class I and II), CMV status, EBV status, vaccination status, genotyping, phenotyping, and FACS analysis. Visit STEMCELL.com/PrimaryCells to learn more about human primary cells. Our portfolio* of ready-to-use, fresh or cryopreserved human primary cells from blood, cord blood, and bone marrow includes: Induced pluripotent stem cells Leukopaks LRS cones Mobilized peripheral blood Mononuclear cells (MNCs) Purified immune cells (e.g. NK, T cells, monocytes, B cells, macrophages, pan-T cells, dendritic cells) Serum-free cultured immune cell subsets (e.g. dendritic cells, macrophages) Hematopoietic stem and progenitor cells (e.g. CD34+ cells) Stromal cells (MSCs) STEMCELL also offers a wide range of disease-state samples and customizations for your needs. Schedule the collection and delivery of fresh cells* at your convenience, or reserve multiple lots of cryopreserved cells while you test them in your assays. If you have a question about ready-to-use fresh or frozen human primary cells from STEMCELL, please contact us. Your Contract Research Organization Partner Contract Assay Services (CAS) is a contract research organization (CRO) established within STEMCELL that performs assay services based on in vitro and in vivo primary cell assays. The use of primary cells in our in vitro assays can provide more physiologically relevant results than cell line-based assays. We specialize in the various applications of the in vitro hematopoietic colony-forming unit (CFU) assay, also known as the colony-forming cell (CFC) assay. In addition, we perform standardized and customized immunological and mesenchymal cell-based assays for use at a variety of points in the drug discovery and development pathway. We combine STEMCELL Technologies' specialized media and reagents with the practical knowledge of our scientists, to provide both standardized and customized assay services that help researchers obtain the high-quality data they require. To explore our full product listing or educational and scientific resources, visit www.stemcell.com. *Certain products are only available in select territories. Please contact your sales representative or the Product & Scientific Support team at [email protected] for further information. STEMCELL employs over 1,400 people worldwide and operates in nine countries. Three locations are in North America: our headquarters in Vancouver, Canada, a sales support office in Cambridge, MA, and a distribution center in Seattle, WA. As well as three European offices, we have five Asia Pacific offices to serve our customers. We provide direct sales and support in more than 30 countries throughout North America, Europe, Asia, and Australia, as well as through a network of distributors. For full contact information worldwide, visit our locations page for specific details.

Wagistrasse 23 8952 Schlieren, Switzerland The Genetics Company provides services for neurodegenerative diseases, antibodies, protein species, and ELISA test kits.

Zollstrasse 7 Trasadingen, CH-8219 Switzerland TPP, the color Yellow is the Swiss Brand that belongs to the international circle of brands for high quality plastic disposable products for tissue culture and laboratory technology since 1966. Field of applications of TPP products can be among others found in biotechnology, pharmaceutical, institutes and universities as well as in research institutes and others. TPP is constantly active in the research and development of new products as well as improvements on treatment of the cell growth areas. Also TPP aims to receive a leading role in the area of hygienically standards in production. These are TPP's engagements towards the end-users receipt of best results. TPP home of tissue culture.

Baar, ZG Switzerland Trichema offers contract manufacting for cosmetics, pharmaceuticals, OTC, medical products, household products, technical products and aerosols.

Magdalenenstrasse 9 Zurich, Zurich, 8050 Switzerland Magnetic particles and magnetic reagents for chemical synthesis and biomolecule separation/purification.

9B Route de la Corniche Epalinges, VD, 1066 Switzerland The mission of TCMetrix is to provide researchers in clinical and basic sciences worldwide with innovative, state-of-the-art T cell monitoring reagents of high quality, to meet the increasing needs for conclusive and comprehensive MHC class I and class II T cell monitoring and analysis. Because blood samples are precious and the value of T cell analysis critically depends on the quality of the reagents used, TCMetrix is committed to provide only highest quality reagents. Each reagent will be delivered with quality control data demonstrating the biochemical purity and integrity of the reagent and whenever possible with T cell staining data. In addition, each shipment will contain a product data sheet providing information on the stability of the reagent, the recommended storage and CD4+ and CD8+ T cell staining conditions. While the primary focus is on the production of reagents for quantification and analysis of tumor antigen-specific T cell responses, TCMetrix endeavours to extend the scope of its services to other disorders, such as infectious diseases, autoimmunity and allergies. Because blood samples usually are small, T cell responses diverse and of low frequencies, especially tumor antigen specific ones, TCMetrix is developing parallel and sequential combinatorial staining strategies that use reversible and irreversible MHC-peptide multimers and antibodies and allow phenotypic and functional analysis on multiple CD8+ and/or CD4+ T cell specificities. A major challenge for TCMetrix is to provide reagents and services that allow integral analysis of antigen-specific T cells for a better understanding of their diverse roles in adaptive immunity, in particular in cancer-specific immune reactions. TCMetrix endorses the MIATA reporting framework and strongly encourages its adoption.

Fanghofli 14, CH-6014 Littau-Luzern, Switzerland Tosoh offers ceramic materials, fine chemicals, fluoro compounds, organic intermediates, and polymer products and services.

Grabenstrasse 8 Nänikon, 8606 Switzerland Trina Bioreactives supplies antigen, antibodies, serum, and plasma products for use in development and manufacture of diagnostic kits and cell cultures. Core capabilities: Quality Controls, Serum plasma division, Clinical trials, Antigens & Antibodies, Biomaterials, Supply Chain

Seestrasse 103 Tecan provides products for liquid handling, microarrays, sample management, microplate reading,software, and consumables (tips, qc kits, stem cell media, etc.).

Mattenstr. 22 Basel, Basel, 4058 Switzerland CDMO for sterile drug product: ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients.

Gewerbestrasse 10 Sissach, Baselland, 4450 Switzerland Founded in 1984 the Swiss company TECOmedical Group and their subsidiaries in Germany, Austria and Benelux are active in the field of medical diagnostics and devices. In the rest of Europe, the United States, the Middle East, India and Japan TECOmedical is distributing the products in cooperation with different partners. As a competent partner of our customers, we like to contribute to the accurate diagnosis and therapy control. Also, we actively support the use of medical devices, e.g. in the preparation and application of therapeutics, for surgical procedures and in the field of wound healing. Custom Assay Development & Services Custom ELISA Assay development and Services are offered to organizations like Biotech companies, CROs, Pharma and Research institutions, requiring specialty assays and studies based on customer specifications. Host Cell Protein testing for recombinant protein pharmaceuticals – Immunogenicity assays to test for Anti Drug Antibodies (ADA) – High sensitive ELISAs – Food safety assays – Veterinary assays– Environmental assays Assay Services include measurement of study samples, validation of new and existing assays, test adaption, pilot to medium size manufacturing of ELISA kits and assay components.

Bern, BE, 3010 Switzerland

Spitalstrasse 21 Basel, 4056 Switzerland The Universitätsspital Basel is one of the leading medical centers in Switzerland with a high international standard. The doctors, doctors and nurses provide round the clock on the basis of the latest scientific findings and state-of-the-art medical equipment for the wellbeing, safety and recovery of patients. The close cooperation between the Universitätsspital Basel and the oldest university in Switzerland and the world's leading life science company in Basel guarantees interdisciplinary treatment concepts and innovations in all medical specialties at the highest level. This transfer of knowledge is also beneficial to teaching and research as well as education and training.

50 Klingelbergstrasse Basel, BS, 4056 Switzerland

Ecublens, VD, 1015 Switzerland

155 Chemin des Boveresses Epalinges, VD, 1066 Switzerland Our mission is simple - to contribute to the elimination of immunological disorders, parasitic infections and cancer. Achieving this goal begins with cutting-edge teaching and research programs, together with seminars and international conferences in biology and medicine for students and researchers from all over the world. We also seek to foster collaborations between our research groups and the industry so as to provide new paths to therapies and clinical approaches.

Hochschulstrasse 6 Bern, 3012 Germany The vision explains the overarching societal developments towards which the University is oriented and clarifies the remit it must fulfil. Knowledge is one of the most important resources in our society, and it will only become more important in the future. Knowledge is the key to solving societal problems and overcoming global challenges. Universities make an indispensable contribution to the evolution and imparting of knowledge, and this task will become increasingly important.

100 Rämistrasse Zürich, ZH, 8006 Switzerland The University Hospital Zurich (UHZ) is open to all patients every day and provides fundamental medical care and cutting-edge medicine in a central location in Zurich. We use our superior academic knowledge to treat a wide range of health issues, taking a personal touch and utilizing highly specialized and up-to-date research.

10 Chemin du Musée Fribourg, FR, 1700 Switzerland

4 Kornfeldstrasse Sursee, LU, 6210 Switzerland UFAG Laboratorien AG is the market-leading, independent service laboratory for foodstuffs and pharmaceutical analytics in Switzerland. While the company, with ca. 110 employees, has occupied the leading position in the area of foodstuffs for a number of years, the younger Pharmaceutical sector of the business has grown very rapidly in the past few years. In the area of foodstuffs, our range of analyses comprehensively covers the requirements of The Food Law. In the pharmaceutical division, services are concentrated on the complex quality controls for raw materials and finished products, the development and validation of analysis methods and cleaning processes, as well as stability studies. Furthermore, UFAG LABORATORIEN is a contract manufacturer in the spray drying sector with our own production facilities. Despite the increasing size of the company, the factors for success typical of a small company are, as before, at the forefront: Quality, personal customer care and expert, individual consultation of an international standard.

9 Rue du Bugnon Lausanne, VD, 1005 Switzerland

Lausanne, VD, 1015 Switzerland

Hallerstrasse 12 Bern, Ch-3012 Switzerland Our group studies the speciation (different chemical species or molecules) of trace elements such as arsenic, antimony or mercury in the environment (air, soil, sediments, water and plants). Indeed, total concentrations of these elements only give a limited view of their biogeochemical cycle since different chemical species possess different mobilities, toxicities and even physico-chemical properties (e.g. inorganic mercury vs. methylmercury). Our focus is mainly on the biomethylation and biovolatilisation of arsenic, antimony and mercury in soils since very little is known about these two intertwined biological mechanisms although they play an important role in the biogeochemical cycle of these elements. To do this, we develop and adapt state-of-the-art extraction and analytical methods such as HPLC-ICP-MS, HPLC-ESI-MS and stable isotope approaches. We then use these methods in soil incubations and in the field to determine the drivers of biomethylation and biovolatilisation and their relative importance toward the global biogeochemical cycle of trace elements.

Hallerstrasse 12 | CH-3012 Bern Our group studies the speciation (different chemical species or molecules) of trace elements such as arsenic, antimony or mercury in the environment (air, soil, sediments, water and plants). Indeed, total concentrations of these elements only give a limited view of their biogeochemical cycle since different chemical species possess different mobilities, toxicities and even physico-chemical properties (e.g. inorganic mercury vs. methylmercury). Our focus is mainly on the biomethylation and biovolatilisation of arsenic, antimony and mercury in soils since very little is known about these two intertwined biological mechanisms although they play an important role in the biogeochemical cycle of these elements. To do this, we develop and adapt state-of-the-art extraction and analytical methods such as HPLC-ICP-MS, HPLC-ESI-MS and stable isotope approaches. We then use these methods in soil incubations and in the field to determine the drivers of biomethylation and biovolatilisation and their relative importance toward the global biogeochemical cycle of trace elements.

7 Marie-Curie-Straße Lörrach, BW, 79539 Germany We control chemical and microbiological analytical methods for investigation and evaluation of: Drugs, agents cosmetics Drinking water bathwater sewage mud floors Contaminated waste gases Complex analytical laboratory services for environmental and pharmaceutical industries are the core competences of our institute: Heavy metal investigations Screening analysis on elements and organic pollutants Corrosion engineering studies Biological tests for determining the degradability and toxicity Determination of pesticides Investigation on PCP, volatile halogenated hydrocarbons LHKW Investigation on organic solvents, BTXE - polycyclic aromatic hydrocarbons (PAH) and petroleum isotopic tests Purity, identity and content testing of drugs and active ingredients under GMP conditions Stability studies under GMP conditions Method development and validation according to ICH guidelines under GMP conditions Viscosity, density, hardness and refractive index analysis In Vitro Dissolution Tests

Marie-Curie-Str. 7 79539 Lörrach We control chemical and microbiological analytical methods for investigation and evaluation of: Drugs, agents cosmetics Drinking water bathwater sewage mud floors Contaminated waste gases Complex analytical laboratory services for environmental and pharmaceutical industries are the core competences of our institute: Heavy metal investigations Screening analysis on elements and organic pollutants Corrosion engineering studies Biological tests for determining the degradability and toxicity Determination of pesticides Investigation on PCP, volatile halogenated hydrocarbons LHKW Investigation on organic solvents, BTXE - polycyclic aromatic hydrocarbons (PAH) and petroleum isotopic tests Purity, identity and content testing of drugs and active ingredients under GMP conditions Stability studies under GMP conditions Method development and validation according to ICH guidelines under GMP conditions Viscosity, density, hardness and refractive index analysis In Vitro Dissolution Tests

101 Rämistrasse Zürich, ZH, 8092 Switzerland

Main building Rämistrasse 101 8092 Zurich Switzerland

Plattenstrasse 11 Zurich, 8032 Switzerland The Departmental research activity and areas of expertise comprise a wide range and multi-faceted perspectives of orthodontic research relevant to the constituent academic sections, which include Cleft clinic, Paediatric Dentistry and Orthodontics. The research portfolio of the Department is extended across areas of clinical, basic and applied interest, for these three components in biomaterials and bonding, clinical orthodontics, systematic diseases and oral manifestations, and a developing component of basic research. The specific topics of the respective aforementioned research areas include: in vivo-ageing and clinical implications in bonding and mechanotherapy; enamel involvement in orthodontic bonding from the aspect of alteration in gloss, color, roughness and composition/structure; development and testing of new adhesives based on non-Bis-GMA containing monomer systems; release of compounds from polymeric materials in the oral environment; BPA release and estrogenicity of polymers; retention protocols, properties of retainer materials and trends in retention schemes among clinicians; modern imaging methods and their accuracy and interpretation; rapid palatal expansion and associated effects on mandibular arches; aesthetics and dental arch dimension in treated cleft patients; TAD research and methods to improve their stability; clinical assessment of oral function in patients with rheumatoid arthritis; cephalometric assessment of growing individuals and airway; and basic research on PDL properties in tension in health and disease using a cell culture model and clinically-derived markers of PDL loading during tooth movement in patients with autoimmune diseases.

Plattenstrasse 11 8032 Zurich The Departmental research activity and areas of expertise comprise a wide range and multi-faceted perspectives of orthodontic research relevant to the constituent academic sections, which include Cleft clinic, Paediatric Dentistry and Orthodontics. The research portfolio of the Department is extended across areas of clinical, basic and applied interest, for these three components in biomaterials and bonding, clinical orthodontics, systematic diseases and oral manifestations, and a developing component of basic research. The specific topics of the respective aforementioned research areas include: in vivo-ageing and clinical implications in bonding and mechanotherapy; enamel involvement in orthodontic bonding from the aspect of alteration in gloss, color, roughness and composition/structure; development and testing of new adhesives based on non-Bis-GMA containing monomer systems; release of compounds from polymeric materials in the oral environment; BPA release and estrogenicity of polymers; retention protocols, properties of retainer materials and trends in retention schemes among clinicians; modern imaging methods and their accuracy and interpretation; rapid palatal expansion and associated effects on mandibular arches; aesthetics and dental arch dimension in treated cleft patients; TAD research and methods to improve their stability; clinical assessment of oral function in patients with rheumatoid arthritis; cephalometric assessment of growing individuals and airway; and basic research on PDL properties in tension in health and disease using a cell culture model and clinically-derived markers of PDL loading during tooth movement in patients with autoimmune diseases.

30 Hofackerstrasse Muttenz, BL, 4132 Switzerland

Bahnhofstr. 6 Windisch, Aargau, 5210 Switzerland

Genuastrasse 15, 4142 Münchenstein, Switzerland VITARIS distributes microbiology, cell culture, and general laboratory equipment and consumables.

9 Blegistrasse Baar, ZG, 6340 Switzerland VITARIS distributes microbiology, cell culture, and general laboratory equipment and consumables.

Flughofstrasse 61 P.O. Box CH-8152 Glattbrugg Switzerland Vifor Pharma produce prescription medicines and OTCs to help the fields of iron deficiency, infectious diseases and consumer healthcare.

Dufourstrasse 107 Zurich, CH-8008 Switzerland VIO Chemicals specializes in custom design and production of specialty chemicals, intermediates and active pharmaceutical ingredients (APIs). The company offers a complete range of services, from process and product research and development to quality control and production in commercial quantities. Through its ISO 9001 & ISO 14001-certified R&D centre in Greece and three production units in China, one cGMP-standard, VIO Chemicals applies cutting-edge science and uses novel technologies to optimize product quality and maximize API capabilities. In addition, the company is specialized in strategic sourcing of catalogue, custom-manufactured and proprietary products, offering complementary GMP/EHS auditing, consulting and regulatory services. Founded in Zurich in 2001, VIO Chemicals is the exclusive and trusted partner for customers and suppliers in the chemical and pharmaceutical industry worldwide. To learn more, visit http://www.viochemicals.com.

Dufourstrasse 107 Switzerland Zurich, 8008 Switzerland VIO Chemicals specializes in custom design and production of specialty chemicals, intermediates and active pharmaceutical ingredients (APIs). The company offers a complete range of services, from process and product research and development to quality control and production in commercial quantities. Through its ISO 9001 & ISO 14001-certified R&D centre in Greece and three production units in China, one cGMP-standard, VIO Chemicals applies cutting-edge science and uses novel technologies to optimize product quality and maximize API capabilities. In addition, the company is specialized in strategic sourcing of catalogue, custom-manufactured and proprietary products, offering complementary GMP/EHS auditing, consulting and regulatory services. Founded in Zurich in 2001, VIO Chemicals is the exclusive and trusted partner for customers and suppliers in the chemical and pharmaceutical industry worldwide. To learn more, visit http://www.viochemicals.com.

Blegistrasse 9 Baar, 6340 Switzerland Swiss Laboratory Distributor focussing on cell culture laboratories dealing with consumables and instruments.

Bristenstrasse 13 Altdorf UR, Uri, 6460 Switzerland Consultant with 15 years of multidisciplinary scientific experience, in holding a valuable expertise in pre-Clinical/Clinical R&D, Project Management & Scientific Writing Expertise: • Pharmaceutical: pre-clinical/clinical DMPK/Bioanalysis, in vitro Pharmacology/Toxicology, cross-functional work (e.g. Safety/CMC/Reg), Regulatory writing (GRP/GLP reports, selected modules from IND/NDA, IB, IMPD), clinical trial OP/writing support. • Life Sciences: Product development (design, feasibility, market research), In vitro diagnostics; Medical Devices; Biocompatibility/toxicology assessments, data analysis & processing. • Academic research (Chemistry/Biology): Qualitative research, meta-analysis, evidence-based answers, secondary data compilation, literature search, writing support (papers, posters, abstracts, slide decks). • Management: Project management; Process optimization; Outsourcing. • Lay Tech/Med writing: documents for lay public about life science topics; patient and specialist information leaflets

Lagerstrasse 6 Buchs, St. Gallen, 9470 Switzerland Consultant with 15 years of multidisciplinary scientific experience, in holding a valuable expertise in pre-Clinical/Clinical R&D, Project Management & Scientific Writing Expertise: • Pharmaceutical: pre-clinical/clinical DMPK/Bioanalysis, in vitro Pharmacology/Toxicology, cross-functional work (e.g. Safety/CMC/Reg), Regulatory writing (GRP/GLP reports, selected modules from IND/NDA, IB, IMPD), clinical trial OP/writing support. • Life Sciences: Product development (design, feasibility, market research), In vitro diagnostics; Medical Devices; Biocompatibility/toxicology assessments, data analysis & processing. • Academic research (Chemistry/Biology): Qualitative research, meta-analysis, evidence-based answers, secondary data compilation, literature search, writing support (papers, posters, abstracts, slide decks). • Management: Project management; Process optimization; Outsourcing. • Lay Tech/Med writing: documents for lay public about life science topics; patient and specialist information leaflets

Lagerstrasse 6 6 Buchs, St. Gallen, 9470 Switzerland Consultant with 15 years of multidisciplinary scientific experience, in holding a valuable expertise in pre-Clinical/Clinical R&D, Project Management & Scientific Writing Expertise: • Pharmaceutical: pre-clinical/clinical DMPK/Bioanalysis, in vitro Pharmacology/Toxicology, cross-functional work (e.g. Safety/CMC/Reg), Regulatory writing (GRP/GLP reports, selected modules from IND/NDA, IB, IMPD), clinical trial OP/writing support. • Life Sciences: Product development (design, feasibility, market research), In vitro diagnostics; Medical Devices; Biocompatibility/toxicology assessments, data analysis & processing. • Academic research (Chemistry/Biology): Qualitative research, meta-analysis, evidence-based answers, secondary data compilation, literature search, writing support (papers, posters, abstracts, slide decks). • Management: Project management; Process optimization; Outsourcing. • Lay Tech/Med writing: documents for lay public about life science topics; patient and specialist information leaflets

Schwarzwaldallee 215, Postfach, CH- 4002 Basel AGREXIS is an independent consulting company. We offer product safety and regulatory consulting to the Agrochemical and Biocidal industry. It is our commitment to provide our clients with high-quality and cost-efficient service. AGREXIS consultants are highly experienced and recognised senior experts.

Stahlermatten 6 6146 Grossdietwil • Switzerland Our goal is to replace chemical pesticides with good biological alternatives, such as beneficial insects, microbial control products and traps. More than 20 years ago, we started our first production of plant protection products based on baculoviruses. In those days, the use of biological control such as the application of baculoviruses against insect pests was thought to be a method only for use in organic production. Today, it has been widely recognized that the use of biological control measures, such as baculoviruses, offers a highly effective tool within IPM programs and alongside conventional agriculture. The world-wide demand for environmental friendly and residue-free food production is increasing. We will continue in our goal to offer biocontrol products, which represent reasonable and effective alternatives to chemical pesticides.

Seefeldstrasse 293 Zurich, 8008 Switzerland

Seefeldstrasse 293 Zurich*, 8008 Switzerland

Frutigenstrasse 25 3600 Thun BE Switzerland Founded in 1980 by Irish biochemist and entrepreneur Dr. Pearse Lyons, Alltech is a leading global biotechnology company whose mission is to improve the health and performance of people, animals and plants through natural nutrition and scientific innovation. We pursue this mission guided by what we call the ACE principle, our promise that in doing business we have a positive impact on the Animal, the Consumer and the Environment. Animal Health Our core business improves animal health and performance by adding nutritional value to feed, naturally, through Alltech’s innovative use of yeast fermentation, enzyme technology, algae and nutrigenomics, which studies the impact of nutrition at the genetic level. Our technologies and support programs enable farmers to realize greater efficiency, profitability and sustainability on their farms. Alltech Crop Science Our Alltech Crop Science division complements our animal nutrition business by focusing on improving the health of crops. Our technologies enable us to improve the productivity of the field, in terms of yield quality and quantity, and to enhance nutrition beginning with the soil and the seed. Human Health We believe scientific innovation in animal and crop sciences is part of a much more important story, that of human health. Healthier animals and crops, nurtured naturally through Alltech’s nutritional solutions, affect human well-being. For example, fruits, vegetables and animal proteins have become less nutrient-rich in the past half-century. From fish to oranges, you need to eat more today to get the same nutritional value. Our work within animal and crop sciences is restoring value and also exploring ways to naturally enrich foods through improving the animal diet or crop produced. For example, laying hens fed a diet rich in Alltech’s algae produce eggs enriched with DHA omega-3, an essential nutrient for human cognitive development and health at all ages.

Wunderlistrasse 24 Zürich, ZH, 8037 Switzerland

Wolfswinkel 18 Zurich, ZH, 8046 Switzerland YugaCell provides specialized solutions in bioinformatics and artificial intelligence/machine learning. Our core expertise is in translational informatics, transcriptomics (bulk, single cell, spatial), and machine learning. We will work with you as your partners, shoulder to shoulder. And if we can’t do it, we will find you someone who can.

Grüental Wädenswil, ZH, 8820 Switzerland The Institute of Biotechnology provides teaching at university level, applied research, continuing education courses, and services in the field of biotechnology. Our understanding of biotechnology is that it involves the linking of discoveries in the natural sciences with technological knowledge, with the aim of applying biological systems to the analysis and manufacture of products. The focus is on applications in the areas of pharma, food and ecology.

34 Einsiedlerstrasse Wädenswil, ZH, 8820 Switzerland We provide a broad range of services to meet our clients’ needs, in particular we respond to your enquiries about self-regulation, complete HACCP analyses, develop training concepts and lead training courses, carry out consumer tests and product testing and assist in developing entirely new products. In so doing we utilise the most modern infrastructure and are ISO 17025 accredited “General requirements for the competence of testing and calibration laboratories” (STS 240).

Grüental Wädenswil, Schweiz 8820 Schweiz The Institute of Chemistry and Biological Chemistry in Waedenswil provides teaching at university level, applied research, continuing education courses, and services in the field of chemistry.

Feldbachstrasse 81 Feldbach, ZH, 8714 Switzerland Carl Zeiss AG Feldbachstrasse 81 8714 Feldbach Switzerland

Feldbachstrasse 18 Feldbach, Zurich, 8714 Switzerland Carl Zeiss AG Feldbachstrasse 81 8714 Feldbach Switzerland

3Brain GmbH Schulstrasse 76 7302 Landquart Switzerland

Industriestrasse 11 4313 Moehlin Switzerland ASM offers the services of development of customized products,optimization of existing products,manufacturing and filling of formulation, and the packaging of the product.

Wangen, SZ Switzerland ANAWA offers more than 20,000 antibodies and antigens, > 2000 products in signal transduction research, almost 5000 radiochemicals [14C, 3H, 125I], more than 3000 peptides, > 1000 immunoassay kits (EIA, LIA, FIA) and many more special biochemicals. Our services include custom syntheses, diff. labelling techniques, peptide syntheses and antibody production and the management of entire turn-key projects.

Unterdorfstrasse 21b CH-8602 Wangen SWITZERLAND ANAWA offers more than 20,000 antibodies and antigens, > 2000 products in signal transduction research, almost 5000 radiochemicals [14C, 3H, 125I], more than 3000 peptides, > 1000 immunoassay kits (EIA, LIA, FIA) and many more special biochemicals. Our services include custom syntheses, diff. labelling techniques, peptide syntheses and antibody production and the management of entire turn-key projects.

Pfeffingerstrasse 45 CH-4153 Reinach BL Switzerland Allpack Group offers packaging and finishing for companies in the pharmaceutical sector.

Clavadelerstrasse 8 Davos, 7270 Switzerland ARI is your Contract Research Organization (CRO) for preclinical projects in the medical device field. Our strength is to have the complete service chain under one roof, offering modular or complete research solutions within ISO9001​, ISO13485, GLP and AAALAC​ accredited facilities. For clinical trials and support in clinical trials contact AOCID​. We are proud to take decades of cumulative knowledge and experience in orthopedic research and make it available to industrial and academic customers within defined timelines.

Clavadelerstrasse 8 7270 Davos, Swi​tzerla​​nd ARI is your Contract Research Organization (CRO) for preclinical projects in the medical device field. Our strength is to have the complete service chain under one roof, offering modular or complete research solutions within ISO9001​, ISO13485, GLP and AAALAC​ accredited facilities. For clinical trials and support in clinical trials contact AOCID​. We are proud to take decades of cumulative knowledge and experience in orthopedic research and make it available to industrial and academic customers within defined timelines.

Site Information

The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.

We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.

Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.

Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.

What is Scientist.com?

Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.

How can I use Scientist.com?

Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at   [email protected] or go to our website   www.scientist.com to speak to someone via our live chat.

Why should I place my order through Scientist.com?

Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.

How do I get my organization listed on the map?

If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.

Information about my organization is incorrect, how do I fix it?

Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

The role of Clinical Trial Units in investigator- and industry-initiated research projects

Affiliation.

• 1 Clinical Trial Unit, Department of Clinical Research, University Hospital and University of Basel, Switzerland.
• PMID: 26134324
• DOI: 10.4414/smw.2015.14161

Six multidisciplinary competence centres (Clinical Trial Units, CTUs) in Basel, Berne, Geneva, Lausanne, St. Gallen and Zurich provide professional support to clinical researchers in the planning, implementation, conduct and evaluation of clinical studies. Through their coordinated network, these units promote high-quality, nationally harmonised and internationally standardised clinical research conduct in Switzerland. We will describe why this network has been established, how it has been successful in stilling the growing need for clinical research support, which training and education opportunities it offers, and how it created national awareness for the still-existing hurdles towards clinical research excellence in Switzerland. Taking the CTU Basel as an example, we show that a considerable number (25%) of the studies submitted for regulatory approval in 2013 were supported by the CTU, decreasing the number of findings in ethics reviews by about one-third. We conclude that these achievements, together with a Swiss national funding model for clinical research, and improved national coordination, will be critical factors to successfully position Swiss clinical research at the international forefront.

PubMed Disclaimer

Similar articles

• The impact of clinical trial units on the value of clinical research in Switzerland. von Niederhäusern B, Magnin A, Pauli-Magnus C. von Niederhäusern B, et al. Swiss Med Wkly. 2018 Apr 26;148:w14615. doi: 10.4414/smw.2018.14615. eCollection 2018. Swiss Med Wkly. 2018. PMID: 29698540 Review.
• American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology. American Society of Clinical Oncology. J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29. J Clin Oncol. 2003. PMID: 12721281
• Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Sudre P, Rickenbach M, Taffé P, Janin P, Volkart AC, Francioli P; Swiss HIV Cohort Study. Sudre P, et al. Schweiz Med Wochenschr. 2000 Oct 14;130(41):1493-500. Schweiz Med Wochenschr. 2000. PMID: 11075414
• Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management. McLennan S, Griessbach A, Briel M; Making Randomized Trials Affordable (MARTA) Group. McLennan S, et al. JAMA Netw Open. 2021 Jun 1;4(6):e2111847. doi: 10.1001/jamanetworkopen.2021.11847. JAMA Netw Open. 2021. PMID: 34076698 Free PMC article.
• Clinical research in Hungary. Infrastructure, organisation, legislation and framework. The situation in 2008. Blaskó G, Kardos G. Blaskó G, et al. Therapie. 2009 Jan-Feb;64(1):33-45. doi: 10.2515/therapie/2009003. Epub 2009 May 26. Therapie. 2009. PMID: 19463251 Review.
• Operational Differences between Product Development Partnership, Pharmaceutical Industry, and Investigator Initiated Clinical Trials. Nebie EI, van Eeuwijk P, Sawadogo HN, Reus E, Utzinger J, Burri C. Nebie EI, et al. Trop Med Infect Dis. 2024 Feb 29;9(3):56. doi: 10.3390/tropicalmed9030056. Trop Med Infect Dis. 2024. PMID: 38535880 Free PMC article.
• The appearance and increase in the quantity and proportion of the clinical research coordinator's service fee in drug clinical trial research fund and its impact on trial quality. Chen L, Chen Z, Chen H. Chen L, et al. Cost Eff Resour Alloc. 2021 Jul 12;19(1):41. doi: 10.1186/s12962-021-00297-1. Cost Eff Resour Alloc. 2021. PMID: 34247648 Free PMC article.
• Present Status and Perspectives on Future Roles of Japanese Clinical Research Coordinators. Yanagawa H, Nokihara H, Yokoi H, Houchi H, Nagai M, Yamashita R, Suganuma N, Hyodo M; Shikoku Collaborative Group for Promotion of Clinical Trials. Yanagawa H, et al. J Clin Med Res. 2018 Dec;10(12):877-882. doi: 10.14740/jocmr3602w. Epub 2018 Oct 30. J Clin Med Res. 2018. PMID: 30425759 Free PMC article.
• Search in MeSH

LinkOut - more resources

Full text sources.

• SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
• MedlinePlus Health Information

• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Become a clinical researcher

Are you a medical student or a resident interested in a clinical research career in Switzerland? Or a senior registrar aiming to run high-quality clinical research projects? This website provides you a clear overview of career support and funding opportunities, available training options and mentoring programmes. Use it to explore typical career tracks and plan your academic career.

• Undergraduate

Fundamental or clinical research internship during semester holidays

Aims at preparing local students for a potential MD-PhD later on

Allows students to mention "research" on their master's degree

Possibility to perform a second internship abroad

Small grant provided (CHF 300/week in Switzerland or up to CHF 2000/month for an internship abroad)

Includes mentoring opportunity until the end of studies

• Junior researcher

PhD curriculum in clinical research

Clinically involved candidates can combine clinical work (50% position) and dedicate the remaining time to a patient-oriented research project

The programme is open to physicians, psychologists, physiotherapists, etc.

• Senior researcher

Supports local talented physician scientists before a professorship so they can remain clinically active throughout the funding period

Includes a mentoring programme

An extension for 6-12 months is possible upon approval of the evaluation committee

Professor Mira Katan Kahles is deputy chair of the Department of Neurology at the University Hospital Basel (USB) and the first female chair of a Stroke Center in Switzerland. In addition, she still holds an affiliation with the University and University Hospital of Zurich (UZH/USZ). Mira Katan Kahles researches the identification, evaluation, and validation of novel diagnostic, prognostic, and aetiological stroke markers to ultimately improve patient outcomes.

An associate professor at the University of Lausanne and Lausanne University Hospital, Oriol Manuel performs patient-oriented clinical research. His research focuses on the prevention of viral infections after solid organ transplantation, a key element for improving the survival of transplant recipients.

As a senior registrar at the Cantonal Hospital St.Gallen and a privat-docent at the University of Zurich, Philipp Kohler is an infectious disease specialist who is particularly involved in antibiotic stewardship and infection prevention. His research focuses on the epidemiology of antibiotic resistant pathogens and ultimately aims at preventing further spread of these resistant pathogens in healthcare settings. He recently seized the opportunity to add another research focus and now leads a multicentre cohort on respiratory infections in healthcare workers.

In addition to being an assistant professor at the University of Basel, Gregor Hutter is a neurosurgeon at the Basel University Hospital.

He leads the Brain Tumor Immunotherapy Lab, which aims to develop therapies to fight against glioblastoma, a fatal brain tumour that is resistant to all treatments. His work focuses on reprogramming the immune tumour microenvironment to regain antitumour functions.

Associate professor at the University of Bern and Co-Chair of the Psychosomatic Medicine Unit within the Neurology Department of the Inselspital in   Bern, Selma Aybek’s research focuses on functional neurological disorder, a disease showing abnormal sensory-motor processing and stress dysregulation. Using neuromodulation and stress reduction therapy, she explores treatment options to improve the life of patients suffering from this disabling disorder.

As a professor and the Head of the Sleep Medicine Unit at the Neurocenter of Southern Switzerland in Lugano, Mauro Manconi combines clinical and basic research to better understand and treat sleep disorders. He takes a particular interest in sleep-related motor disorders such as restless legs syndrome.

A talented researcher at the University of Geneva and Geneva University Hospitals, Sophie de Seigneux successfully combines clinical care and translational clinical research. Her research focuses on optimising the diagnosis and non-invasive monitoring of renal diseases and on the pathophysiology of chronic renal failure.

The Science-First CRO. ™

The scientific full service cro and consultancy integrating strategic planning, regulatory strategy, and clinical trial execution to rapidly advance your complex or novel therapies..

READ THE PRESS RELEASE

Specialty Expertise

Our team of scientific experts is easy to work with, even for the rarest, most complex, and never done before novel therapies..

Driving Success

Advancing Novel Therapies to Success with Veristat READ SPONSOR SUCCESS STORIES 

Phase I/II Trial After NH Trial

Rare Disease Gene Therapy Trial

Tackling problems big or small we can help.

What Are Your Challenges?

Be Part of the Team That Cares

At Veristat, we contribute and add value to our company’s mission - improving and saving lives. Whether you’re a scientific expert or an operations guru, explore the chance to become part of our fast-paced, agile team. 

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Article Menu

• Subscribe SciFeed
• Recommended Articles
• Google Scholar
• on Google Scholar
• Table of Contents

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

JSmol Viewer

The role of patient organizations in shaping research, health policies, and health services for rare genetic diseases: the dutch experience, 1. introduction, aims and objectives, 2. materials and methods, 2.1. key methods, 2.2. material, 3.1. the beginning—a father’s story, 3.2. challenges of living with a rare genetic disease: unmet needs and founding a parent/patient organization for neuromuscular diseases.

• Address the knowledge gap and the lack of informed care; provide appropriate, actionable education and information for parents about home care, transportation, technical help, financial help, and recreation; and organize support by setting up mutual help groups for different neuromuscular diseases;
• Promote needs-led research, cooperation, and active involvement in the field of research and in the development of therapies;
• Generate attention and publicity to reach all involved patients and parents and to find financial resources to support (V)SN’s activities.

3.2.1. (V)SN: Early Milestones and Achievements

• Implementing standing working groups to realize home visits for advice by an experienced member plus supplementing telephone consultation to fill home visit gaps;
• Organization of a special symposium aiming at the creation of a professional structural framework for (V)SN;
• Establishing a committee to raise attention for genetic muscular diseases in the medical and scientific communities;
• Organizing regular meetings with medical experts and researchers to facilitate members’ access to state-of-the-art information, to keep members informed and updated on current research projects and on latest research findings, and, last but not least, mentoring medical experts on patients’ needs and advocating needs-led research.

3.2.2. (V)SN Involvement in Orphan Drug Development

• Contacting and lobbying manufacturers to prepare for their assessment of cost-effectiveness and reimbursement procedures in The Netherlands;
• Lobbying the National Health Care Institute (Zorginstituut Nederland) [ 31 ] and the Ministry of Health (VWS) of The Netherlands [ 32 ];
• Educating physicians and researchers with respect to their role in the admission and reimbursement of orphan drugs. (V)SN is committed as well to the management of expectations of patients with regard to gene therapy.

3.2.3. (V)SN: Newborn Screening for Spinal Muscular Atrophy (SMA)

3.2.4. (v)sn today, 3.2.5. neuromuscular diseases internationally united, networking and partnering—from a patients’ initiative to pan-european research institutions: establishing the european alliance of neuromuscular disorders associations (eamda) and the european neuromuscular centre (enmc), 3.3. founding the first national patient umbrella organization for rgds in europe and shaping the infrastructure for genetic services and counseling centres in the netherlands, 3.3.1. shaping and implementing genetic service centres, including genetic counselling centres in the netherlands, 3.3.2. key steps taken by vsop to promote genetic counselling services and to raise public awareness about genetics.

• (i) Raising public awareness, addressing “genetic illiteracy”
• (ii) Capacity building for genetic services

3.3.3. National Umbrella Patient Organizations Internationally United and Partnering

• The development of educational material about next-generation sequencing (“Next generation sequencing in diagnostiek”) for the public, patients, and healthcare providers in collaboration with Erfocentrum [ 100 ];
• Joining of the supervisory board of H2O (Health Outcomes Observatory), a European project financed by both the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA) [ 101 ]. EFPIA represents the biopharmaceutical industry operating in Europe [ 102 ]. This project is intended to provide insight into clinical data and patient-reported data for patients from different disease areas and healthcare providers via dashboards, for example, for joint decision-making [ 103 ];
• Close involvement—through support to access to empirical data- in the document “Advice from the Health Council of The Netherlands” (Gezondheidsraad) to the government in November 2023 on preconception carrier screening. The Health Council recommends pilot research to determine whether preconception carrier screening could be responsibly offered to all prospective parents in The Netherlands to equip them with the information they need to enable them to make informed reproductive decisions [ 104 ];
• Co-ordinating the input of patients and patient organizations into the Clinical Genetics Knowledge Agenda, which describes the top 10 knowledge gaps in clinical genetic care. The two overarching knowledge questions are: what barriers are in place for healthy family members who are at increased risk of a hereditary condition with treatment options to be referred for genetic counselling and possibly DNA testing, and how can the identified barriers be overcome? The agenda was published at the end of 2022 [ 105 ]. The Netherlands Association of Clinical Geneticists (VKGN) is currently exploring the possibilities for further research to address these knowledge gaps, including input from the patient perspective.
• Participation in the decision-making process to add an NIPT (Non-Invasive Prenatal Test) in April 2023 as a standard option—if the pregnant woman wishes so—in the prenatal screening program of The Netherlands [ 106 ].

4. Where We Are Today, Future Prospects, and Challenges

4.1. challenges, 4.1.1. availability of treatment and costs of cell and gene therapies, 4.1.2. diagnostic odyssey and child mortality, 4.1.3. lack of diversity in genomics studies, 4.2. limitations, 5. epilogue and the lessons i learned, author contributions, institutional review board statement, informed consent statement, data availability statement, acknowledgments, conflicts of interest.

• Watson, J.D.; Crick, F.H.C. Molecular Structure of Nucleic Acids: A Structure of Deoxyribonucleic Acid. Nature 1953 , 171 , 737–738. [ Google Scholar ] [ CrossRef ]
• International HapMap Consortium. The International HapMap Project. Nature 2003 , 426 , 789–796. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• O’Brien, S.J. A decade of GigaScience: A perspective on conservation genetics. GigaScience 2022 , 11 , giac055. [ Google Scholar ] [ CrossRef ]
• McKusick, V. A New Discipline, A New Name, A New Journal. Genomics 1987 , 1 , 1–2. [ Google Scholar ] [ CrossRef ]
• Claussnitzer, M.; Cho, J.H.; Collins, R.; Cox, N.J.; Dermitzakis, E.T.; Hurles, M.E.; Kathiresan, S.; Kenny, E.E.; Lindgren, C.M.; MacArthur, D.G.; et al. A brief history of human disease genetics. Nature 2020 , 577 , 179–189. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• OMIM Gene Map Statistics, Updated 30 August 2024. Available online: https://omim.org/statistics/geneMap (accessed on 31 August 2024).
• OMIM. Available online: https://www.omim.org/statistics/paceGraph (accessed on 5 June 2024).
• Nguengang Wakap, S.; Lambert, D.M.; Olry, A.; Rodwell, C.; Gueydan, C.; Lanneau, V.; Murphy, D.; Le Cam, Y.; Rath, A. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. Eur. J. Hum. Genet. 2020 , 28 , 165–173. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Muscular Dystrophy Association. Available online: https://www.mda.org (accessed on 5 June 2024).
• Cystic Fibrosis Association. Available online: https://www.cff.org (accessed on 5 June 2024).
• Bach, M.-A. Building the French Muscular Dystrophy Association: The Role of Doctor/Patient Interactions. Soc. Hist. Med. 1998 , 11 , 233–253. [ Google Scholar ] [ CrossRef ]
• Interview with Yann Le Cam: Reflecting on a Quarter Century as Chief Executive Officer, September 2023. Available online: https://www.eurordis.org/reflecting-on-a-quarter-century/ (accessed on 5 June 2024).
• De Knecht-van Eekelen, A. Erfelijkheid op de Agenda, Actualiteit van 25 jaar VSOP ; VSOP Alliantie voor Erfelijkheidsvraagstukken: Soestdijk, The Netherlands, 2004; pp. 19, 29, 49, 51, 53, 55, 57, 71–75, 94. Available online: https://vsop.nl/media/uploads/file/Erfelijkheid%20op%20de%20agenda%20-%20met%20hoofdstukken.pdf (accessed on 5 June 2024).
• Nishio, H.; Niba, E.T.E.; Saito, T.; Okamoto, K.; Takeshima, Y.; Awano, H. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci. 2023 , 24 , 11939. [ Google Scholar ] [ CrossRef ]
• Muscular Dystrophy, UK. Available online: https://www.musculardystrophyuk.org/ (accessed on 5 June 2024).
• Spierziekten Nederland. Available online: https://www.spierziekten.nl/overzicht/ (accessed on 5 June 2024).
• Orphanet Expert-Centres. Available online: https://www.orpha.net/en/expert-centres/network/483646 (accessed on 5 June 2024).
• Spierziekten Centrum Nederland. Available online: https://www.spierziektencentrum.nl/ (accessed on 5 June 2024).
• Official Journal of the European Union, 3.7.2009, C 151/7. Available online: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF (accessed on 5 June 2024).
• EUCERD. Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States, 24 October 2011. Available online: http://www.rd-action.eu/eucerd/EUCERD_Recommendations/eucerd-recommendations(1).pdf (accessed on 5 June 2024).
• European Reference Network (ERN). Available online: https://health.ec.europa.eu/european-reference-networks_en (accessed on 5 June 2024).
• European Reference Network for Rare Neuromuscular Diseases. Available online: https://ern-euro-nmd.eu/ (accessed on 5 June 2024).
• European Patient Advocacy Groups (ePAGs) Essentials. Available online: https://www.eurordis.org/our-priorities/european-reference-networks/epag/epag/224 (accessed on 5 June 2024).
• Teresinha, E. Le réseau européen de référence pour les maladies neuromusculaires rares (EURO-NMD). De sa constitution à ses premiers pas. Médecine/Sciences 2019 , 35 , 51–54. Available online: https://www.medecinesciences.org/en/articles/medsci/pdf/2019/11/medsci190180s.pdf (accessed on 30 August 2024).
• Oosterwijk, C. Connecting Patient Organisations to Centres of Expertise by a Legal Role in the Designation Process. EURORDIS Membership Meeting 14 May 2021. Available online: https://download2.eurordis.org/EMM/EMM%202021/speaker%20presentations/EMM%202021_WS4_Cor%20Oosterwljilk.pdf (accessed on 5 June 2024).
• Prinses Beatrix Spierfonds. Available online: https://www.spierfonds.nl (accessed on 5 June 2024).
• van der Ploeg, A.T.; Reuser, A.J. Pompe’s disease. Lancet 2008 , 372 , 1342–1353. [ Google Scholar ] [ CrossRef ]
• IPA Conferences, Pompe’s Disease in Historical Perspective and the Way to Therapy, 30 November 1999. Available online: https://worldpompe.org/ipa-conferences/pompeas-disease-in-historical-perspective-and-the-way-to-therapy/ (accessed on 5 June 2024).
• High-Level Expertise in Pompe Disease. Available online: https://clmz.nl/en/pompe-center (accessed on 5 June 2024).
• Van den Brink, R. Reimbursement of orphan drugs: The Pompe and Fabry case in The Netherlands. Orphanet J. Rare Dis. 2014 , 9 (Suppl. S1), O17. Available online: http://www.ojrd.com/content/9/S1/O17 (accessed on 30 August 2024). [ CrossRef ]
• National Health Care Institute. Available online: https://english.zorginstituutnederland.nl/ (accessed on 5 June 2024).
• Government of The Netherlands, Ministry of Health, Welfare and Sport. Available online: https://www.government.nl/ministries/ministry-of-health-welfare-and-sport (accessed on 5 June 2024).
• Health Council of The Netherlands. Neonatal screening for spinal muscular atrophy. Available online: https://www.healthcouncil.nl/documents/advisory-reports/2019/07/23/neonatal-screening-for-spinal-muscular-atrophy (accessed on 1 August 2024).
• The Netherlands’ Zorginstituut (ZIN). Package Advice Package Lock Medicinal Product Onasemnogene Abeparvovec. (Zolgensma®) for the Treatment of SMA. Available online: https://english.zorginstituutnederland.nl/publications/reports/2021/05/06/package-advice-package-lock-medicinal-product-onasemnogene-abeparvovec-zolgensma (accessed on 1 August 2024).
• Kirschner, J.; Butoianu, N.; Goemans, C.; Haberlova, D.; Kostera-Pruszczyk, A.; Mercurig, E.; van der Pol, L.; Quijano-Roy, S.; Sejersen, T.; Tizzano, E.F.; et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur. J. Paediatr. Neurol. 2020 , 28 , 38–43. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Zafeirio, D. Editorial Commentary: Gene therapy for spinal muscular atrophy: Solomon’s consensus in Covid times. Eur. J. Pediatr. Neurol. 2020 , 28 , 2–3. [ Google Scholar ] [ CrossRef ]
• Nuijten, M. Pricing Zolgensma—The world’s most expensive drug. J. Mark. Access Health Policy 2022 , 10 , 2022353. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Beneluxa Initiative on Pharmaceutical Policy. Available online: https://beneluxa.org/collaboration (accessed on 5 June 2024).
• Netherlands Kicks off Zolgensma Review for BeNeLuxA, Posted on 11 November 2020. Available online: https://www.eversana.com/2020/11/11/netherlands-kicks-off-zolgensma-review-for-beneluxa/ (accessed on 5 June 2024).
• National Health Care Institute, The Netherlands. Available online: https://www.zorginstituutnederland.nl/actueel/nieuws/2021/05/07/medicijn-zolgensma-voor-zeldzame-spierziekte-sma-alleen-in-basispakket-na-prijsonderhandeling (accessed on 5 June 2024).
• Outcome of Joint Negotiations for Zolgensma. 8 October 2021. Available online: https://beneluxa.org/statements#toc-08-october-2021-outcome-of-joint-negotiations-for-zolgensma (accessed on 5 June 2024).
• Atalaia, A.; Wandrei, D.; Lalout, N.; Thompson, R.; Tassoni, A.; Hoen, P.A.C.; Athanasiou, D.; Baker, S.-A.; Sakellariou, P.; Paliouras, G.; et al. EURO-NMD registry: Federated FAIR infrastructure, innovative technologies and concepts of a patient-centred registry for rare neuromuscular disorders. Orphanet J. Rare Dis. 2024 , 19 , 66. [ Google Scholar ] [ CrossRef ]
• Federation of European Myotonic Dystrophy Associations. Available online: https://euro-dyma.eu/member-organizations (accessed on 5 June 2024).
• Wouter, B.; Broekgaarden, R. The role of patient advocacy organisations in neuromuscular disease R&D—The case of the Dutch neuromuscular disease association VSN. Neuromuscul. Disord. 2010 , 20 , 148–151. [ Google Scholar ] [ CrossRef ]
• European Alliance of Neuromuscular Disorders Associations. Available online: http://www.eamda.eu/ (accessed on 5 June 2024).
• Vololona, R. The struggle against neuromuscular diseases in France and the emergence of the “partnership model” of patient organisation. Soc. Sci. Med. 2003 , 57 , 2127–2136. [ Google Scholar ] [ CrossRef ]
• European Neuromuscular Centre (ENMC). Available online: https://www.enmc.org/ (accessed on 5 June 2024).
• Emery, A. The European Neuromuscular Centre (ENMC): Importance of collaborative research. Neuromuscul. Disord. 1997 , 7 , 135–137. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Rüdel, R.; Nigro, G.; Poortman, Y. Ten years of ENMC from a patient’s initiative to a successful European research institution: The story of ENMC. Neuromuscul. Disord. 2000 , 10 , 75–82. [ Google Scholar ] [ CrossRef ]
• Emery, A.; Rutgers, M. European collaboration in research into rare diseases: Experience of the European Neuromuscular Centre. Clin. Med. 2001 , 1 , 200–202. [ Google Scholar ] [ CrossRef ]
• CWTS, B.V. Centre for Science and Technology Studies, Leiden University, September 2018 Bibliometric Research Performance of the European Neuromuscular Centre (ENMC) 2000–2016/17. Available online: https://www.enmc.org/wp-content/uploads/2019/04/ENMC_2000-2016-Final-Report-by-CWTS-Oct2018.pdf (accessed on 5 June 2024).
• Lochmüller, H.; Ambrosini, A.; van Engelen, B.; Hansson, M.; Tibben, A.; Breukel, A.; Sterrenburg, E.; Schrijvers, G.; Meijer, I.; Padberg, G.; et al. Meeting Report: The Position of Neuromuscular Patients in Shared Decision Making. Report from the 235th ENMC Workshop: Milan, Italy, 19–20 January 2018. J. Neuromuscul. Dis. 2019 , 6 , 161–172. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Breukel, A.; Willmann, R.; Padberg, G.; Sterrenburg, E.; Meijer, I. The impact of European Neuromuscular Centre (ENMC) workshops on the neuromuscular field; 25 years on …. Neuromuscul. Disord. 2019 , 29 , 330–340. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Ambrosini, A.; Quinlivan, R.; Sansone, V.A.; Meijer, I.; Schrijvers, G.; Tibben, A.; Padberg, G.; de Wit, M.; Sterrenburg, E.; Mejat, A.; et al. “Be an ambassador for change that you would like to see”: A call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease. Orphanet J. Rare Dis. 2019 , 14 , 126. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• SMA Europe. Available online: https://www.sma-europe.eu/ (accessed on 5 June 2024).
• Euro-Ataxia. Available online: https://www.euroataxia.org (accessed on 5 June 2024).
• Patient Alliance for Rare and Genetic Diseases. Available online: https://vsop.nl/english (accessed on 5 June 2024).
• Rodwell, C.; Aymé, S. (Eds.) 2014 Report on the State of the Art of Rare Disease Activities in Europe, July 2014., European Union, 2014.; p. 56, Figure 15: Countries in Europe with a National Alliance for Rare Disease Patient Organizations and Year Founded. Available online: http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesV.pdf (accessed on 5 June 2024).
• Harper, P. Some pioneers of European human genetics. Eur. J. Hum. Genet. 2017 , 25 , 1–18. [ Google Scholar ] [ CrossRef ]
• Gezondheitsraad: Advies Inzake Genetic Counseling, Rijswijk 1977. Gezondheidsraad: Genetic Counseling. Den Haag, Gezondheidsraad, 1977; Publicatie nr. 77/14. Available online: https://www.nationaalarchief.nl/onderzoeken/archief/2.15.36 (accessed on 30 August 2024).
• Abacan, M.; Alsubaie, L.; Barlow-Stewart, K.; Caanen, B.; Cordier, C.; Courtney, E.; Davoine, E.; Edwards, J.; Elackatt, N.J.; Gardiner, K.; et al. The Global State of the Genetic Counseling Profession. Eur. J. Hum. Genet. 2019 , 27 , 183–197. [ Google Scholar ] [ CrossRef ]
• Hans Galjaard. Available online: https://www.ae-info.org/attach/User/Galjaard_Hans/CV/hans-galjaard-interview.pdf (accessed on 5 June 2024).
• Ten Kate, L.P. Community genetics in The Netherlands. In Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease ; Khoury, M.J., Burke, W., Thomson, E., Eds.; Oxford University: Oxford, UK, 2000; pp. 291–300. [ Google Scholar ] [ CrossRef ]
• De Smit, D.J. Information about Congenital Disorders: An Attempt to Improve Its Quality in Primary Care. Ph.D. Thesis, Research and Graduation Internal, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 1997. [ Google Scholar ]
• Baars, M.J.H.; A Scherpbier, A.J.J.; Schuwirth, L.W.; Henneman, L.; Beemer, F.A.; Cobben, J.M.; Hennekam, R.C.M.; Verweij, M.M.J.J.; Cornel, M.C.; Kate, L.P.T. Deficient knowledge of genetics relevant for daily practice among medical students nearing graduation. Genet. Med. 2005 , 7 , 295–301. [ Google Scholar ] [ CrossRef ]
• Poortman, E.A. Erfelijkheid en Ziekten ; De Fontain: Utrecht, The Netherlands, 1998; p. 16. [ Google Scholar ]
• Erfocentrum (Dutch National Genetic Resource and Information Centre). Available online: https://www.erfelijkheid.nl/content/over-ons (accessed on 5 June 2024).
• Poortman, Y. The European alliance of genetic support groups, their ethical code and the provision of genetic services. In The New Genetics: From Research into Health Care ; Nippert, I., Neitzel, H., Wolff, G., Eds.; Springer: Berlin/Heidelberg, Germany, 1999; pp. 125–130. Available online: https://link.springer.com/book/10.1007/978-3-642-58486-2 (accessed on 30 August 2024).
• Mikami, K. Citizens under the umbrella: Citizenship projects and the development of genetic umbrella organizations in the USA and the UK. New Genet. Soc. 2020 , 39 , 148–172. [ Google Scholar ] [ CrossRef ]
• European Genetic Alliances’ Network. Available online: https://egan.eu/contact/ (accessed on 5 June 2024).
• International Genetic Alliance. Available online: https://egan.eu/our-activities/international/iga/ (accessed on 5 June 2024).
• VSOP. Available online: https://vsop.nl/english/cooperation/ (accessed on 5 June 2024).
• The European Forum of Good Clinical Practice. Available online: https://efgcp.eu/ (accessed on 5 June 2024).
• The European Platform for Patient Organisations, Science and Industry. Available online: https://www.bionity.com/en/associations/37636/european-platform-for-patients-organisations-science-industry-epposi.htm (accessed on 5 June 2024).
• March of Dimes. Available online: https://www.marchofdimes.org (accessed on 5 June 2024).
• WAO. Available online: https://uia.org/s/or/en/1100035456 (accessed on 5 June 2024).
• EURORDIS—Rare Diseases Europe. Available online: https://www.eurordis.org/ (accessed on 5 June 2024).
• Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Off. J. Eur. Communities 2000 , L18 , 1–5. Available online: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF (accessed on 30 August 2024).
• Communicatiom from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions Rare Diseases: Europe’s challenges (2008). Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52008DC0679 (accessed on 5 June 2024).
• Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the Application of Patients’ Rights in Cross-Border Healthcare. Off. J. Eur. Communities . Available online: https://data.europa.eu/eli/dir/2011/24/oj (accessed on 30 August 2024).
• Aymé, S.; Rodwell, C. (Eds.) 2012 Report on the State of the Art of Rare Disease Activities in Europe of the European Union Committee of Experts on Rare Diseases; July 2012. Available online: https://www.eucerd.eu/upload/file/Reports/2012ReportStateofArtRDActivitiesV.PDF (accessed on 30 August 2024).
• The Solve-RD Project. Available online: https://solve-rd.eu/ (accessed on 5 June 2024).
• European Patient Advocacy Groups (ePAGs). Available online: https://www.eurordis.org/our-priorities/european-reference-networks/epag/epag/ (accessed on 5 June 2024).
• EURORDIS—Rare Diseases Europe. Available online: https://www.eurordis.org/publications/eurordis-recommendations-on-the-integration-of-european-reference-networks-erns-into-national-health-systems/ (accessed on 5 June 2024).
• Statement of the ERN Board of Member States on Integration of the European Reference Networks to the Healthcare Systems of Member States. Available online: https://health.ec.europa.eu/system/files/2019-07/integration_healthcaresystems_en_0.pdf (accessed on 5 June 2024).
• Available online: https://download2.eurordis.org/publications/One-Pager_JARDIN-Joint-Action.pdf (accessed on 5 June 2024).
• Integration of European Reference Networks and National Healthcare Systems—Minimum viable Product. Available online: https://www.eesc.europa.eu/sites/default/files/2024-03/graessner_-_jardin_eesc_session_1_holm_graessner.pdf (accessed on 5 June 2024).
• Rare 2030 Foresight in Rare Disease Policy. Available online: https://www.rare2030.eu/ (accessed on 5 June 2024).
• International Rare Diseases Research Consortium. Available online: https://irdirc.org/about-us/people-organisation/members-organizations/ (accessed on 5 June 2024).
• Boycott, K.M.; Rath, A.; Chong, J.X.; Hartley, T.; Alkuraya, F.S.; Baynam, G.; Brookes, A.J.; Brudno, M.; Carracedo, A.; Dunnen, J.T.D.; et al. International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases. Am. J. Hum. Genet. 2017 , 100 , 695–705. [ Google Scholar ] [ CrossRef ]
• First-Ever United Nations Resolution to Increase Visibility for the 300 Million Persons Living with a Rare Disease. Available online: http://download2.eurordis.org/pressreleases/EN_FINAL_International_PressRelease_UNResolution_EURORDIS.pdf (accessed on 5 June 2024).
• Report from the Inauguration of the NGO Committee for Rare Diseases. Available online: http://download2.eurordis.org.s3.amazonaws.com/ngocommittee/ngocommittee_report.pdf (accessed on 5 June 2024).
• NGO Committee for Rare Diseases. Available online: https://www.ngocommitteerarediseases.org/ (accessed on 5 June 2024).
• #30millionreasons for European on Rare Diseases. Available online: https://reasons.eurordis.org/ (accessed on 5 June 2024).
• Final Report Summary—PATIENTPARTNER (Identifying the Needs for Patients Partnering in Clinical Research). Available online: https://cordis.europa.eu/project/id/201720/reporting (accessed on 1 August 2024).
• European Patients’ Academy on Therapeutic Innovation. Available online: https://www.imi.europa.eu/projects-results/project-factsheets/eupati (accessed on 5 June 2024).
• EUPATIConnect. Available online: https://eupati.eu/ (accessed on 5 June 2024).
• Preparing for Life. Available online: https://preparingforlife.net/ (accessed on 5 June 2024).
• Preconception Care to Reduce Maternal and Childhood Mortality and Morbidity. Available online: https://www.who.int/publications/i/item/9789241505000 (accessed on 5 June 2024).
• Werk in Opdracht. Available online: https://www.erfocentrum.nl/over_ons/werk-opdracht (accessed on 5 June 2024).
• European Federation of Pharmaceutical Industries and Associations. Available online: https://www.efpia.eu/ (accessed on 5 June 2024).
• Capacity Building: How can Patient Organisations Shape the Future of Drug Development? Available online: https://www.efpia.eu/news-events/the-efpia-view/blog-articles/capacity-building-how-can-patient-organisations-shape-the-future-of-drug-development (accessed on 5 June 2024).
• Strengthening the Patient Voice in Health Care. Available online: https://health-outcomes-observatory.eu/ (accessed on 5 June 2024).
• Preconceptionele Dragerschapsscreening, Nr. 2023/18 Den Haag 15 November 2023. Available online: https://open.overheid.nl/documenten/c1bd9fbf-b747-4a75-b71a-c627c196a76f/file (accessed on 5 June 2024).
• VSOP, Jaarverslagen 2022. Available online: https://vsop.nl/over-ons/jaarverslagen (accessed on 5 June 2024).
• National Institute for Public Health and the Environment. Available online: https://www.rivm.nl/en/news/nipt-available-as-standard-option-for-all-pregnant-women-from-1-april (accessed on 5 June 2024).
• ZonMw—(The Netherlands Organisation for Health Research and Development). Available online: https://www.zonmw.nl/en/about-zonmw/international (accessed on 5 June 2024).
• Dutch Forum for Biotechnology and Genetics. Available online: https://www.forumbg.nl/dutch-forum-for-biotechnology-and-genetics/ (accessed on 5 June 2024).
• State of the Art for Rare Disease Activities in EU Member States and Other European Countries—Netherlands Report. Available online: http://www.rd-action.eu/wp-content/uploads/2017/10/Netherlands-Report-06.10.2017.pdf (accessed on 5 June 2024).
• Grody, W.W. The transformation of medical genetics by clinical genomics: Hubris meets humility. Genet. Med. 2019 , 9 , 1916–1926. [ Google Scholar ] [ CrossRef ]
• Braga, L.A.M.; Conte Filho, C.G.; Mota, F.B. Future of genetic therapies for rare genetic diseases: What to expect for the next 15 years? Ther. Adv. Rare Dis. 2022 , 3 , 26330040221100840. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Smith, C.I.E.; Bergman, P.; Hagey, D.W. Estimating the number of diseases—The concept of rare, ultra-rare, and hyper-rare. iScience 2022 , 25 , 104698. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Amaral, M.D. Precision medicine for rare diseases: The times they are A-Changin’. Curr. Opin. Pharmacol. 2022 , 63 , 102201. [ Google Scholar ] [ CrossRef ]
• Available online: https://www.weforum.org/agenda/2023/03/rare-diseases-changing-the-status-quo/ (accessed on 5 June 2024).
• Cost of Sequencing a Full Human Genome. Available online: https://ourworldindata.org/grapher/cost-of-sequencing-a-full-human-genome (accessed on 5 June 2024).
• Available online: https://www.wmbfnews.com/2024/04/30/newborn-twins-fight-rare-disease-family-says-itll-cost-42-million-save-their-lives/ (accessed on 5 June 2024).
• Sabatini, M.T.; Xia, T.; Chalmers, M. Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies. Pharm. Med. 2022 , 36 , 265–274. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Smith, G. 20. März 2024, Bloomberg.com: World’s Most Expensive Drug Is Now $ 4.25 Million Gene Therapy. Available online: https://www.bloomberg.com/news/articles/2024-03-20/world-s-most-expensive-drug-is-now-4-25-million-gene-therapy (accessed on 5 June 2024).
• Sabatini, M.T.; Chalmers, M. The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies. Pharm. Med. 2023 , 37 , 365–375. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Aartsma-Rus, A. Individualized ASO therapy for rare diseases. Commun. Med. 2023 , 3 , 27. [ Google Scholar ] [ CrossRef ]
• Editorial The gene-therapy revolution risks stalling if we don’t talk about drug pricing. Nature 2023 , 616 , 629–630. [ CrossRef ]
• Harrison, P.T.; Friedmann, T. Cost of gene therapy. Gene Ther. 2023 , 30 , 737. [ Google Scholar ] [ CrossRef ]
• Joffe, S.; Conti, R.M.; Contreras, J.L.; Largent, E.A.; Lynch, H.F.; Mitchell, D.; Sachs, R.E.; Whelan, A.M.; McCoy, M.S. Access to affordable medicines: Obligations of universities and academic medical centers. Gene Ther. 2023 , 30 , 753–755. [ Google Scholar ] [ CrossRef ]
• The Diagnostic Odyssey of People Living with a Rare Disease. Available online: https://www.eurordis.org/wp-content/uploads/2024/05/Diagnosis-printer-.pdf (accessed on 5 June 2024).
• Calcaterra, V.; Zuccotti, G. Non-Communicable Diseases and Rare Diseases: A Current and Future Public Health Challenge within Pediatrics. Children 2022 , 9 , 1491. [ Google Scholar ] [ CrossRef ]
• Gunne, E.; McGarvey, C.; Hamilton, K.; Treacy, E.; Lambert, D.M.; Lynch, S.A. Retrospective review of the contribution of rare diseases to paediatric mortality in Ireland. Orphanet J. Rare Dis. 2020 , 15 , 311. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Bavisetty, S.; Grody, W.W.; Yazdani, S. Emergence of pediatric rare diseases: Review of present policies and opportunities for improvement. Rare Dis. 2013 , 1 , e23579. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Fatumo, S.; Chikowore, T.; Choudhury, A.; Ayub, M.; Martin, A.R.; Kuchenbaecker, K. A roadmap to increase diversity in genomic studies. Nat. Med. 2022 , 28 , 243–250. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Popejoy, A.; Fullerton, S. Genomics is failing on diversity. Nature 2016 , 538 , 161–164. [ Google Scholar ] [ CrossRef ]
• World Economic Forum, World Scenario Series, The Future Role of Civil Society. January 2013. Available online: https://www3.weforum.org/docs/WEF_FutureRoleCivilSociety_Report_2013.pdf (accessed on 5 June 2024).

Share and Cite

Poortman, Y.; Ens-Dokkum, M.; Nippert, I. The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience. Genes 2024 , 15 , 1162. https://doi.org/10.3390/genes15091162

Poortman Y, Ens-Dokkum M, Nippert I. The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience. Genes . 2024; 15(9):1162. https://doi.org/10.3390/genes15091162

Poortman, Ysbrand, Martina Ens-Dokkum, and Irmgard Nippert. 2024. "The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience" Genes 15, no. 9: 1162. https://doi.org/10.3390/genes15091162

Article Metrics

Article access statistics, further information, mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

• Open access
• Published: 02 September 2024

Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia

• Eyob Girma Abera   ORCID: orcid.org/0000-0002-9030-4328 1 , 2 ,
• Kedir Negesso Tukeni 3 , 4 ,
• Temesgen Kabeta Chala 5 ,
• Daniel Yilma 2 , 3 &
• Esayas Kebede Gudina 2 , 3  

BMC Infectious Diseases volume  24 , Article number:  908 ( 2024 ) Cite this article

Metrics details

Studying the characteristics of hospitalized Coronavirus Disease 2019 (COVID-19) patients is vital for understanding the disease and preparing for future outbreaks. The aim of this study was to analyze and describe the clinical profiles and factors associated with mortality among COVID-19 patients admitted to Jimma Medical Center COVID-19 Treatment Center (JMC CTC) in Ethiopia.

All confirmed COVID-19 patients admitted to JMC CTC between 17 April 2020 and 05 March 2022 were included in this study. Socio-demographic data, clinical information, and outcome variables were collected retrospectively from medical records and COVID-19 database at the hospital. Bivariable and multivariable analyses were performed to determine factors associated with COVID-19 severity and mortality. A P-value < 0.05 was considered statistically significant.

A total of 542 confirmed COVID-19 patients were admitted to JMC CTC, of which 322 (59.4%) were male. Their median age was 48 years (IQR 32–64). About 51% ( n  = 277) of them had severe COVID-19 upon admission. Patients with hypertension [AOR: 2.8 (95% CI: 1.02–7.7, p  = 0.046)], diabetes [AOR: 8.8 (95% CI: 1.2–17.3, p  = 0.039)], and underlying respiratory diseases [AOR: 18.8 (95% CI: 2.06–71.51, p  = 0.009)] were more likely to present with severe COVID-19 cases. Overall, 129 (23.8%) died in the hospital. Death rate was higher among patients admitted with severe disease [AHR = 5.5 (3.07–9.9) p  < 0.001)] and those with comorbidities such as hypertension [AHR = 3.5 (2.28–5.41), p  < 0.001], underlying respiratory disease [AHR = 3.4 (1.97–5.94), p  < 0.001], cardiovascular disease (CVDs) [AHR = 2.8 (1.73–4.55), p  < 0.001], and kidney diseases [AHR = 3.7 (2.3–5.96), p  < 0.001].

About half of COVID-19 cases admitted to the hospital had severe disease upon admission. Comorbidities such as hypertension, diabetes, and respiratory diseases were linked to severe illness. COVID-19 admissions were associated with high inpatient mortality, particularly among those with severe disease and comorbidities.

Peer Review reports

Introduction

More than four years after its declaration as a global pandemic, COVID-19 remains a dynamic public health concern, with the emergence of new variants influencing transmission patterns and epidemiological trends [ 1 , 2 ]. While global vaccination efforts have significantly reduced severe cases and mortality, disparities in vaccine access and uptake persist, especially in low- and middle-income countries [ 3 ]. By late 2023, there was a notable resurgence of cases in several regions, including Europe and North America, primarily due to the emergence of more transmissible variants [ 4 ]. In sub-Saharan Africa, challenges such as limited healthcare infrastructure and underreporting of cases continue to pose significant obstacles. Many African countries still experience lower testing rates compared to other regions, contributing to an underestimation of the true burden of COVID-19 [ 5 ]. The gap between documented cases and estimated seroprevalence rates suggests ongoing underreporting, underscoring the need for improved surveillance and reporting systems to better capture the pandemic’s full impact [ 6 , 7 ].

Vaccinations have significantly reduced COVID-19 transmission, severe illness, and mortality. However, disparities in vaccine distribution and acceptance, especially in low- and middle-income countries, hinder global herd immunity [ 8 , 9 ]. Africa faces particular challenges with low vaccination rates due to supply shortages, logistical issues, vaccine hesitancy, and limited healthcare infrastructure [ 10 , 11 ]. The emergence of new SARS-CoV-2 variants complicates efforts to combat the pandemic, as these variants may affect transmissibility, disease severity, and vaccine efficacy [ 12 , 13 , 14 ]. Some variants, like Delta, have shown increased transmissibility and can lead to breakthrough infections among vaccinated individuals, partly due to mutations in the spike protein [ 15 ].

Various risk factors are associated with severe illness and mortality from COVID-19. These include advanced age, underlying health conditions such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease, obesity, and states of immunocompromise [ 16 , 17 ]. Furthermore, demographic factors such as male gender [ 18 ], socioeconomic status, and access to healthcare resources have also been recognized as playing roles in determining the severity and fatality of the disease [ 19 ].

Ethiopia faced significant challenges during the COVID-19 pandemic, including limited healthcare infrastructure and economic constraints [ 20 ]. The government quickly implemented measures such as lockdowns, travel restrictions, and hygiene promotion [ 21 ]. Despite these efforts, the country’s response was hampered by limited testing and medical resources [ 22 ]. The Ethiopian Public Health Institute and the Ministry of Health led initiatives for surveillance, contact tracing, and public awareness, with international support, including vaccines through COVAX [ 23 ]. The response aimed to balance public health measures with economic and social impacts, highlighting the challenges of managing a pandemic in a developing country [ 24 , 25 ].

Furthermore, the lack of comprehensive scientific data on COVID-19 outcomes has hindered evidence-based decision-making and the implementation of targeted public health interventions in Ethiopia. Strengthening research infrastructure and fostering international collaborations will not only enhance the current response but also pave the way for more effective future preparedness efforts, ensuring the protection of public health in Ethiopia and beyond [ 26 ]. Therefore, this study aimed to assess the clinical profile and outcomes of hospitalized COVID-19 patients at Jimma Medical Center (JMC) in southwest Ethiopia.

Study design and setting

We reviewed medical records of all patients admitted with COVID-19 to the Jimma Medical Center (JMC) COVID-19 Treatment Center (CTC) between 17 April 2020 and 05 March 2022. The center, established on 13 March 2020, had a capacity of 23 beds and was equipped with mechanical ventilators, oxygen concentrators, and patient monitors. Integrated with JMC, it was the only COVID-19 intensive care facility in southwest Ethiopia. The center consisted of management and operation sections, with the management team including a scientific advisory council and the operation section divided into six sub-teams: [ 1 ] Isolation & Case Management, [ 2 ] Surveillance, [ 3 ] Risk Communication & Community Engagement (RCCE), [ 4 ] Water, Sanitation, & Hygiene (WASH) and Infection Prevention Control (IPC), [ 5 ] Research, Innovation, and Diagnostics, and [ 6 ] Administration, Data Management, and Finance [ 27 ].

Inclusion criteria

Patients whose medical records confirmed the presence of the virus through the identification of viral ribonucleic acid (RNA) in nasopharyngeal swab samples using reverse transcription polymerase chain reaction (RT-PCR) either upon admission or during hospitalization, regardless of whether they exhibited symptoms, were included in the study.

Data collection

Patient sociodemographic and clinical characteristics were collected from medical records and the COVID-19 database at JMC-CTC. The collected data included various aspects such as demographics, clinical manifestations, comorbidities, disease severity upon admission, time/date of admission, length of stay, and discharge outcome.

Operational definitions .

COVID-19 specific symptoms (classic): Fever, cough, shortness of breath, loss of smell or taste [ 28 ].

Extended symptoms: Sore throat, runny nose, arthralgia, fatigue, and headache [ 28 ].

Mild illness: A person has any of the COVID-19 symptoms except for shortness of breath and difficulty breathing [ 29 ].

Moderate illness: A person may have lower respiratory tract illness with clinical or radiographic evidence. However, their blood oxygen levels remain at 94% or higher [ 29 ].

Critical COVID: A COVID-19 case requiring mechanical ventilation or hemodynamic support. This includes patients with acute respiratory distress syndrome, multi-organ dysfunction or failure, and shock [ 29 ].

Non-severe COVID-19: A person with mild to moderate symptoms that do not require hospitalization. This includes individuals with mild symptoms (any COVID-19 symptoms except shortness of breath and difficulty breathing) and moderate symptoms (lower respiratory tract illness with clinical or radiographic evidence but blood oxygen levels at 94% or higher) [ 29 , 30 ].

Severe illness: A person has blood oxygen levels that are less than 94%, a high breathing rate (≥ 30 breaths/min), and signs of severe lung disease (lung infiltrates > 50%) [ 29 ].

Symptom categorization

Category 1: One or more classic symptom without extended symptoms.

Category 2: One or more classic symptom with extended symptom.

Category 3: One or more extended symptom without classic symptoms.

Data analysis

The original data collected in Microsoft Excel was reviewed for completeness and consistency before being exported to SPSS ® version 26 (IBM ® , New York, USA) for analysis. Normality tests were conducted using visual inspections of histograms and Q-Q plots, as well as the Kolmogorov-Smirnov and Shapiro-Wilk tests. For the bivariate analysis, independent variables with a p-value less than 0.25 were selected as candidates for the multivariable logistic regression analysis. A binary logistic regression model was then used to explore risk factors for the severity of COVID-19 infection. Additionally, a Cox regression analysis was employed to identify predictors of mortality in COVID-19 patients. The equality of survival distributions for different severity levels was tested using Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon), and Tarone-Ware tests. A p-value of less than 0.05 was used as the threshold for statistical significance.

Socio-demographic and clinical characteristics

From April 2020 to March 2022, a total of 542 COVID-19 patients were admitted to JMC CTC, of which 322 (59.4%) were male. The median age was 48 years (IQR 32–64), with a range of 3 to 102 years. More than half (50.8%) of the cases were younger than 50 years of age. The most frequently reported symptoms were dyspnea (60%) and cough (57.6%). Among those with severe disease, 57.4% and 54% of patients exhibited cough and dyspnea, respectively. Comorbidities were reported in 21.8% of the admitted patients. Among those who died, the majority had comorbidities (80.6%), with hypertension being the most common at 44.2% (Table  1 ).

Trends in COVID-19 admissions by severity

Until November 2020, most admissions were due to non-severe cases. Subsequently, the non-severe admission declined, while admissions due to severe cases gradually increased reaching peak of 49 in April 2021. From June to August 2021, only two cases, both of which were severe, were admitted to the center. The number of admissions, primarily due to severe cases, increased after September 2021 (Fig.  1 ).

Pattern of admission and clinical severity of COVID-19 cases admitted to JMC CTC since April 2020 to March 2022

Factors associated with COVID-19 severity

Univariate binary logistic regression analyses were conducted to assess the individual factors associated with severe COVID-19 cases. Subsequently, candidate variables for the final multivariate analysis were selected based on their statistical significance in the univariate analyses. Accordingly, age, admission symptoms, and comorbidities such as hypertension, diabetes, respiratory disease, cardiovascular diseases (CVDs), and kidney diseases, were selected for inclusion in the multivariate logistic regression analysis.

The analysis indicated that with each additional year of age, the odds of experiencing a more severe form of the disease increased by 4% (AOR: 1.04, 95% CI: 1.03–1.05, p  < 0.001).

Additionally, individual comorbidities were independently analyzed after adjusting for the presence and absence of comorbidities. Hypertensive patients showed a nearly threefold increased odds of more severe disease compared to non-hypertensive patients [AOR: 2.8 (95% CI: 1.02–7.7, p  = 0.046)]. Diabetic patients had approximately nine times higher odds of experiencing severe disease compared to non-diabetic patients [AOR: 8.8 (95% CI: 1.2–17.3, p  = 0.039)]. Patients with respiratory diseases exhibited the highest odds of severe disease, with an 18.8-fold increase compared to those without respiratory conditions [AOR: 18.8 (95% CI: 2.06–71.51, p  = 0.009)] (Table  2 ).

Mortality and discharge outcomes

A total of 129 (23.8%) patients died during their hospitalization. The median length of hospital stay was 9.5 days (IQR: 6–15), with duration ranging from one to 40 days. Most of the deceased patients ( n  = 81, 62.8%) died within the first 7 days of admission. Additionally, 120 (22.1%) patients were transferred to home-based care or nearby facilities for further treatment and follow-up.

Trend of mortality with severe case admission

During the first five months, there were no admissions of severe cases and death at the center. However, as time progressed, there was a gradual increase in severe cases, culminating in the highest number of deaths during three peak periods: April 2021 ( n  = 18), October 2021 ( n  = 19), and January 2022 ( n  = 16) (Fig.  2 ).

Trends in Mortality and Severe Case Admissions among COVID-19 Patients at JMC CTC from April 2020 to March 2022

Time to mortality and hazard factors in COVID-19 patients

The clinical severity status at admission was significantly associated with survival outcomes (p-value < 0.001) (Supplementary Table 1 ). Patients who were severely ill at the time of admission had poorer survival rates and a shorter time to death (Fig.  3 ).

Kaplan–Meier curves displaying the estimated survival time of patients with COVID-19 stratified by the severity status on admission and length of hospital stay at JMC CTC from April 2020 to March 2022

Univariate Cox regression analyses assessed individual factors associated with the hazard of death among COVID-19 patients. Variables with fewer than 5 occurrences were excluded due to insufficient sample size for reliable estimates. Factors significant in univariate analyses, including age, clinical severity, and comorbidities (hypertension, diabetes, respiratory disease, cardiovascular disease, and kidney disease), were selected for the multivariate Cox regression analysis.

Severe disease was associated with a 5.5-fold increased hazard of death compared to non-severe cases (AHR: 5.5; 95% CI: 3.07–9.9, p  < 0.001). Additionally, individual comorbidities were independently analyzed after adjusting for the presence and absence of comorbidities. Hypertension, respiratory disease, cardiovascular disease, and kidney disease were linked to increased COVID-19 mortality risk, with the following AHR and 95% CI: hypertension [3.5(2.28–5.41), p  < 0.001], respiratory disease [3.4(1.97–5.94), p  < 0.001], cardiovascular disease [2.8(1.73–4.55), p  < 0.001], and kidney disease [3.7(2.3–5.96), p  < 0.001] (Table  3 ).

A total of 542 patients were admitted to JMC CTC between April 2020 and March 2022. Cough and dyspnea were the most frequently reported symptoms. Approximately 51% of the patients were classified as having severe COVID-19 at the time of hospitalization. The mortality rate was 23.8%, with a significant majority of the deceased patients (80.6%) having comorbidities, particularly hypertension. Conditions such as hypertension, respiratory disease, and cardiovascular disease were strongly associated with severe outcomes and increased risk of mortality.

During the first few months of the COVID-19 pandemic, Ethiopia did not experience a major outbreak with very low mortality rate [ 31 ]. However, by August 2020, the country began active case finding through a large-scale community-based activity and testing (CoMBaT) strategy [ 32 ]. This resulted in an increase in admissions for both severe and non-severe cases. Our study also revealed that there were no admissions due to severe COVID-19 or COVID-19 related deaths at JMC until August 2020. The low number of cases during that period may have been a result of limited testing and low disease outbreak. However, starting in September 2020, non-severe admissions decreased as Ethiopia revised its strategy of blanket admission of all confirmed COVID-19 cases to only severe cases and high-risk patients.

Since February 2021, there has been a notable increase in severe cases. The highest number of overall admissions occurred in April 2021, with a majority being severe cases ( n  = 49) out of a total of 69 admissions. Following this peak, there was a substantial decline over the next four months: May ( n  = 29), June ( n  = 0), July ( n  = 0), and August ( n  = 2). This pattern can be attributed to the second wave, which began in late January 2021 and persisted until the end of May 2021 [ 33 ]. During this period, the Alpha variant, known for its increased transmissibility [ 34 ] and higher hospitalization rates compared to earlier strains [ 35 ], predominated COVID-19 cases in Ethiopia [ 33 ]. These findings align with a study conducted from publicly available data on COVID-19 admissions in Ethiopia [ 36 ]. Our study also revealed that admissions due to severe COVID-19 and deaths peaked in October 2021 and January 2022. These peaks corresponded with the third and the fourth waves of COVID-19 outbreak in Ethiopia, which were dominated by the Delta and Omicron variants, respectively [ 37 ].

Ethiopia began COVID-19 vaccination in March 2021 [ 38 ]. Although the number of admissions and deaths at the hospital significantly decreased between May and August 2021, it is difficult to attribute this to the vaccination because only less than 5% of the population was vaccinated during this time [ 39 ].

Clinical parameters, including symptom category at admission and pre-existing comorbidities, were found to be associated with COVID-19 severity. Patients with one or more classic COVID-19 symptoms were more likely to present with severe illness compared to asymptomatic individuals by 15.9 folds. The odds increased to 17.2 among those with classic symptoms plus extended symptoms. This finding aligns with a retrospective analysis from China, which reported that the likelihood of developing severe illness increased with an increasing number of presenting symptoms at hospital admission [ 40 ]. This finding is also consistent with a global systematic review and meta-analysis that involved data from 14 countries [ 41 ]. Previous studies have suggested that an aberrant host immune response and cytokine storm may significantly contribute to the severity of COVID-19 [ 42 ].

In this study, age was associated with the severity of COVID-19. For each additional year of age, the likelihood of experiencing a more severe form of the disease increased by 4%, which aligns with findings from previous studies [ 43 , 44 , 45 ]. Additionally, patients with comorbidities such as hypertension, diabetes, and respiratory diseases were more likely to experience severe COVID-19 illness. Several systematic reviews have found similar patterns in both developing and developed countries, indicating that the relationship between comorbidities and the severity of COVID-19 is consistent across different socioeconomic contexts [ 41 , 46 , 47 ].

The median length of hospital stay was 9.5 days (IQR 6–15), with range of one to 40 days. This is consistent with findings from other studies conducted in Ethiopia [ 48 , 49 ]. However, this finding is lower than studies from China [ 50 ], US [ 51 ], and Sweden [ 52 ]. The shorter median hospital stay observed in our study compared to those from China, the US, and Sweden may reflect variations in treatment protocols, healthcare resources,, and patient demographics across these regions.

Our study also showed that clinical severity and pre-existing comorbidities were significantly associated with the risk of death. Severe disease was associated with a 5.5-fold increased hazard of death compared to non-severe cases. This finding is consistent with systematic reviews and meta-analyses from Sub-Saharan countries [ 53 ] as well as Asia, North America, Europe, and South America [ 54 ]. Additionally, comorbidities including, hypertension (AHR: 3.5), respiratory disease (AHR: 3.4), cardiovascular disease (AHR: 2.8), and kidney disease (AHR: 3.7) were linked to increased COVID-19 mortality risk. Our findings are consistent with different systematic review meta-analysis studies [ 53 , 54 , 55 , 56 , 57 , 58 ]. This is because chronic conditions are often associated with a subclinical inflammation, weakened innate immune responses, and increased expression of ACE-2 receptor, which facilitates the entry of SARS-CoV-2 into the host cells and is associated with higher COVID-19 mortality [ 45 ].

Strength and limitation

This study covered nearly two years of COVID-19 pandemic, focusing on COVID-19 related hospitalizations to a tertiary teaching hospital in Ethiopia, and provides valuable insights into COVID-19 in African contexts. While the study offers original findings, it is limited by its retrospective design. Retrieving data from medical records was found to be a challenge due to incomplete documentations and lost records. Moreover, the lack of routinely recorded laboratory and imaging results, as well as case management details, prevented their inclusion in this study.

This study found that patients hospitalized with severe symptoms and comorbidities—such as hypertension, respiratory disease, cardiovascular disease, and kidney disease—faced a significantly higher risk of in-hospital mortality. The study also identified distinct patterns in admissions and mortality that corresponded with the pandemic waves and variant prevalence in Ethiopia. Although vaccination efforts began in March 2021, their impact on admissions and mortality was minimal during the study period due to low vaccination coverage. Overall, this research enhances our understanding of COVID-19 outcomes in African contexts and highlights the importance of ongoing monitoring and management, especially with the emergence of new variants and evolving data.

Data availability

All relevant data are within the manuscript.

Organization WH. Coronavirus disease (COVID-19) Epidemiological Updates and Monthly Operational Updates. 2024.

CDC COVID Data Tracker. Home [Internet]. [cited 2024 Aug 5]. https://covid.cdc.gov/covid-data-tracker/#datatracker-home

Gozzi N, Chinazzi M, Dean NE, Longini IM Jr, Halloran ME, Perra N, et al. Estimating the impact of COVID-19 vaccine inequities: a modeling study. Nat Commun. 2023;14(1):3272.

Article   CAS   PubMed   PubMed Central   Google Scholar  

Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2. Science (80-). 2022;375(6585):1116–21.

Nguimkeu P, Tadadjeu S. Why are the Number of COVID-19 Cases Lower Than Expected in Sub-Saharan Africa? A Cross-Sectional Analysis of the Role of Demographic, Epidemiologic and Environmental Factors. USA: Working Paper, Georgia State University; 2020.

Ngere I, Dawa J, Hunsperger E, Otieno N, Masika M, Amoth P, et al. High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya. Int J Infect Dis. 2021;112:25–34.

Manabe YC, Sharfstein JS, Armstrong K. The need for more and better testing for COVID-19. JAMA. 2020;324(21):2153–4.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.

Article   CAS   PubMed   Google Scholar  

Onigbinde OA, Ajagbe AO. COVID-19 vaccination and herd immunity In Africa: An incentive-based approach could be the game-changer to vaccine hesitancy. Public Heal Pract (Oxford, England). 2022;4:100282.

Abosede DA, Ajadi A. COVID-19 vaccines in Africa: challenges and implications for the future. Int J Dev Sustain Int J Dev Sustain. (11 1):16–27.

Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. PLoS Med. 2013;10(3):e1001405.

Article   PubMed   PubMed Central   Google Scholar  

Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin Microbiol Infect. 2021;27(8):1109–17.

Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa Abo El-Ella D, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–40.

Khan A, Khan T, Ali S, Aftab S, Wang Y, Qiankun W, et al. SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 2021;143:112176.

Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595(7865):17–8.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.

Galbadage T, Peterson BM, Awada J, Buck AS, Ramirez DA, Wilson J, et al. Systematic review and meta-analysis of sex-specific COVID-19 clinical outcomes. Front Med. 2020;7:348.

Article   Google Scholar  

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.

First case of COVID-19 confirmed in Ethiopia | WHO |. Regional Office for Africa [Internet]. [cited 2022 Dec 19]. https://www.afro.who.int/news/first-case-covid-19-confirmed-ethiopia

Deressa W, Worku A, Abebe W, Getachew S, Amogne W. Social distancing and preventive practices of government employees in response to COVID-19 in Ethiopia. PLoS ONE. 2021;16(9):e0257112.

Ayele W, Gage A, Kapoor NR, Kassahun Gelaw S, Hensman D, Derseh Mebratie A, et al. Quality of routine health data at the onset of the COVID-19 pandemic in Ethiopia, Haiti, Laos, Nepal, and South Africa. Popul Health Metr. 2023;21(1):1–11.

Dima FG, Girma S. Review on Covid-19 distribution, Socio-Economic Impact and Its Preventive Measures in Ethiopia.

Engidaw AE. Small businesses and their challenges during COVID-19 pandemic in developing countries: in the case of Ethiopia. J Innov Entrep. 2022;11(1):1.

Angaw KW. Policy responses and social solidarity imperatives to respond the COVID-19 pandemic socioeconomic crises in Ethiopia. Clin Outcomes Res. 2021;279–87.

Khatri RB, Endalamaw A, Erku D, Wolka E, Nigatu F, Zewdie A, et al. Preparedness, impacts, and responses of public health emergencies towards health security: qualitative synthesis of evidence. Arch Public Heal. 2023;81(1):208.

Chala TK, Abera EG, Tukeni KN, Didu GH, Abbagidi FA, Yesuf EA, et al. The need to establish and sustain public health emergency operation centers for managing infectious disease outbreaks: lesson from response to louse-borne relapsing fever outbreak in Jimma, Ethiopia. Disaster Med Public Health Prep. 2023;17:e535.

Article   PubMed   Google Scholar  

Antonelli M, Capdevila J, Chaudhari A, Granerod J, Canas LS, Graham MS, et al. Optimal symptom combinations to aid COVID-19 case identification: analysis from a community-based, prospective, observational cohort. J Infect. 2021;82(3):384–90.

Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383(18):1757–66.

Sisay G, Mantefardo B, Beyene A. Time from symptom onset to severe COVID-19 and risk factors among patients in Southern Ethiopia: a survival analysis. J Int Med Res. 2022;50(8):03000605221119366.

Gudina EK, Gobena D, Debela T, Yilma D, Girma T, Mekonnen Z, et al. COVID-19 in Oromia Region of Ethiopia: a review of the first 6 months’ surveillance data. BMJ Open. 2021;11(3):e046764.

WHO Regional Office for Africa, BULLETIN. COVID-19 2020, 05 AUGUST ETHIOPIA. 2020;(August). https://www.afro.who.int/sites/default/files/2020-08/ETHIOPIA_COVID19 response bulletin_05AUG2020%282%29_0.pdf.

Sisay A, Tshiabuila D, van Wyk S, Tesfaye A, Mboowa G, Oyola SO et al. Molecular epidemiology and diversity of SARS-CoV-2 in Ethiopia, 2020–2022. Genes (Basel). 2023;14(3):705.

Pascall DJ, Vink E, Blacow R, Bulteel N, Campbell A, Campbell R, et al. The SARS-CoV-2 alpha variant was associated with increased clinical severity of COVID-19 in Scotland: a genomics-based retrospective cohort analysis. PLoS ONE. 2023;18(4):e0284187.

Paredes MI, Lunn SM, Famulare M, Frisbie LA, Painter I, Burstein R et al. Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. Medrxiv. 2022.

Amhare AF, Tao Y, Li R, Zhang L. Early and subsequent epidemic characteristics of COVID-19 and their impact on the epidemic size in Ethiopia. Front Public Heal. 2022;10:834592.

Hasenauer J, Merkt S, Ali S, Gudina EK, Adissu W, Muenchhoff M et al. Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity. 2023.

Ayele AD, Ayenew NT, Tenaw LA, Kassa BG, Yehuala ED, Aychew EW, et al. Acceptance of COVID-19 vaccine and associated factors among health professionals working in hospitals of South Gondar Zone, Northwest Ethiopia. Hum Vaccin Immunother. 2021;17(12):4925–33.

Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–53.

Wang F, Cao J, Yu Y, Ding J, Eshak ES, Liu K, et al. Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: evidence from a retrospective observational study. Int J Epidemiol. 2020;49(6):1940–50.

Article   PubMed Central   Google Scholar  

Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS ONE. 2021;16(3):e0247461.

Assal HH, Abdel-hamid HM, Magdy S, Salah M, Ali A, Elkaffas RH, et al. Predictors of severity and mortality in COVID-19 patients. Egypt J Bronchol. 2022;16(1):1–9.

Starke KR, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Heal. 2021;6(12):e006434.

Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics. 2020;146(4).

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Heal. 2020;8(8):e1003–17.

Honardoost M, Janani L, Aghili R, Emami Z, Khamseh ME. The association between presence of comorbidities and COVID-19 severity: a systematic review and meta-analysis. Cerebrovasc Dis. 2021;50(2):132–40.

Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: a comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS ONE. 2020;15(12):e0243191.

Memirie ST, Yigezu A, Zewdie SA, Mirkuzie AH, Bolongaita S, Verguet S. Hospitalization costs for COVID-19 in Ethiopia: empirical data and analysis from Addis Ababa’s largest dedicated treatment center. PLoS ONE. 2022;17(1):e0260930.

Kaso AW, Agero G, Hurissa Z, Kaso T, Ewune HA, Hareru HE, et al. Survival analysis of COVID-19 patients in Ethiopia: a hospital-based study. PLoS ONE. 2022;17(5):e0268280.

Wang Z, Liu Y, Wei L, Ji JS, Liu Y, Liu R, et al. What are the risk factors of hospital length of stay in the novel coronavirus pneumonia (COVID-19) patients? A survival analysis in southwest China. PLoS ONE. 2022;17(1):e0261216.

Ohl ME, Miller DR, Lund BC, Kobayashi T, Miell KR, Beck BF, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Netw open. 2021;4(7):e2114741–2114741.

Larsson E, Brattström O, Agvald-Öhman C, Grip J, Campoccia Jalde F, Strålin K, et al. Characteristics and outcomes of patients with COVID‐19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. Acta Anaesthesiol Scand. 2021;65(1):76–81.

Bepouka B, Mayasi N, Mandina M, Longokolo M, Odio O, Mangala D, et al. Risk factors for mortality in COVID-19 patients in sub-saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2022;17(10):e0276008.

Noor FM, Islam MM. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. J Community Health. 2020;45(6):1270–82.

Ghislain MR, Muzumbukilwa WT, Magula N. Risk factors for death in hospitalized COVID-19 patients in Africa: a systematic review and meta-analysis. Med (Baltim). 2023;102(35):e34405.

Sepandi M, Taghdir M, Alimohamadi Y, Afrashteh S, Hosamirudsari H. Factors associated with mortality in COVID-19 patients: a systematic review and meta-analysis. Iran J Public Health. 2020;49(7):1211.

PubMed   PubMed Central   Google Scholar  

Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS ONE. 2020;15(8):e0238215.

Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021; 12 (1): e03647-20. https://doi.org/10.1128/mBio . 03647-20. PMID.

Download references

Acknowledgements

We extend our heartfelt gratitude to the Jimma Emergency Operation Center, Jimma Medical Center, and the dedicated study teams for their invaluable support during the intervention and data collection process.

This research received no specific grant from any funding agency in the public, commercial, or non-profit sectors.

Author information

Authors and affiliations.

Department of Public Health, Jimma University, P.O.Box 378, Jimma, Oromia, Ethiopia

Eyob Girma Abera

Clinical Trial Unit, Jimma University, Oromia, Ethiopia

Eyob Girma Abera, Daniel Yilma & Esayas Kebede Gudina

Department of Internal Medicine, Jimma University, Jimma, Oromia, Ethiopia

Kedir Negesso Tukeni, Daniel Yilma & Esayas Kebede Gudina

Center Hospitalier Saint-Joseph Saint-Luc, Lyon, France

Kedir Negesso Tukeni

Department of Health Policy and Management, Jimma University, Jimma, Oromia, Ethiopia

Temesgen Kabeta Chala

You can also search for this author in PubMed   Google Scholar

Contributions

EGA and EKG conceptualized and designed the study. EGA analyzed the data and wrote the original draft. TKC and KNT involved for data curation. EKG and DY provided supervision for the overall activities. All authors accepted responsibility for all aspects of the research, including writing, reviewing, and editing, and approved the final version of the manuscript.

Corresponding author

Correspondence to Eyob Girma Abera .

Ethics declarations

Ethical clearance and consent to participate.

Ethical approval for the study was obtained from the Institutional Review Board (IRB) of Jimma University, Institute of Health (Reference number: RPGD/978/2020). The IRB of Jimma University, Institute of Health, also granted a waiver for the requirement of informed consent to participate, as the study involved a retrospective review of anonymized medical records. All data were handled with strict confidentiality to ensure participant anonymity.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ .

Reprints and permissions

About this article

Cite this article.

Abera, E.G., Tukeni, K.N., Chala, T.K. et al. Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia. BMC Infect Dis 24 , 908 (2024). https://doi.org/10.1186/s12879-024-09836-6

Download citation

Received : 02 April 2024

Accepted : 29 August 2024

Published : 02 September 2024

DOI : https://doi.org/10.1186/s12879-024-09836-6

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Comorbidity

BMC Infectious Diseases

ISSN: 1471-2334

• General enquiries: [email protected]